

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
18 September 2003 (18.09.2003)

PCT

(10) International Publication Number  
**WO 03/076567 A2**

(51) International Patent Classification<sup>7</sup>:

C12N

(21) International Application Number:

PCT/US03/03120

(22) International Filing Date:

21 February 2003 (21.02.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/361,948                    5 March 2002 (05.03.2002)    US

(71) Applicant (*for all designated States except US*): **ELI LILLY AND COMPANY** [US/US]; Lilly Corporate Center, Indianapolis, IN 46285 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **BEALS, John, Michael** [US/US]; 6710 Bluffridge Parkway, Indianapolis, IN 46278 (US). **KUCHIBHOTLA, Uma** [IN/US]; 12604 Bent Oak Lane, Indianapolis, IN 46236 (US).

(74) Agents: **STEWART, Mark, J.** et al.; ELI LILLY AND COMPANY, P. O. Box 6288, Indianapolis, IN 47206-6288 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT (utility model), AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (utility model), DE, DK (utility model), DK, DM, DZ, EC, EE (utility model), EE, ES, FI (utility model), FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK (utility model), SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



**WO 03/076567 A2**

(54) Title: HETEROLOGOUS G-CSF FUSION PROTEINS

(57) Abstract: The present invention encompasses heterologous fusion proteins comprising a hyperglycosylated G-CSF analog fused to proteins such as albumin and the Fc portion of an immunoglobulin which act to extend the in vivo half-life of the protein compared to native G-CSF. These fusion proteins are particularly suited for the treatment of conditions treatable by stimulation of circulating neutrophils, such as after chemotherapy regimens or in chronic congenital neutropenia.

WO 03/076567

PCT/US03/03120

**HETEROLOGOUS G-CSF FUSION PROTEINS**

The present invention relates to heterologous fusion proteins, including analogs and derivatives thereof, fused to proteins that have the effect of extending the *in vivo* half-life of the proteins. These fusion proteins are significant in human medicine, particularly in the treatment of conditions treatable by stimulation of circulating neutrophils, such as after chemotherapy regimens or in chronic congenital neutropenia. More specifically, the invention relates to novel heterologous fusion proteins with granulocyte-colony stimulating factor activity.

Among all blood cell lineages, the modulation of neutrophil and platelet production has been of highest interest to clinical oncologists and hematologists. Myelosuppression is the single most severe complication of cancer chemotherapy, and a major cause of treatment delay during multiple-cycle or combination chemotherapy. It is also the major dose-limiting factor for most chemotherapeutic agents. Due to the short half-lives of neutrophils in peripheral blood, life-threatening falls in neutrophil levels are seen after a number of conventional anti-tumor chemotherapy regimens.

The most prominent regulator of granulopoiesis is granulocyte-colony stimulating factor (G-CSF). G-CSF induces proliferation and differentiation of hematopoietic progenitor cells resulting in increased numbers of circulating neutrophils. G-CSF also stimulates the release of mature neutrophils from bone marrow and activates their functional state. [Souza L.M., et al. (1986) *Science* 232:61-65]. Thus, therapeutic proteins with G-CSF activity have tremendous value in situations where there are reduced circulating levels of neutrophilic granulocytes.

However, the usefulness of therapy using G-CSF peptides has been limited by their short plasma half-life. Thus,

WO 03/076567

PCT/US03/03120

- 2 -

they must be administered intravenously or subcutaneously at fairly frequent intervals (once or twice a day) in order to maintain their neutrophil stimulating properties. In addition, this short half-life limits the performance of the drug to traditional drug delivery systems. It would clearly benefit the treatment of patients with abnormally low neutrophils, and reduce the discomfort and inconvenience associated with frequent injections to provide a pharmaceutical agent that could be administered less frequently and optionally by alternative routes of administration. Thus, a need exists to develop agents that stimulate the production of mature neutrophils and are more optimal in their duration of effect.

The present invention overcomes the problems associated with delivering a compound that has a short plasma half-life in two respects. First, G-CSF is hyperglycosylated. The carbohydrate content of G-CSF is altered by substituting amino acids that can act as substrates for glycosylating enzymes in mammalian cells. Most significantly, the present invention encompasses fusion of these hyperglycosylated G-CSF analogs to another protein with a long circulating half-life such as the Fc portion of an immunoglobulin or albumin.

Compounds of the present invention include heterologous fusion proteins comprising a hyperglycosylated G-CSF analog fused to a polypeptide selected from the group consisting of

- a) human albumin;
- b) human albumin analogs; and
- c) fragments of human albumin.

Compounds of the present invention also include heterologous fusion proteins comprising a hyperglycosylated G-CSF analog fused to a polypeptide selected from the group consisting of

- a) human albumin;
- b) human albumin analogs; and
- c) fragments of human albumin,

WO 03/076567

PCT/US03/03120

- 3 -

wherein the hyperglycosylated G-CSF analog is fused to the polypeptide via a peptide linker.

Additional compounds of the present invention include a heterologous fusion protein comprising a hyperglycosylated G-CSF analog fused to a polypeptide selected from the group consisting of

- a) the Fc portion of an immunoglobulin;
- b) an analog of the Fc portion of an immunoglobulin;  
and
- c) fragments of the Fc portion of an immunoglobulin.

The G-CSF analog may be fused to the polypeptide via a peptide linker. It is preferable that the peptide linker is selected from the group consisting of:

- a) a glycine rich peptide;
- b) a peptide having the sequence [Gly-Gly-Gly-Gly-Ser]<sub>n</sub> where n is 1, 2, 3, 4, or 5; and
- c) a peptide having the sequence [Gly-Gly-Gly-Gly-Ser]<sub>3</sub>.

The present invention further provides data showing that these G-CSF analogs are glycosylated in mammalian cells and retain their activity.

One aspect of the present invention includes heterologous fusion proteins, wherein the hyperglycosylated G-CSF analogs have the Formula (I) [SEQ ID NO:1]

1	5	10	15
Thr Pro Leu Gly Pro Ala Ser Ser	Leu Pro Gln Ser Phe	Leu Leu Lys	
20	25	30	
Xaa Leu Glu Gln Val Arg Lys Ile Gln Gly Asp	Gly Ala Ala Leu Gln		
35	40	45	
Glu Lys Leu Cys Xaa Xaa Xaa Lys Leu Cys His	Pro Glu Glu Leu Val		
50	55	60	
Leu Leu Gly His Ser Leu Gly Ile Xaa Xaa Xaa Xaa Xaa Xaa Xaa			
65	70	75	80
Xaa Xaa Xaa Xaa Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser			
85	90	95	
Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Xaa Xaa Xaa Ser			
100	105	110	
Xaa Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp			
115	120	125	
Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro			
130	135	140	
Ala Leu Gln Pro Xaa Xaa Xaa Ala Met Pro Ala Phe Xaa Xaa Xaa Phe			
145	150	155	160
Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe			

WO 03/076567

PCT/US03/03120

- 4 -

165                    170  
Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro (I)

wherein:

Xaa at position 17 is Cys, Ala, Leu, Ser, or Glu;  
Xaa at position 37 is Ala or Asn;  
Xaa at position 38 is Thr, or any other amino acid except  
Pro;  
Xaa at position 39 is Tyr, Thr, or Ser;  
Xaa at position 57 is Pro or Val;  
Xaa at position 58 is Trp or Asn;  
Xaa at position 59 is Ala or any other amino acid except  
Pro;  
Xaa at position 60 is Pro, Thr, Asn, or Ser,  
Xaa at position 61 is Leu, or any other amino acid except  
Pro;  
Xaa at position 62 is Ser or Thr;  
Xaa at position 63 is Ser or Asn;  
Xaa at position 64 is Cys or any other amino acid except  
Pro;  
Xaa at position 65 is Pro, Ser, or Thr;  
Xaa at position 66 is Ser or Thr;  
Xaa at position 67 is Gln or Asn;  
Xaa at position 68 is Ala or any other amino acid except  
Pro;  
Xaa at position 69 is Leu, Thr, or Ser  
Xaa at position 93 is Glu or Asn  
Xaa at position 94 is Gly or any other amino acid except  
Pro;  
Xaa at position 95 is Ile, Asn, Ser, or Thr;  
Xaa at position 97 is Pro, Ser, Thr, or Asn;  
Xaa at position 133 is Thr or Asn;  
Xaa at position 134 is Gln or any other amino acid except  
Pro;  
Xaa at position 135 is Gly, Ser, or Thr  
Xaa at position 141 is Ala or Asn;  
Xaa at position 142 is Ser or any other amino acid except  
Pro; and  
Xaa at position 143 is Ala, Ser, or Thr;

and wherein:

Xaa at positions 37, 38, and 39 constitute region 1;  
Xaa at positions 58, 59, and 60 constitute region 2;  
Xaa at positions 59, 60, and 61 constitute region 3;  
Xaa at positions 60, 61, and 62 constitute region 4;  
Xaa at positions 61, 62, and 63 constitute region 5;

WO 03/076567

PCT/US03/03120

- 5 -

Xaa at positions 62, 63, and 64 constitute region 6;  
Xaa at positions 63, 64, and 65 constitute region 7;  
Xaa at positions 64, 65, and 66 constitute region 8;  
Xaa at positions 67, 68, and 69 constitute region 9;  
Xaa at positions 93, 94, and 95 constitute region 10;  
Xaa at positions 94, 95, and Ser at position 96  
constitute region 11;  
Xaa at positions 95, and 97, and Ser at position 96  
constitute region 12;  
Xaa at positions 133, 134, and 135 constitute  
region 13;  
Xaa at positions 141, 142, and 143 constitute  
region 14;

and provided that at least one of regions 1 through 14  
comprises the sequence Asn Xaa1 Xaa2 wherein Xaa1 is any  
amino acid except Pro and Xaa2 is Ser or Thr.

Thus, the heterologous fusion proteins of the present  
invention include analogs wherein one or any combination of  
two or more regions comprise the sequence Asn Xaa1 Xaa2  
wherein Xaa1 is any amino acid except Pro and Xaa2 is Ser or  
Thr.

Preferred hyperglycosylated G-CSF analogs that make up part  
of the heterologous fusion proteins of the present  
invention, include the following:

- a) G-CSF [A37N, Y39T]
- b) G-CSF [P57V, W58N, P60T]
- c) G-CSF [P60N, S62T]
- d) G-CSF [S63N, P65T]
- e) G-CSF [Q67N, L69T]
- f) G-CSF [E93N, I95T]
- g) G-CSF [T133N, G135T]
- h) G-CSF [A141N, A143T]
- i) G-CSF [A37N, Y39T, P57V, W58N, P60T]
- j) G-CSF [A37N, Y39T, P60N, S62T]
- k) G-CSF [A37N, Y39T, S63N, P65T]
- l) G-CSF [A37N, Y39T, Q67N, L69T]
- m) G-CSF [A37N, Y39T, E93N, I95T]
- n) G-CSF [A37N, Y39T, T133N, G135T]
- o) G-CSF [A37N, Y39T, A141N, A143T]

WO 03/076567

PCT/US03/03120

- 6 -

- p) G-CSF [A37N, Y39T, P57V, W58N, P60T, S63N, P65T]
- q) G-CSF [A37N, Y39T, P57V, W58N, P60T, Q67N, L69T]
- r) G-CSF [A37N, Y39T, S63N, P65T, E93N, I95T]

The present invention also includes heterologous fusion proteins, which are the product of the expression in a host cell of an exogenous DNA sequence, which comprises a DNA sequence encoding a heterologous fusion protein of Formula I (described above) fused to a DNA sequence encoding human albumin or the Fc portion of an immunoglobulin.

The present invention includes an isolated nucleic acid sequence, comprising a polynucleotide encoding a heterologous fusion protein described above. Exemplary isolated nucleic acids of the present invention include isolated nucleic acid sequence comprising a hyperglycosylated G-CSF analog selected from the group consisting of:

a) SEQ ID NO:2  
ACC CCC CTG GGC CCT GCC AGC TCC CTG CCC CAG AGC TTC CTG CTC AAG  
TGG GGG GAC CCG GGA CGG TCG AGG GAC GGG GTC TCG AAG GAC GAG TTC  
  
GCC TTA GAG CAA GTG AGG AAG ATC CAG GGC GAT GGC GCA GCG CTC CAG  
CGG AAT CTC GTT CAC TCC TTC TAG GTC CCG CTA CCG CGT CGC GAG GTC  
  
GAG AAG CTG TGT GCC ACC TAC AAG CTG TGC CAC CCC GAG GAG CTG GTG  
CTC TTC GAC ACA CGG TGG ATG TTC GAC ACG GTG GGG CTC CTC GAC CAC  
  
CTG CTC GGA CAC TCT CTG GGC ATC CCC TGG GCT CCC CTG AGC AGC TGC  
GAC GAG CCT GTG ACA GAC CCG TAG GGG ACC CGA GGG GAC TCG TCG ACG  
  
CCC AGC CAG GCC CTG CAG CTG GCA GGC TGC TTG AGC CAA CTC CAT AGC  
GGG TCG GTC CGG GAC GTC GAC CGT CCG ACG AAC TCG GTT GAG GTA TCG  
  
GGC CTT TTC CTC TAC CAG GGG CTC CTG CAG GCC CTG GAA GGG ATC TCC  
CCG GAA AAG GAG ATG GTC CCC GAG GAC GTC CGG GAC CTT CCC TAG AGG  
  
CCC GAG TTG GGT CCC ACC TTG GAC ACA CTG CAG CTG GAC GTC GCC GAC  
GGG CTC AAC CCA GGG TGG AAC CTG TGT GAC GTC GAC CTG CAG CGG CTG  
  
TTT GCC ACC ACC ATC TGG CAG CAG ATG GAA GAA CTG GGA ATG GCC CCT  
AAA CGG TGG TGG TAG ACC GTC GTC TAC CTT GAC CCT TAC CGG GGA  
  
GCC CTG CAG CCC AAC CAG ACC GCC ATG CCG GCC TTC GCC TCT GCT TTC  
CGG GAC GTC GGG TTG GTC TGG CGG TAC GGC CGG AAG CGG AGA CGA AAG  
  
CAG CGC CGG GCA GGA GGG GTC CTG GTT GCC TCC CAT CTG CAG AGC TTC  
GTC GCG GCC CGT CCT CCC CAG GAC CAA CGG AGG GTA GAC GTC TCG AAG

WO 03/076567

PCT/US03/03120

- 7 -

CTG GAG GTG TCG TAC CGC GTC TTA AGG CAC CTT GCC CAG CCC  
GAC CTC CAC AGC ATG GCG CAG AAT TCC GTG GAA CGG GTC GGG

b) SEQ ID NO:3

ACC CCC CTG GGC CCT GCC AGC TCC CTG CCC CAG AGC TTC CTG CTC AAG  
TGG GGG GAC CCG GGA CGG TCG AGG GAC GGG GTC TCG AAG GAC GAG TTC

GCC TTA GAG CAA GTG AGG AAG ATC CAG GGC GAT GGC GCA GCG CTC CAG  
CGG AAT CTC GTT CAC TCC TTC TAG GTC CCG CTA CCG CGT CGC GAG GTC

GAG AAG CTG TGT GCC ACC TAC AAG CTG TGC CAC CCC GAG GAG CTG GTG  
CTC TTC GAC ACA CGG TGG ATG TTC GAC ACG GTG GGG CTC CTC GAC CAC

CTG CTC GGA CAC TCT CTG GGC ATC CCC TGG GCT CCC CTG AGC AGC TGC  
GAC GAG CCT GTG ACA GAC CCG TAG GGG ACC CGA GGG GAC TCG TCG ACG

CCC AGC CAG GCC CTG CAG CTG GCA GGC TGC TTG AGC CAA CTC CAT AGC  
GGG TCG GTC CGG GAC GTC GAC CGT CCG ACG AAC TCG GTT GAG GTA TCG

GGC CTT TTC CTC TAC CAG GGG CTC CTG CAG GCC CTG GAA GGG ATC TCC  
CCG GAA AAG GAG ATG GTC CCC GAG GAC GTC CGG GAC CTT CCC TAG AGG

CCC GAG TTG GGT CCC ACC TTG GAC ACA CTG CAG CTG GAC GTC GCC GAC  
GGG CTC AAC CCA GGG TGG AAC CTG TGT GAC GTC GAC CTG CAG CGG CTG

TTT GCC ACC ACC ATC TGG CAG CAG ATG GAA GAA CTG GGA ATG GCC CCT  
AAA CGG TGG TGG TAG ACC GTC GTC TAC CTT CTT GAC CCT TAC CGG GGA

GCC CTG CAG CCC ACC CAG GGT GCC ATG CCG GCC TTC AAC TCT ACC TTC  
CCG GAC GTC CGG TGG GTC CCA CGG TAC GGC CGG AAG TTG AGA TGG AAG

CAG CGC CGG GCA GGA GGG GTC CTG GTT GCC TCC CAT CTG CAG AGC TTC  
GTC GCG GCC CGT CCT CCC CAG GAC CAA CGG AGG GTA GAC GTC TCG AAG

CTG GAG GTG TCG TAC CGC GTC TTA AGG CAC CTT GCC CAG CCC  
GAC CTC CAC AGC ATG GCG CAG AAT TCC GTG GAA CGG GTC GGG

c) SEQ ID NO:4

ACC CCC CTG GGC CCT GCC AGC TCC CTG CCC CAG AGC TTC CTG CTC AAG  
TGG GGG GAC CCG GGA CGG TCG AGG GAC GGG GTC TCG AAG GAC GAG TTC

GCC TTA GAG CAA GTG AGG AAG ATC CAG GGC GAT GGC GCA GCG CTC CAG  
CGG AAT CTC GTT CAC TCC TTC TAG GTC CCG CTA CCG CGT CGC GAG GTC

GAG AAG CTG TGT AAC ACC AAG CTG TGC CAC CCC GAG GAG CTG GTG  
CTC TTC GAC ACA TTG TGG TGG TTC GAC ACG GTG GGG CTC CTC GAC CAC

CTG CTC GGA CAC TCT CTG GGC ATC CCC TGG GCT CCC CTG AGC AGC TGC  
GAC GAG CCT GTG ACA GAC CCG TAG GGG ACC CGA GGG GAC TCG TCG ACG

CCC AGC CAG GCC CTG CAG CTG GCA GGC TGC TTG AGC CAA CTC CAT AGC  
GGG TCG GTC CGG GAC GTC GAC CGT CCG ACG AAC TCG GTT GAG GTA TCG

GGC CTT TTC CTC TAC CAG GGG CTC CTG CAG GCC CTG GAA GGG ATC TCC  
CCG GAA AAG GAG ATG GTC CCC GAG GAC GTC CGG GAC CTT CCC TAG AGG

CCC GAG TTG GGT CCC ACC TTG GAC ACA CTG CAG CTG GAC GTC GCC GAC  
GGG CTC AAC CCA GGG TGG AAC CTG TGT GAC GTC GAC CTG CAG CGG CTG

WO 03/076567

PCT/US03/03120

- 8 -

TTT GCC ACC ACC ATC TGG CAG CAG ATG GAA GAA CTG GGA ATG GCC CCT  
AAA CGG TGG TGG TAG ACC GTC GTC TAC CTT CTT GAC CCT TAC CGG GGA  
  
GCC CTG CAG CCC ACC CAG GGT GCC ATG CCG GCC TTC GCC TCT GCT TTC  
CGG GAC GTC GGG TGG GTC CCA CGG TAC GGC CGG AAG CGG AGA CGA AAG  
  
CAG CGC CGG GCA GGA GGG GTC CTG GTT GCC TCC CAT CTG CAG AGC TTC  
GTC GCG GCC CGT CCT CCC CAG GAC CAA CGG AGG GTA GAC GTC TCG AAG  
  
CTG GAG GTG TCG TAC CGC GTC TTA AGG CAC CTT GCC CAG CCC  
GAC CTC CAC AGC ATG GCG CAG AAT TCC GTG GAA CGG GTC CGG

d) SEQ ID NO:5

ACC CCC CTG GGC CCT GCC AGC TCC CTG CCC CAG AGC TTC CTG CTC AAG  
TGG GGG GAC CCG GGA CGG TCG AGG GAC GGG GTC TCG AAG GAC GAG TTC  
  
GCC TTA GAG CAA GTG AGG AAG ATC CAG GGC GAT GGC GCA GCG CTC CAG  
CGG AAT CTC GTT CAC TCC TTC TAG GTC CCG CTA CGT CGC GAG GTC  
  
GAG AAG CTG TGT GCC ACC TAC AAG CTG TGC CAC CCC GAG GAG CTG GTG  
CTC TTC GAC ACA CGG TGG ATG TTC GAC ACG GTG GGG CTC CTC GAC CAC  
  
CTG CTC GGA CAC TCT CTG GGC ATC CCC TGG GCT AAC ACT AGC AGC TGC  
GAC GAG CCT GTG ACA GAC CCG TAG GGG ACC CGA TTG GAC TCC TCG ACG  
  
CCC AGC CAG GCC CTG CAG CTG GCA GGC TGC TTG AGC CAA CTC CAT AGC  
GGG TCG GTC CGG GAC GTC GAC CGT CCG ACG AAC TCG GTT GAG GTA TCG  
  
GGC CTT TTC CTC TAC CAG GGG CTC CTG CAG GCC CTG GAA GGG ATC TCC  
CCG GAA AAG GAG ATG GTC CCC GAG GAC GTC CGG GAC CTT CCC TAG AGG  
  
CCC GAG TTG GGT CCC ACC TTG GAC ACA CTG CAG CTG GAC GTC GCC GAC  
GGG CTC AAC CCA CGG TGG AAC CTG TGT GAC GTC GAC CTG CAG CGG CTG  
  
TTT GCC ACC ACC ATC TGG CAG CAG ATG GAA GAA CTG GGA ATG GCC CCT  
AAA CGG TGG TGG TAG ACC GTC GTC TAC CTT CTT GAC CCT TAC CGG GGA  
  
GCC CTG CAG CCC ACC CAG GGT GCC ATG CCG GCC TTC GCC TCT GCT TTC  
CGG GAC GTC GGG TGG GTC CCA CGG TAC GGC CGG AAG CGG AGA CGA AAG  
  
CAG CGC CGG GCA GGA GGG GTC CTG GTT GCC TCC CAT CTG CAG AGC TTC  
GTC GCG GCC CGT CCT CCC CAG GAC CAA CGG AGG GTA GAC GTC TCG AAG  
  
CTG GAG GTG TCG TAC CGC GTC TTA AGG CAC CTT GCC CAG CCC  
GAC CTC CAC AGC ATG GCG CAG AAT TCC GTG GAA CGG GTC CGG

e) SEQ ID NO:6

ACC CCC CTG GGC CCT GCC AGC TCC CTG CCC CAG AGC TTC CTG CTC AAG  
TGG GGG GAC CCG GGA CGG TCG AGG GAC GGG GTC TCG AAG GAC GAG TTC  
  
GCC TTA GAG CAA GTG AGG AAG ATC CAG GGC GAT GGC GCA GCG CTC CAG  
CGG AAT CTC GTT CAC TCC TTC TAG GTC CCG CTA CGT CGC GAG GTC  
  
GAG AAG CTG TGT GCC ACC TAC AAG CTG TGC CAC CCC GAG GAG CTG GTG  
CTC TTC GAC ACA CGG TGG ATG TTC GAC ACG GTG GGG CTC CTC GAC CAC  
  
CTG CTC GGA CAC TCT CTG GGC ATC CCC TGG GCT CCC CTG AGC AAT TGC

WO 03/076567

PCT/US03/03120

- 9 -

GAC GAG CCT GTG ACA GAC CCG TAG GGG ACC CGA GGG GAC TCG TTA ACG  
ACC AGC CAG GCC CTG CAG CTG GCA GGC TGC TTG AGC CAA CTC CAT AGC  
TGG TCG GTC CGG GAC GTC CAG CGT CCG ACG AAC TCG GTT GAG GTA TCG  
GGC CTT TTC CTC TAC CAG GGG CTC CTG CAG GCC CTG GAA GGG ATC TCC  
CCG GAA AAG GAG ATG GTC CCC GAG GAC GTC CGG GAC CTT CCC TAG AGG  
CCC GAG TTG GGT CCC ACC TTG GAC ACA CTG CAG CTG GAC GTC GCC GAC  
GGG CTC AAC CCA GGG TGG AAC CTG TGT GAC GTC GAC CTG CAG CGG CTG  
TTT GCC ACC ACC ATC TGG CAG CAG ATG GAA GAA CTG GGA ATG GCC CCT  
AAA CGG TGG TGG TAG ACC GTC GTC TAC CTT GAC CCT TAC CGG GGA  
GCC CTG CAG CCC ACC CAG GGT GCC ATG CCG GCC TTC GCC TCT GCT TTC  
CGG GAC GTC GGG TGG GTC CCA CGG TAC GGC CGG AAG CGG AGA CGA AAG  
CAG CGC CGG GCA GGA GGG GTC CTG GTT GCC TCC CAT CTG CAG AGC TTC  
GTC GCG GCC CGT CCT CCC CAG GAC CAA CGG AGG GTA GAC GTC TCG AAG  
CTG GAG GTG TCG TAC CGC GTC TTA AGG CAC CTT GCC CAG CCC  
GAC CTC CAC AGC ATG GCG CAG AAT TCC GTG GAA CGG GTC GGG

f) SEQ ID NO: 7

ACC CCC CTG GGC CCT GCC AGC TCC CTG CCC CAG AGC TTC CTG CTC AAG  
TGG GGG GAC CCG GGA CGG TCG AGG GAC GGG GTC TCG AAG GAC GAG TTC

GCC TTA GAG CAA GTG AGG AAG ATC CAG GGC GAT GGC GCA GCG CTC CAG  
CGG AAT CTC GTT CAC TCC TTC TAG GTC CCG CTA CCG CGT CGC GAG GTC

GAG AAG CTG TGT GCC ACC TAC AAG CTG TGC CAC CCC GAG GAG CTG GTG  
CTC TTC GAC ACA CGG TGG ATG TTC GAC ACG GTG GGG CTC CTC GAC CAC

CTG CTC GGA CAC TCT CTG GGC ATC GTT AAC GCT ACC CTG AGC AGC TGC  
GAC GAG CCT GTG ACA GAC CCG TAG CAA TTG CGA TGG GAC TCG TCG ACG

CCC AGC CAG GCC CTG CAG CTG GCA GGC TGC TTG AGC CAA CTC CAT AGC  
GGG TCG GTC CGG GAC GTC GAC CGT CCG ACG AAC TCG GTT GAG GTA TCG

GCC CTT TTC CTC TAC CAG GGG CTC CTG CAG GCC CTG GAA GGG ATC TCC  
CCG GAA AAG GAG ATG GTC CCC GAG GAC GTC CGG GAC CTT CCC TAG AGG

CCC GAG TTG GGT CCC ACC TTG GAC ACA CTG CAG CTG GAC GTC GCC GAC  
GGG CTC AAC CCA GGG TGG AAC CTG TGT GAC GTC GAC CTG CAG CGG CTG

TTT GCC ACC ACC ATC TGG CAG CAG ATG GAA GAA CTG GGA ATG GCC CCT  
AAA CGG TGG TGG TAG ACC GTC GTC TAC CTT CTT GAC CCT TAC CGG GGA

GCC CTG CAG CCC ACC CAG GGT GCC ATG CCG GCC TTC GCC TCT GCT TTC  
CGG GAC GTC GGG TGG GTC CCA CGG TAC GGC CGG AAG CGG AGA CGA AAG

CAG CGC CGG GCA GGA GGG GTC CTG GTT GCC TCC CAT CTG CAG AGC TTC  
GTC GCG GCC CGT CCT CCC CAG GAC CAA CGG AGG GTA GAC GTC TCG AAG

CTG GAG GTG TCG TAC CGC GTC TTA AGG CAC CTT GCC CAG CCC  
GAC CTC CAC AGC ATG GCG CAG AAT TCC GTG GAA CGG GTC GGG

WO 03/076567

PCT/US03/03120

- 10 -

g) SEQ ID NO:8

ACC CCC CTG GGC CCT GCC AGC TCC CTG CCC CAG AGC TTC CTG CTC AAG  
TGG GGG GAC CCG GGA CGG TCG AGG GAC GGG GTC TCG AAG GAC GAG TTC  
  
GCC TTA GAG CAA GTG AGG AAG ATC CAG GGC GAT GGC GCA GCG CTC CAG  
CGG AAT CTC GTT CAC TCC TTC TAG GTC CCG CTA CCG CGT CGC GAG GTC  
  
GAG AAG CTG TGT GCC ACC TAC AAG CTG TGC CAC CCC GAG GAG CTG GTG  
CTC TTC GAC ACA CGG TGG ATG TTC GAC ACG GTG GGG CTC CTC GAC CAC  
  
CTG CTC GGA CAC TCT CTG GGC ATC CCC TGG GCT CCC CTG AGC AGC TGC  
GAC GAG CCT GTG ACA GAC CCG TAG GGG ACC CGA GGG GAC TCG TCG ACG  
  
CCC AGC AAC GCC ACC CAG CTG GCA GGC TGC TTG AGC CAA CTC CAT AGC  
GGG TCG TTG CGG TGG GTC GAC CGT CCG AAC TCG GTT GAG GTA TCG  
  
GGC CTT TTC CTC TAC CAG GGG CTC CTG CAG GCC CTG GAA GGG ATC TCC  
CCG GAA AAG GAG ATG GTC CCC GAG GAC GTC CGG GAC CTT CCC TAG AGG  
  
CCC GAG TTG GGT CCC ACC TTG GAC ACA CTG CAG CTG GAC GTC GCC GAC  
GGG CTC AAC CCA GGG TGG AAC CTG TGT GAC GTC CTG CAG CGG CTG  
  
TTT GCC ACC ACC ATC TGG CAG CAG ATG GAA GAA CTG GGA ATG GCC CCT  
AAA CGG TGG TGG TAG ACC GTC GTC TAC CTT CTT GAC CCT TAC CGG GGA  
  
GCC CTG CAG CCC ACC CAG GGT GCC ATG CCG GCC TTC GCC TCT GCT TTC  
CCG GAC GTC GGG TGG GTC CCA CGG TAC GGC CGG AAG CGG AGA CGA AAG  
  
CAG CGC CGG GCA GGA GGG GTC CTG GTT GCC TCC CAT CTG CAG AGC TTC  
GTC GCG GCC CGT CCT CCC CAG GAC CAA CGG AGG GTA GAC GTC TCG AAG  
  
CTG GAG GTG TCG TAC CGC GTC TTA AGG CAC CTT GCC CAG CCC  
GAC CTC CAC AGC ATG GCG CAG AAT TCC GTG GAA CGG GTC GGG

h) SEQ ID NO:9

ACC CCC CTG GGC CCT GCC AGC TCC CTG CCC CAG AGC TTC CTG CTC AAG  
TGG GGG GAC CCG GGA CGG TCG AGG GAC GGG GTC TCG AAG GAC GAG TTC  
  
GCC TTA GAG CAA GTG AGG AAG ATC CAG GGC GAT GGC GCA GCG CTC CAG  
CGG AAT CTC GTT CAC TCC TTC TAG GTC CCG CTA CCG CGT CGC GAG GTC  
  
GAG AAG CTG TGT GCC ACC TAC AAG CTG TGC CAC CCC GAG GAG CTG GTG  
CTC TTC GAC ACA CGG TGG ATG TTC GAC ACG GTG GGG CTC CTC GAC CAC  
  
CTG CTC GGA CAC TCT CTG GGC ATC CCC TGG GCT CCC CTG AGC AGC TGC  
GAC GAG CCT GTG ACA GAC CCG TAG GGG ACC CGA GGG GAC TCG TCG ACG  
  
CCC AGC CAG GCC CTG CAG CTG GCA GGC TGC TTG AGC CAA CTC CAT AGC  
GGG TCG GTC CGG GAC GTC GAC CGT CCG ACN AAC TCG GTT GAG GTA TCG  
  
GGC CTT TTC CTC TAC CAG GGG CTC CTG CAG GCC CTG AAC GGG ACC TCC  
CCG GAA AAG GAG ATG GTC CCC GAG GAC GTC CGG GAC TTG CCC TGG AGG  
  
CCC GAG TTG GGT CCC ACC TTG GAC ACA CTG CAG CTG GAC GTC GCC GAC  
GGG CTC AAC CCA GGG TGG AAC CTG TGT GAC GTC GAC CTG CAG CGG CTG  
  
TTT GCC ACC ACC ATC TGG CAG CAG ATG GAA GAA CTG GGA ATG GCC CCT  
AAA CGG TGG TGG TAG ACC GTC GTC TAC CTT GAC CCT TAC CGG GGA

WO 03/076567

PCT/US03/03120

- 11 -

GCC CTG CAG CCC ACC CAG GGT GCC ATG CCG GCC TTC GCC TCT GCT TTC  
CGG GAC GTC GGG TGG GTC CCA CGG TAC GGC CGG AAG CGG AGA CGA AAG

CAG CGC CGG GCA GGA GGG GTC CTG GTT GCC TCC CAT CTG CAG AGC TTC  
GTC GCG GCC CGT CCT CCC CAG GAC CAA CGG AGG GTA GAC GTC TCG AAG

CTG GAG GTG TCG TAC CGC GTC TTA AGG CAC CTT GCC CAG CCC  
GAC CTC CAC AGC ATG GCG CAG AAT TCC GTG GAA CGG GTC GGG

i) SEQ ID NO:10

ACC CCC CTG GGC CCT GCC AGC TCC CTG CCC CAG AGC TTC CTG CTC AAG  
TGG GGG GAC CCG GGA CGG TCG AGG GAC GGG GTC TCG AAG GAC GAG TTC

GCC TTA GAG CAA GTG AGG AAG ATC CAG GGC GAT GGC GCA GCG CTC CAG  
CGG AAT CTC GTT CAC TCC TTC TAG GTC CCG CTA CCG CGT CGC GAG GTC

GAG AAG CTG TGT AAC ACC ACC AAG CTG TGC CAC CCC GAG GAG CTG GTG  
CTC TTC GAC ACA TTG TGG TTC GAC ACG GTG GGG CTC CTC GAC CAC

CTG CTC GGA CAC TCT CTG GGC ATC CCC TGG GCT CCC CTG AGC AGC TGC  
GAC GAG CCT GTG ACA GAC CCG TAG GGG ACC CGA GGG GAC TCG TCG ACG

CCC AGC CAG GCC CTG CAG CTG GCA GGC TGC TTG AGC CAA CTC CAT AGC  
GGG TCG GTC CGG GAC GTC CGT CCG ACG AAC TCG GTT GAG GTA TCG

GGC CTT TTC CTC TAC CAG GGG CTC CTG CAG GCC CTG GAA GGG ATC TCC  
CCG GAA AAG GAG ATG GTC CCC GAG GAC GTC CGG GAC CTT CCC TAG AGG

CCC GAG TTG GGT CCC ACC TTG GAC ACA CTG CAG CTG GAC GTC GCC GAC  
GGG CTC AAC CCA GGG TGG AAC CTG TGT GAC GTC GAC CTG CAG CGG CTG

TTT GCC ACC ACC ATC TGG CAG CAG ATG GAA GAA CTG GGA ATG GCC CCT  
AAA CGG TGG TGG TAG ACC GTC GTC TAC CTT CTT GAC CCT TAC CGG GGA

GCC CTG CAG CCC AAC CAG ACC GCC ATG CCG GCC TTC GCC TCT GCT TTC  
CGG GAC GTC GGG TTG GTC TGG CGG TAC GGC CGG AAG CGG AGA CGA AAG

CAG CGC CGG GCA GGA GGG GTC CTG GTT GCC TCC CAT CTG CAG AGC TTC  
GTC GCG GCC CGT CCT CCC CAG GAC CAA CGG AGG GTA GAC GTC TCG AAG

CTG GAG GTG TCG TAC CGC GTC TTA AGG CAC CTT GCC CAG CCC  
GAC CTC CAC AGC ATG GCG CAG AAT TCC GTG GAA CGG GTC GGG

j) SEQ ID NO:11

ACC CCC CTG GGC CCT GCC AGC TCC CTG CCC CAG AGC TTC CTG CTC AAG  
TGG GGG GAC CCG GGA CGG TCG AGG GAC GGG GTC TCG AAG GAC GAG TTC

GCC TTA GAG CAA GTG AGG AAG ATC CAG GGC GAT GGC GCA GCG CTC CAG  
CGG AAT CTC GTT CAC TCC TTC TAG GTC CCG CTA CCG CGT CGC GAG GTC

GAG AAG CTG TGT AAC ACC ACC AAG CTG TGC CAC CCC GAG GAG CTG GTG  
CTC TTC GAC ACA TTG TGG TTC GAC ACG GTG GGG CTC CTC GAC CAC

CTG CTC GGA CAC TCT CTG GGC ATC CCC TGG GCT CCC CTG AGC AGC TGC  
GAC GAG CCT GTG ACA GAC CCG TAG GGG ACC CGA GGG GAC TCG TCG ACG

WO 03/076567

PCT/US03/03120

- 12 -

CCC AGC CAG GCC CTG CAG CTG GCA GGC TGC TTG AGC CAA CTC CAT AGC  
GGG TCG GTC CGG GAC GTC GAC CGT CCG ACG AAC TCG GTT GAG GTA TCG  
  
GGC CTT TTC CTC TAC CAG GGG CTC CTG CAG GCC CTG GAA GGG ATC TCC  
CCG GAA AAG GAG ATG GTC CCC GAG GAC GTC CGG GAC CTT CCC TAG AGG  
  
CCC GAG TTG GGT CCC ACC TTG GAC ACA CTG CAG CTG GAC GTC GCC GAC  
GGG CTC AAC CCA GGG TGG AAC CTG TGT GAC GTC GAC CTG CAG CGG CTG  
  
TTT GCC ACC ACC ATC TGG CAG CAG ATG GAA GAA CTG GGA ATG GCC CCT  
AAA CGG TGG TGG TAG ACC GTC GTC TAC CTT GAC CCT TAC CGG GGA  
  
GCC CTG CAG CCC ACC CAG GGT GCC ATG CCG GCC TTC AAC TCT ACC TTC  
CGG GAC GTC GGG TGG GTC CCA CGG TAC GGC CGG AAG TTG AGA TGG AAG  
  
CAG CGC CGG GCA GGA GGG GTC CTG GTT GCC TCC CAT CTG CAG AGC TTC  
GTC GCG GCC CGT CCT CCC CAG GAC CAA CGG AGG GTA GAC GTC TCG AAG  
  
CTG GAG GTG TCG TAC CGC GTC TTA AGG CAC CTT GCC CAG CCC  
GAC CTC CAC AGC ATG GCG CAG AAT TCC GTG GAA CGG GTC GGG  
  
k) SEQ ID NO:12

ACC CCC CTG GGC CCT GCC AGC TCC CTG CCC CAG AGC TTC CTG CTC AAG  
TGG GGG GAC CCG GGA CGG TCG AGG GAC GGG GTC TCG AAG GAC GAG TTC  
  
GCC TTA GAG CAA GTG AGG AAG ATC CAG GGC GAT GGC GCA GCG CTC CAG  
CGG AAT CTC GTT CAC TCC TTC TAG GTC CCG CTA CCG CGT CGC GAG GTC  
  
GAG AAG CTG TGT AAC ACC ACC AAG CTG TGC CAC CCC GAG GAG CTG GTG  
CTC TTC GAC ACA TTG TGG TGG TTC GAC ACG GTG GGG CTC CTC GAC CAC  
  
CTG CTC GGA CAC TCT CTG GGC ATC GTT AAC GCT ACC CTG AGC AGC TGC  
GAC GAG CCT GTG ACA GAC CCG TAG CAA TTG CGA TGG GAC TCG TCG ACG  
  
CCC AGC CAG GCC CTG CAG CTG GCA GGC TGC TTG AGC CAA CTC CAT AGC  
GGG TCG GTC CGG GAC GTC GAC CGT CCG ACG AAC TCG GTT GAG GTA TCG  
  
GGC CTT TTC CTC TAC CAG GGG CTC CTG CAG GCC CTG GAA GGG ATC TCC  
CCG GAA AAG GAG ATG GTC CCC GAG GAC GTC CGG GAC CTT CCC TAG AGG  
  
CCC GAG TTG GGT CCC ACC TTG GAC ACA CTG CAG CTG GAC GTC GCC GAC  
GGG CTC AAC CCA GGG TGG AAC CTG TGT GAC GTC GAC CTG CAG CGG CTG  
  
TTT GCC ACC ACC ATC TGG CAG CAG ATG GAA GAA CTG GGA ATG GCC CCT  
AAA CGG TGG TGG TAG ACC GTC GTC TAC CTT GAC CCT TAC CGG GGA  
  
GCC CTG CAG CCC ACC CAG GGT GCC ATG CCG GCC TTC GCC TCT GCT TTC  
CGG GAC GTC GGG TGG GTC CCA CGG TAC GGC CGG AAG CGG AGA CGA AAG  
  
CAG CGC CGG GCA GGA GGG GTC CTG GTT GCC TCC CAT CTG CAG AGC TTC  
GTC GCG GCC CGT CCT CCC CAG GAC CAA CGG AGG GTA GAC GTC TCG AAG  
  
CTG GAG GTG TCG TAC CGC GTC TTA AGG CAC CTT GCC CAG CCC  
GAC CTC CAC AGC ATG GCG CAG AAT TCC GTG GAA CGG GTC GGG

1) SEQ ID NO:13

ACC CCC CTG GGC CCT GCC AGC TCC CTG CCC CAG AGC TTC CTG CTC AAG  
TGG GGG GAC CCG GGA CGG TCG AGG GAC GGG GTC TCG AAG GAC GAG TTC

WO 03/076567

PCT/US03/03120

- 13 -

GCC TTA GAG CAA GTG AGG AAG ATC CAG GGC GAT GGC GCA GCG CTC CAG  
CGG AAT CTC GTT CAC TCC TTC TAG GTC CCG CTA CCG CGT CGC GAG GTC  
  
GAG AAG CTG TGT AAC ACC ACC AAG CTG TGC CAC CCC GAG GAG CTG GTG  
CTC TTC GAC ACA TTG TGG TGG TTC GAC ACG GTG GGG CTC CTC GAC CAC  
  
CTG CTC GGA CAC TCT CTG GGC ATC CCC TGG GCT CCC CTG AGC AGC TGC  
GAC GAG CCT GTG ACA GAC CCG TAG GGG ACC CGA GGG GAC TCG TCG ACG  
  
CCC AGC AAC GCC ACC CAG CTG GCA GGC TGC TTG AGC CAA CTC CAT AGC  
GGG TCG TTG CGG TGG GTC GAC CGT CCG ACG AAC TCG GTT GAG GTA TCG  
  
GGC CTT TTC CTC TAC CAG GGG CTC CTG CAG GCC CTG GAA GGG ATC TCC  
CCG GAA AAG GAG ATG GTC CCC GAG GAC GTC CGG GAC CTT CCC TAG AGG  
  
CCC GAG TTG GGT CCC ACC TTG GAC ACA CTG CAG CTG GAC GTC GCC GAC  
GGG CTC AAC CCA GGG TGG AAC CTG TGT GAC GTC CTG CAG CGG CTG  
  
TTT GCC ACC ACC ATC TGG CAG CAG ATG GAA GAA CTG GGA ATG GCC CCT  
AAA CGG TGG TAG ACC GTC GTC TAC CTT GAC CCT TAC CGG GGA  
  
GCC CTG CAG CCC ACC CAG GGT GCC ATG CCG GCC TTC GCC TCT GCT TTC  
CCG GAC GTC GGG TGG GTC CCA CGG TAC GGC CGG AAG CGG AGA CGA AAG  
  
CAG CGC CGG GCA GGA GGG GTC CTG GTT GCC TCC CAT CTG CAG AGC TTC  
GTC GCG GCC CGT CCT CCC CAG GAC CAA CGG AGG GTA GAC GTC TCG AAG  
  
CTG GAG GTG TCG TAC CGC GTC TTA AGG CAC CTT GCC CAG CCC  
GAC CTC CAC AGC ATG GCG CAG AAT TCC GTG GAA CGG GTC GGG  
  
m) SEQ ID NO:14  
ACC CCC CTG GGC CCT GCC AGC TCC CTG CCC CAG AGC TTC CTG CTC AAG  
TGG GGG GAC CCG GGA CGG TCG AGG GAC GGG GTC TCG AAG GAC GAG TTC  
  
GCC TTA GAG CAA GTG AGG AAG ATC CAG GGC GAT GGC GCA GCG CTC CAG  
CGG AAT CTC GTT CAC TCC TTC TAG GTC CCG CTA CCG CGT CGC GAG GTC  
  
GAG AAG CTG TGT AAC ACC ACC AAG CTG TGC CAC CCC GAG GAG CTG GTG  
CTC TTC GAC ACA TTG TGG TGG TTC GAC ACG GTG GGG CTC CTC GAC CAC  
  
CTG CTC GGA CAC TCT CTG GGC ATC CCC TGG GCT CCC CTG AGC AGC TGC  
GAC GAG CCT GTG ACA GAC CCG TAG GGG ACC CGA GGG GAC TCG TCG ACG  
  
CCC AGC CAG GCC CTG CAG CTG GCA GGC TGC TTG AGC CAA CTC CAT AGC  
GGG TCG GTC CGG GAC GTC GAC CGT CCG ACG AAC TCG GTT GAG GTA TCG  
  
GGC CTT TTC CTC TAC CAG GGG CTC CTG CAG GCC CTG GAA GGG ATC TCC  
CCG GAA AAG GAG ATG GTC CCC GAG GAC GTC CGG GAC CTT CCC TAG AGG  
  
AAC GGT ACC GGT CCC ACC TTG GAC ACA CTG CAG CTG GAC GTC GCC GAC  
TTG CCA TGG CCA GGG TGG AAC CTG TGT GAC GTC GAC CTG CAG CGG CTG  
  
TTT GCC ACC ACC ATC TGG CAG CAG ATG GAA GAA CTG GGA ATG GCC CCT  
AAA CGG TGG TGG TAG ACC GTC GTC TAC CTT GAC CCT TAC CGG GGA  
  
GCC CTG CAG CCC ACC CAG GGT GCC ATG CCG GCC TTC GCC TCT GCT TTC

WO 03/076567

PCT/US03/03120

- 14 -

CGG GAC GTC GGG TGG GTC CCA CGG TAC GGC CGG AAG CGG AGA CGA AAG  
CAG CGC CGG GCA GGA GGG GTC CTG GTT GCC TCC CAT CTG CAG AGC TTC  
GTC GCG GCC CGT CCT CCC CAG GAC CAA CGG AGG GTA GAC GTC TCG AAG  
CTG GAG GTG TCG TAC CGC GTC TTA AGG CAC CTT GCC CAG CCC  
GAC CTC CAC AGC ATG GCG CAG AAT TCC GTG GAA CGG GTC GGG

n) SEQ ID NO:15

ACC CCC CTG GGC CCT GCC AGC TCC CTG CCC CAG AGC TTC CTG CTC AAG  
TGG GGG GAC CCG GGA CGG TCG AGG GAC GGG GTC TCG AAG GAC GAG TTC

GCC TTA GAG CAA GTG AGG AAG ATC CAG GGC GAT GGC GCA GCG CTC CAG  
CGG AAT CTC GTT CAC TTC TAG GTC CCG CTA CGT CGC GAG GTC

GAG AAG CTG TGT AAC ACC ACC AAG CTG TGC CAC CCC GAG GAG CTG GTG  
CTC TTC GAC ACA TTG TGG TTC GAC ACG GTG GGG CTC CTC GAC CAC

CTG CTC GGA CAC TCT CTG GGC ATC GTT AAC GCT ACC CTG AGC AGC TGC  
GAC GAG CCT GTG ACA GAC CCG TAG CAA TTG CGA TGG GAC TCG TCG ACG

CCC AGC AAC GCC ACC CAG CTG GCA GGC TGC TTG AGC CAA CTC CAT AGC  
GGG TCG TTG CGG TGG GTC GAC CGT CCG ACG AAC TCG GTT GAG GTA TCG

GGC CTT TTC CTC TAC CAG GGG CTC CTG CAG GCC CTG GAA GGG ATC TCC  
CCG GAA AAG GAG ATG GTC CCC GAG GAC GTC CGG GAC CTT CCC TAG AGG

CCC GAG TTG GGT CCC ACC TTG GAC ACA CTG CAG CTG GAC GTC GCC GAC  
GGG CTC AAC CCA GGG TGG AAC CTG TGT GAC GTC GAC CTG CAG CGG CTG

TTT GCC ACC ACC ATC TGG CAG CAG ATG GAA GAA CTG GGA ATG GCC CCT  
AAA CGG TGG TGG TAG ACC GTC GTC TAC CTT CTT GAC CCT TAC CGG GGA

GCC CTG CAG CCC ACC CAG GGT GCC ATG CCG GCC TTC GCC TCT GCT TTC  
CGG GAC GTC GGG TGG GTC CCA CGG TAC GGC CGG AAG CGG AGA CGA AAG

CAG CGC CGG GCA GGA GGG GTC CTG GTT GCC TCC CAT CTG CAG AGC TTC  
GTC GCG GCC CGT CCT CCC CAG GAC CAA CGG AGG GTA GAC GTC TCG AAG

CTG GAG GTG TCG TAC CGC GTC TTA AGG CAC CTT GCC CAG CCC  
GAC CTC CAC AGC ATG GCG CAG AAT TCC GTG GAA CGG GTC GGG

o) SEQ ID NO:16

ACC CCC CTG GGC CCT GCC AGC TCC CTG CCC CAG AGC TTC CTG CTC AAG  
TGG GGG GAC CCG GGA CGG TCG AGG GAC GGG GTC TCG AAG GAC GAG TTC

GCC TTA GAG CAA GTG AGG AAG ATC CAG GGC GAT GGC GCA GCG CTC CAG  
CGG AAT CTC GTT CAC TTC TAG GTC CCG CTA CGT CGC GAG GTC

GAG AAG CTG TGT AAC ACC ACC AAG CTG TGC CAC CCC GAG GAG CTG GTG  
CTC TTC GAC ACA TTG TGG TGG TTC GAC ACG GTG GGG CTC CTC GAC CAC

CTG CTC GGA CAC TCT CTG GGC ATC CCC TGG GCT CCC CTG AGC AAT TGC  
GAC GAG CCT GTG ACA GAC CCG TAG GGG ACC CGA GGG GAC TCG TTA ACG

ACC AGC CAG GCC CTG CAG CTG GCA GGC TGC TTG AGC CAA CTC CAT AGC  
TGG TCG GTC CGG GAC GTC GAC CGT CCG ACG AAC TCG GTT GAG GTA TCG

WO 03/076567

PCT/US03/03120

- 15 -

GGC CTT TTC CTC TAC CAG GGG CTC CTG CAG GCC CTG AAC GGG ACC TCC  
CCG GAA AAG GAG ATG GTC CCC GAG GAC GTC CGG GAC TTG CCC TGG AGG  
  
CCC GAG TTG GGT CCC ACC TTG GAC ACA CTG CAG CTG GAC GTC GCC GAC  
GGG CTC AAC CCA GGG TGG AAC CTG TGT GAC GTC GAC CTG CAG CGG CTG  
  
TTT GCC ACC ACC ATC TGG CAG CAG ATG GAA GAA CTG GGA ATG GCC CCT  
AAA CGG TGG TGG TAG ACC GTC GTC TAC CTT CTT GAC CCT TAC CGG GGA  
  
GCC CTG CAG CCC ACC CAG GGT GCC ATG CCG GCC TTC GCC TCT GCT TTC  
CGG GAC GTC GGG TGG GTC CCA CGG TAC GGC CGG AAG CGG AGA CGA AAG  
  
CAG CGC CGG GCA GGA GGG GTC CTG GTT GCC TCC CAT CTG CAG AGC TTC  
GTC GCG GCC CGT CCT CCC CAG GAC CAA CGG AGG GTA GAC GTC TCG AAG  
  
CTG GAG GTG TCG TAC CGC GTC TTA AGG CAC CTT GCC CAG CCC  
GAC CTC CAC AGC ATG GCG CAG AAT TCC GTG GAA CGG GTC GGG

A hyperglycosylated heterologous fusion protein of the present invention also includes polynucleotides encoding the heterologous fusion protein described herein, vectors comprising these polynucleotides and host cells transfected or transformed with the vectors described herein. Also included is a process for producing a heterologous fusion protein comprising the steps of transcribing and translating a polynucleotide described herein under conditions wherein the heterologous fusion protein is expressed in detectable amounts.

The present invention encompasses a method for increasing neutrophil levels in a mammal comprising the administration of a therapeutically effective amount of a heterologous fusion protein described above. The present invention also includes the use of the heterologous fusion proteins described above for the manufacture of a medicament for the treatment of patients with insufficient circulating neutrophil levels.

The present invention also encompasses a pharmaceutical formulation adapted for the treatment of patients with insufficient neutrophil levels comprising a glycosylated protein as described above.

WO 03/076567

PCT/US03/03120

- 16 -

BRIEF DESCRIPTION OF THE FIGURES

The invention is further illustrated with reference to the following drawings:

Figure 1: Schematic illustrating fourteen regions in human G-CSF wherein the amino acid sequence can be mutated to create functional glycosylation sites.

Figure 2a: IgG1 Fc amino acid sequence encompassing the hinge region, CH2 and CH3 domains.

Figure 2b: IgG4 Fc amino acid sequence encompassing the hinge region, CH2 and CH3 domains.

Figure 3: Human serum albumin amino acid sequence

Figure 4: IgG1 Fc DNA sequence

Figure 5: IgG4 Fc DNA sequence with Ser229Pro mutation.

Figure 6: G-CSF/IgG1 Fc fusion protein

Figure 7: G-CSF/IgG4 Fc fusion protein

Figure 8: G-CSF/HA fusion protein.

The present invention comprises a heterologous fusion protein. As used herein, the term heterologous fusion protein means a hyperglycosylated G-CSF analog fused to human albumin, a human albumin analog, a human albumin fragment, the Fc portion of an immunoglobulin, an analog of the Fc portion of an immunoglobulin, or a fragment of the Fc portion of an immunoglobulin. The G-CSF analog may be fused directly, or fused via a peptide linker, to an albumin or Fc protein. The albumin and Fc portion may be fused to the G-CSF analogs at either terminus or at both termini. These heterologous fusion proteins are biologically active and have an increased half-life compared to native G-CSF.

*Hyperglycosylated G-CSF Analogs*

Encompassed by the invention are certain hyperglycosylated analogs of G-CSF. Analogs of G-CSF refer to human G-CSF with one or more changes in the amino acid

WO 03/076567

PCT/US03/03120

- 17 -

sequence which result in an increase in the number of sites for carbohydrate attachment compared with native human G-CSF expressed in animal cells *in vivo*. In addition, G-CSF analogs include human G-CSF wherein the O-linked glycosylation site at position 133 is replaced with an N-linked glycosylation site. Analogs are generated by site directed mutagenesis having substitution of amino acid residues creating new sites that are available for glycosylation. Analogs having a greater carbohydrate content than that found in native human G-CSF are generated by adding glycosylation sites that do not perturb the secondary, tertiary, and quaternary structure required for activity. Furthermore, because the hyperglycosylated analogs of the present invention have a larger mass and an increased negative charge compared to native G-CSF, they will not be as rapidly cleared from the circulation.

It is preferred that the G-CSF analog have 1, 2, 3, or 4 additional sites for N-glycosylation. Figure 1 illustrates fourteen different regions that can be glycosylated with very little effect on *in vitro* activity. Each region may be mutated to the consensus site for N-glycosylation addition which is Asn X<sub>1</sub> X<sub>2</sub> wherein X<sub>1</sub> is any amino acid except Pro and X<sub>2</sub> is Ser or Thr. It is preferred that the X<sub>1</sub> amino acid be any other amino acid except Trp, Asp, Glu, or Leu and it is most preferred that the X<sub>1</sub> amino acid be the naturally occurring amino acid. The scope of the present invention includes analogs wherein a single region (1 through 14) is mutated or wherein a region is mutated in combination with one or more other regions.

Analogs having carbohydrate attached to only a single mutated site have been expressed, purified, characterized, and tested for activity. Similarly analogs with multiple glycosylation sites have been expressed, purified, characterized, and tested for activity. For example G-CSF[A37N,Y39T] is G-CSF wherein the amino acids at positions 37 and 39 have been substituted to create a glycosylation

WO 03/076567

PCT/US03/03120

- 18 -

site. This site of carbohydrate attachment is illustrated as region 1 in Figure 1. G-CSF [A37N, Y39T, P57V, W58N, P60T] is an example of a G-CSF analog wherein amino acids in region 1 and region 2 are mutated to provide two functional glycosylation sites on a single molecule (Figure 1).

G-CSF [A37N, Y39T, P57V, W58N, P60T, Q67N, L69T] is an example of a G-CSF analog wherein the amino acids in region 1, region 2, and region 9 are mutated to provide three functional glycosylation sites on a single molecule (Figure 1).

Native G-CSF can be used as the backbone to create the glycosylated G-CSF analogs of the present invention. In addition, the native G-CSF backbone used to create the analogs of the present invention can be modified such that substitutions in the regions defined in Figure 1 are made in the context of a different or improved G-CSF protein. For example, native G-CSF with a Cysteine to Alanine substitution at position 17 may reduce aggregation and enhance stability and thus, can be used as the backbone used to create the glycosylated G-CSF analogs of the present invention.

In addition, Reidhaar-Olson et al., through alanine scanning mutagenesis, describe residues critical to the activity of human G-CSF. [Reidhaar-Olson et al. (1996) *Biochemistry* 35:9034-9041; See also Young et al. (1997) *Protein Science* 6:1228-1236]. Thus, the glycosylated analogs of the present invention can be modified by substituting amino acids outside the glycosylated regions described in Figure 1.

As outlined above, amino acid substitutions in the fusion proteins of the present invention can be based on the relative similarity of the amino acid side-chain substituents, for example, their hydrophobicity,

WO 03/076567

PCT/US03/03120

- 19 -

hydrophilicity, charge, size, etc. Furthermore, substitutions can be made based on secondary structure propensity. For example, a helical amino acid can be replaced with an amino acid that would preserve the helical structure. Exemplary substitutions that take various of the foregoing characteristics into consideration in order to produce conservative amino acid changes resulting in silent changes within the present peptides, etc., can be selected from other members of the class to which the naturally occurring amino acid belongs.

The present invention also encompasses G-CSF analogs wherein the O-linked glycosylation site at position 133 is mutated to serve as an N-linked glycosylation site. The N-linked carbohydrate will generally have a higher sialic acid content which will protect it from the rapid clearance mechanisms associated with native G-CSF.

The functions of a carbohydrate chain greatly depends on the structure of the attached carbohydrate moiety. Typically compounds with a higher sialic acid content will have better stability and longer half-lives *in vivo*. The N-linked oligosaccharides contain sialic acid in both an  $\alpha$ 2,3 and an  $\alpha$ 2,6 linkage to galactose. [Takeuchi et al. (1988) *J. Biol. Chem.* 263:3657]. Typically the sialic acid in the  $\alpha$ 2,3 linkage is added to galactose on the mannose  $\alpha$ 1,6 branch and the sialic acid in the  $\alpha$ 2,6 linkage is added to the galactose on the mannose  $\alpha$ 1,3 branch. The enzymes that add these sialic acids ( $\beta$ -galactoside  $\alpha$ 2,3 sialyltransferase and  $\beta$ -galactoside  $\alpha$ 2,6 sialyltransferase) are most efficient at adding sialic acid to the mannose  $\alpha$ 1,6 and mannose  $\alpha$ 1,3 branches respectively.

Tetra-antennary N-linked oligosaccharides most commonly provide four possible sites for sialic acid attachment while bi- and tri-antennary oligosaccharide chains, which can substitute for the tetra-antennary form at Asn-like sites, commonly have at most only two or three sialic acids attached. O-linked oligosaccharides commonly provide only

WO 03/076567

PCT/US03/03120

- 20 -

two sites for sialic acid attachment. Mammalian cell cultures can be screened for those cells that preferentially add teta-antennary chains to the G-CSF analogs of the present invention, thereby maximizing the number of sites for sialic acid attachment. Different types of mammalian cells also differ with respect to the transferase enzymes present and consequently the sialic acid content and type of oligosachharide attached at each site. One way to optimize the carbohydrate content for a given G-CSF analog is to express the analog in a cell line wherein an expression plasmid containing DNA encoding a specific sialyl transferase (e.g.,  $\alpha$ 2,6 sialyltrasnferase) is co-transfected with the G-CSF analog expression plasmid. Alternatively a host cell line may be stably transfected with a sialyltransferase cDNA and that host cell used to express the G-CSF analog of interest. Thus, it is preferable if the oligosaccharide structure and sialic acid content are optimized for each analog encompassed by the present invention.

Heterologous Fc fusion proteins:

The hyperglycosylated G-CSF analogs described above can be fused directly or via a peptide linker to the Fc portion of an immunoglobulin. (See Figures 6-7).

Immunoglobulins are molecules containing polypeptide chains held together by disulfide bonds, typically having two light chains and two heavy chains. In each chain, one domain (V) has a variable amino acid sequence depending on the antibody specificity of the molecule. The other domains (C) have a rather constant sequence common to molecules of the same class.

As used herein, the Fc portion of an immunoglobulin has the meaning commonly given to the term in the field of immunology. Specifically, this term refers to an antibody fragment which is obtained by removing the two antigen binding regions (the Fab fragments) from the antibody.

WO 03/076567

PCT/US03/03120

- 21 -

Thus, the Fc portion is formed from approximately equal sized fragments of the constant region from both heavy chains, which associate through non-covalent interactions and disulfide bonds. The Fc portion can include the hinge regions and extend through the CH<sub>2</sub> and CH<sub>3</sub> domains to the C-terminus of the antibody. Representative hinge regions for human and mouse immunoglobulins can be found in *Antibody Engineering, A Practical Guide*, Borrebaeck, C.A.K., ed., W.H. Freeman and Co., 1992, the teachings of which are herein incorporated by reference. The amino acid sequence of a representative Fc protein containing a hinge region, CH<sub>2</sub> and CH<sub>3</sub> domains is shown in Figures 2a and 2b.

There are five types of human immunoglobulin Fc regions with different effector and pharmacokinetic properties: IgG, IgA, IgM, IgD, and IgE. IgG is the most abundant immunoglobulin in serum. IgG also has the longest half-life in serum of any immunoglobulin (23 days). Unlike other immunoglobulins, IgG is efficiently recirculated following binding to an Fc receptor. There are four IgG subclasses G1, G2, G3, and G4, each of which have different effector functions. G1, G2, and G3 can bind C1q and fix complement while G4 cannot. Even though G3 is able to bind C1q more efficiently than G1, G1 is more effective at mediating complement-directed cell lysis. G2 fixes complement very inefficiently. The C1q binding site in IgG is located at the carboxy terminal region of the CH<sub>2</sub> domain.

All IgG subclasses are capable of binding to Fc receptors (CD16, CD32, CD64) with G1 and G3 being more effective than G2 and G4. The Fc receptor-binding region of IgG is formed by residues located in both the hinge and the carboxy terminal regions of the CH<sub>2</sub> domain.

IgA can exist both in a monomeric and dimeric form held together by a J-chain. IgA is the second most abundant Ig in serum, but it has a half-life of only 6 days. IgA has three effector functions. It binds to an IgA specific receptor on macrophages and eosinophils, which drives

WO 03/076567

PCT/US03/03120

- 22 -

phagocytosis and degranulation, respectively. It can also fix complement via an unknown alternative pathway.

IgM is expressed as either a pentamer or a hexamer, both of which are held together by a J-chain. IgM has a serum half-life of 5 days. It binds weakly to C1q via a binding site located in its CH3 domain. IgD has a half-life of 3 days in serum. It is unclear what effector functions are attributable to this Ig. IgE is a monomeric Ig and has a serum half-life of 2.5 days. IgE binds to two Fc receptors which drives degranulation and results in the release of proinflammatory agents.

Depending on the desired *in vivo* effect, the heterologous fusion proteins of the present invention may contain any of the isotypes described above or may contain mutated Fc regions wherein the complement and/or Fc receptor binding functions have been altered. For example, one embodiment of the present invention is a Ser229Pro mutation in IgG4 Fc, which reduces monomer formation. See Figure 5.

The heterologous fusion proteins of the present invention may contain the entire Fc portion of an immunoglobulin, fragments of the Fc portion of an immunoglobulin, or analogs thereof fused to a G-CSF analog. Furthermore, the Fc portion may be fused at either terminus or at both termini.

The heterologous fusion proteins of the present invention can consist of single chain proteins or as multi-chain polypeptides. Two or more Fc fusion proteins can be produced such that they interact through disulfide bonds that naturally form between Fc regions. These multimers can be homogeneous with respect to the G-CSF analog or they may contain different G-CSF analogs fused at the N-terminus of the Fc portion of the fusion protein.

Regardless of the final structure of the fusion protein, the Fc or Fc-like region must serve to prolong the *in vivo* plasma half-life of the G-CSF analog compared to the native G-CSF. Furthermore, the fused G-CSF analog must

WO 03/076567

PCT/US03/03120

- 23 -

retain some biological activity. Biological activity can be determined by in vitro and in vivo methods known in the art.

Since the Fc region of IgG produced by proteolysis has the same in vivo half-life as the intact IgG molecule and Fab fragments are rapidly degraded, it is believed that the relevant sequence for prolonging half-life resides in the CH<sub>2</sub> and/or CH<sub>3</sub> domains. Further, it has been shown in the literature that the catabolic rates of IgG variants that do not bind the high-affinity Fc receptor or C1q are indistinguishable from the rate of clearance of the parent wild-type antibody, indicating that the catabolic site is distinct from the sites involved in Fc receptor or C1q binding. [Wawrzynczak et al., (1992) *Molecular Immunology* 29:221]. Site-directed mutagenesis studies using a murine IgG1 Fc region suggested that the site of the IgG1 Fc region that controls the catabolic rate is located at the CH<sub>2</sub>-CH<sub>3</sub> domain interface.

Based on these studies, Fc regions can be modified at the catabolic site to optimize the half-life of the fusion proteins. It is preferable that the Fc region used for the heterologous fusion proteins of the present invention be derived from an IgG1 (see Figure 4) or an IgG4 Fc region. It is even more preferable that the Fc region be IgG4 or derived from IgG4. Preferably the IgG Fc region contains both the CH<sub>2</sub> and CH<sub>3</sub> regions including the hinge region.

#### Heterologous albumin fusion proteins:

The G-CSF analogs described above can be fused directly or via a peptide linker to albumin or an analog, fragment, or derivative thereof. (See Figure 8).

Generally the albumin proteins making up part of the fusion proteins of the present invention can be derived from albumin cloned from any species. However, human albumin and fragments and analogs thereof are preferred to reduce the risk of the fusion protein being immunogenic in humans. Human serum albumin (HA) consists of a single non-

WO 03/076567

PCT/US03/03120

- 24 -

glycosylated polypeptide chain of 585 amino acids with a formula molecular weight of 66,500. The amino acid sequence of human HA is shown in Figure 3. [See Meloun, et al. (1975) FEBS Letters 58:136; Behrens, et al. (1975) Fed. Proc. 34:591; Lawn, et al. (1981) Nucleic Acids Research 9:6102-6114; Minghetti, et al. (1986) J. Biol. Chem. 261:6747]. A variety of polymorphic variants as well as analogs and fragments of albumin have been described. [See Weitkamp, et al., (1973) Ann. Hum. Genet. 37:219]. For example, in EP 322,094, the inventors disclose various shorter forms of HA. Some of these fragments include HA(1-373), HA(1-388), HA(1-389), HA(1-369), and HA(1-419) and fragments between 1-369 and 1-419. EP 399,666 discloses albumin fragments that include HA(1-177) and HA(1-200) and fragments between HA(1-177) and HA(1-200).

It is understood that the heterologous fusion proteins of the present invention include G-CSF analogs that are coupled to any albumin protein including fragments, analogs, and derivatives wherein such fusion protein is biologically active and has a longer plasma half-life than the G-CSF analog alone. Thus, the albumin portion of the fusion protein need not necessarily have a plasma half-life equal to that of native human albumin. In addition, the albumin may be fused to either terminus or both termini of the hyperglycosylated G-CSF analog. Fragments, analogs, and derivatives are known or can be generated that have longer half-lives or have half-lives intermediate to that of native human albumin and the G-CSF analog of interest.

The heterologous fusion proteins of the present invention encompass proteins having conservative amino acid substitutions in the G-CSF analog and/or the Fc or albumin portion of the fusion protein. A "conservative substitution" is the replacement of an amino acid with another amino acid that has the same net electronic charge and approximately the same size and shape. Amino acids with aliphatic or substituted aliphatic amino acid side chains

WO 03/076567

PCT/US03/03120

- 25 -

have approximately the same size when the total number carbon and heteroatoms in their side chains differs by no more than about four. They have approximately the same shape when the number of branches in their side chains differs by no more than one. Amino acids with phenyl or substituted phenyl groups in their side chains are considered to have about the same size and shape. Except as otherwise specifically provided herein, conservative substitutions are preferably made with naturally occurring amino acids.

However, the term "amino acid" is used herein in its broadest sense, and includes naturally occurring amino acids as well as non-naturally occurring amino acids, including amino acid analogs and derivatives. The latter includes molecules containing an amino acid moiety. One skilled in the art will recognize, in view of this broad definition, that reference herein to an amino acid includes, for example, naturally occurring proteogenic L-amino acids; D-amino acids; chemically modified amino acids such as amino acid analogs and derivatives; naturally occurring non-proteogenic amino acids such as norleucine,  $\beta$ -alanine, ornithine, GABA, etc.; and chemically synthesized compounds having properties known in the art to be characteristic of amino acids. As used herein, the term "proteogenic" indicates that the amino acid can be incorporated into a peptide, polypeptide, or protein in a cell through a metabolic pathway.

The incorporation of non-natural amino acids, including synthetic non-native amino acids, substituted amino acids, or one or more D-amino acids into the heterologous fusion proteins of the present invention can be advantageous in a number of different ways. D-amino acid-containing peptides, etc., exhibit increased stability *in vitro* or *in vivo* compared to L-amino acid-containing counterparts. Thus, the construction of peptides, etc., incorporating D-amino acids can be particularly useful when greater intracellular

WO 03/076567

PCT/US03/03120

- 26 -

stability is desired or required. More specifically, D-peptides, etc., are resistant to endogenous peptidases and proteases, thereby providing improved bioavailability of the molecule, and prolonged lifetimes *in vivo* when such properties are desirable. Additionally, D-peptides, etc., cannot be processed efficiently for major histocompatibility complex class II-restricted presentation to T helper cells, and are therefore less likely to induce humoral immune responses in the whole organism.

*General methods for making the heterologous fusion proteins of the present invention.*

Although the heterologous fusion proteins of the present invention can be made by a variety of different methods, recombinant methods are preferred. For purposes of the present invention, as disclosed and claimed herein, the following general molecular biology terms and abbreviations are defined below. The terms and abbreviations used in this document have their normal meanings unless otherwise designated. For example, "°C" refers to degrees Celsius; "mmol" refers to millimole or millimoles; "mg" refers to milligrams; "μg" refers to micrograms; "ml or mL" refers to milliliters; and "μl or μL" refers to microliters. Amino acids abbreviations are as set forth in 37 C.F.R. § 1.822 (b) (2) (1994).

"Base pair" or "bp" as used herein refers to DNA or RNA. The abbreviations A,C,G, and T correspond to the 5'-monophosphate forms of the deoxyribonucleosides (deoxy)adenosine, (deoxy)cytidine, (deoxy)guanosine, and thymidine, respectively, when they occur in DNA molecules. The abbreviations U,C,G, and A correspond to the 5'-monophosphate forms of the ribonucleosides uridine, cytidine, guanosine, and adenosine, respectively when they occur in RNA molecules. In double stranded DNA, base pair may refer to a partnership of A with T or C with G. In a DNA/RNA, heteroduplex base pair may refer to a partnership

WO 03/076567

PCT/US03/03120

- 27 -

of A with U or C with G. (See the definition of "complementary", infra.)

"Digestion" or "Restriction" of DNA refers to the catalytic cleavage of the DNA with a restriction enzyme that acts only at certain sequences in the DNA ("sequence-specific endonucleases"). The various restriction enzymes used herein are commercially available and their reaction conditions, cofactors, and other requirements were used as would be known to one of ordinary skill in the art. Appropriate buffers and substrate amounts for particular restriction enzymes are specified by the manufacturer or can be readily found in the literature.

"Ligation" refers to the process of forming phosphodiester bonds between two double stranded nucleic acid fragments. Unless otherwise provided, ligation may be accomplished using known buffers and conditions with a DNA ligase, such as T4 DNA ligase.

"Plasmid" refers to an extrachromosomal (usually) self-replicating genetic element. Plasmids are generally designated by a lower case "p" followed by letters and/or numbers. The starting plasmids herein are either commercially available, publicly available on an unrestricted basis, or can be constructed from available plasmids in accordance with published procedures. In addition, equivalent plasmids to those described are known in the art and will be apparent to the ordinarily skilled artisan.

"Recombinant DNA cloning vector" as used herein refers to any autonomously replicating agent, including, but not limited to, plasmids and phages, comprising a DNA molecule to which one or more additional DNA segments can or have been added.

"Recombinant DNA expression vector" as used herein refers to any recombinant DNA cloning vector in which a promoter to control transcription of the inserted DNA has been incorporated.

WO 03/076567

PCT/US03/03120

- 28 -

"Transcription" refers to the process whereby information contained in a nucleotide sequence of DNA is transferred to a complementary RNA sequence.

"Transfection" refers to the uptake of an expression vector by a host cell whether or not any coding sequences are, in fact, expressed. Numerous methods of transfection are known to the ordinarily skilled artisan, for example, calcium phosphate co-precipitation, liposome transfection, and electroporation. Successful transfection is generally recognized when any indication of the operation of this vector occurs within the host cell.

"Transformation" refers to the introduction of DNA into an organism so that the DNA is replicable, either as an extrachromosomal element or by chromosomal integration. Methods of transforming bacterial and eukaryotic hosts are well known in the art, many of which methods, such as nuclear injection, protoplast fusion or by calcium treatment using calcium chloride are summarized in J. Sambrook, et al., *Molecular Cloning: A Laboratory Manual*, (1989). Generally, when introducing DNA into Yeast the term transformation is used as opposed to the term transfection.

"Translation" as used herein refers to the process whereby the genetic information of messenger RNA (mRNA) is used to specify and direct the synthesis of a polypeptide chain.

"Vector" refers to a nucleic acid compound used for the transfection and/or transformation of cells in gene manipulation bearing polynucleotide sequences corresponding to appropriate protein molecules which, when combined with appropriate control sequences, confers specific properties on the host cell to be transfected and/or transformed. Plasmids, viruses, and bacteriophage are suitable vectors. Artificial vectors are constructed by cutting and joining DNA molecules from different sources using restriction enzymes and ligases. The term "vector" as used herein

WO 03/076567

PCT/US03/03120

- 29 -

includes Recombinant DNA cloning vectors and Recombinant DNA expression vectors.

"Complementary" or "Complementarity", as used herein, refers to pairs of bases (purines and pyrimidines) that associate through hydrogen bonding in a double stranded nucleic acid. The following base pairs are complementary: guanine and cytosine; adenine and thymine; and adenine and uracil.

"Hybridization" as used herein refers to a process in which a strand of nucleic acid joins with a complementary strand through base pairing. The conditions employed in the hybridization of two non-identical, but very similar, complementary nucleic acids varies with the degree of complementarity of the two strands and the length of the strands. Such techniques and conditions are well known to practitioners in this field.

"Isolated amino acid sequence" refers to any amino acid sequence, however, constructed or synthesized, which is locationally distinct from the naturally occurring sequence.

"Isolated DNA compound" refers to any DNA sequence, however constructed or synthesized, which is locationally distinct from its natural location in genomic DNA.

"Isolated nucleic acid compound" refers to any RNA or DNA sequence, however constructed or synthesized, which is locationally distinct from its natural location.

"Primer" refers to a nucleic acid fragment which functions as an initiating substrate for enzymatic or synthetic elongation.

"Promoter" refers to a DNA sequence which directs transcription of DNA to RNA.

"Probe" refers to a nucleic acid compound or a fragment, thereof, which hybridizes with another nucleic acid compound.

"Stringency" of hybridization reactions is readily determinable by one of ordinary skill in the art, and generally is an empirical calculation dependent upon probe

WO 03/076567

PCT/US03/03120

- 30 -

length, washing temperature, and salt concentration. In general, longer probes require higher temperatures for proper annealing, while short probes need lower temperatures. Hybridization generally depends on the ability of denatured DNA to re-anneal when complementary strands are present in an environment below their melting temperature. The higher the degree of desired homology between the probe and hybridizable sequence, the higher the relative temperature that can be used. As a result, it follows that higher relative temperatures would tend to make the reactions more stringent, while lower temperatures less so. For additional details and explanation of stringency of hybridization reactions, see Ausubel et al., *Current Protocols in Molecular Biology*, Wiley Interscience Publishers, 1995.

"Stringent conditions" or "high stringency conditions", as defined herein, may be identified by those that (1) employ low ionic strength and high temperature for washing, for example, 15 mM sodium chloride/1.5 mM sodium citrate/0.1% sodium dodecyl sulfate at 50°C; (2) employ during hybridization a denaturing agent, such as formamide, for example, 50% (v/v) formamide with 0.1% bovine serum albumin/0.1% ficoll/0.1% polyvinylpyrrolidone/50 mM sodium phosphate buffer at pH 6.5 with 750 mM sodium chloride/75 mM sodium citrate at 42°C; or (3) employ 50% formamide, 5X SSC (750 mM sodium chloride, 75 mM sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5X Denhardt's solution, sonicated salmon sperm DNA (50 µg/ml), 0.1% SDS, and 10% dextran sulfate at 42°C with washes at 42°C in 0.2X SSC (30 mM sodium chloride/3 mM sodium citrate) and 50% formamide at 55°C, followed by a high-stringency wash consisting of 0.1X SSC containing EDTA at 55°C.

"Moderately stringent conditions" may be identified as described by Sambrook et al. [*Molecular Cloning: A Laboratory Manual*, New York: Cold Spring Harbor Press, (1989)], and include the use of washing solution and hybridization conditions (e.g., temperature, ionic strength, and %SDS) less

WO 03/076567

PCT/US03/03120

- 31 -

stringent than those described above. An example of moderately stringent conditions is overnight incubation at 37°C in a solution comprising: 20% formamide, 5X SSC (750 mM sodium chloride, 75 mM sodium citrate), 50 mM sodium phosphate at pH 7.6, 5X Denhardt's solution, 10% dextran sulfate, and 20 mg/mL denatured sheared salmon sperm DNA, followed by washing the filters in 1X SSC at about 37-50°C. The skilled artisan will recognize how to adjust the temperature, ionic strength, etc., as necessary to accommodate factors such as probe length and the like.

"PCR" refers to the widely-known polymerase chain reaction employing a thermally-stable DNA polymerase.

"Leader sequence" refers to a sequence of amino acids which can be enzymatically or chemically removed to produce the desired polypeptide of interest.

"Secretion signal sequence" refers to a sequence of amino acids generally present at the N-terminal region of a larger polypeptide functioning to initiate association of that polypeptide with the cell membrane and secretion of that polypeptide through the cell membrane.

*Construction of DNA encoding the heterologous fusion proteins of the present invention:*

Wild type albumin and immunoglobulin proteins can be obtained from a variety of sources. For example, these proteins can be obtained from a cDNA library prepared from tissue or cells which express the mRNA of interest at a detectable level. Libraries can be screened with probes designed using the published DNA or protein sequence for the particular protein of interest.

Screening a cDNA or genomic library with the selected probe may be conducted using standard procedures, such as described in Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, NY (1989). An alternative means to isolate a gene encoding an albumin or immunoglobulin protein is to use PCR methodology

WO 03/076567

PCT/US03/03120

- 32 -

[Sambrook et al., *supra*; Dieffenbach et al., *PCR Primer: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, NY (1995)]. PCR primers can be designed based on published sequences.

Generally the full-length wild-type sequences cloned from a particular species can serve as a template to create analogs, fragments, and derivatives that retain the ability to confer a longer plasma half-life on the G-CSF analog that is part of the fusion protein. It is preferred that the Fc and albumin portions of the heterologous fusion proteins of the present invention be derived from the native human sequence in order to reduce the risk of potential immunogenicity of the fusion protein in humans.

In particular, it is preferred that the immunoglobulin portion of a fusion protein encompassed by the present invention contain only an Fc fragment of the immunoglobulin. Depending on whether particular effector functions are desired and the structural characteristics of the fusion protein, an Fc fragment may contain the hinge region along with the CH2 and CH3 domains or some other combination thereof. These Fc fragments can be generated using PCR techniques with primers designed to hybridize to sequences corresponding to the desired ends of the fragment. Similarly, if fragments of albumin are desired, PCR primers can be designed which are complementary to internal albumin sequences. PCR primers can also be designed to create restriction enzyme sites to facilitate cloning into expression vectors.

DNA encoding human G-CSF can be obtained from a cDNA library prepared from tissue or cells which express G-CSF mRNA at a detectable level such as monocytes, macrophages, vascular endothelial cells, fibroblasts, and some human malignant and leukemic myeloblastic cells. Libraries can be screened with probes designed using the published DNA sequence for human G-CSF. [Souza L. et al. (1986) *Science* 232:61-65]. Screening a cDNA or genomic library with the

WO 03/076567

PCT/US03/03120

- 33 -

selected probe may be conducted using standard procedures, such as described in Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, NY (1989). An alternative means to isolate the gene encoding human G-CSF is to use PCR methodology [Sambrook et al., *supra*; Dieffenbach et al., *PCR Primer: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, NY (1995)].

The glycosylated G-CSF analogs of the present invention can be constructed by a variety of mutagenesis techniques well known in the art. Specifically, a representative number of glycosylated G-CSF analogs were constructed using mutagenic PCR from a cloned wild-type human G-CSF DNA template (Example 1).

The glycosylated G-CSF analogs of the present invention may be produced by other methods including recombinant DNA technology or well known chemical procedures, such as solution or solid-phase peptide synthesis, or semi-synthesis in solution beginning with protein fragments coupled through conventional solution methods.

Recombinant DNA methods are preferred for producing the glycosylated G-CSF analogs of the present invention. Host cells are transfected or transformed with expression or cloning vectors described herein for glycosylated G-CSF analog production and cultured in conventional nutrient media modified as appropriate for inducing promoters, selecting transformants, or amplifying the genes encoding the desired sequences (Example 2). The culture conditions, such as media, temperature, pH and the like, can be selected by the skilled artisan without undue experimentation.

Physical stability is an essential feature for therapeutic formulations. The physical stability of the heterologous fusion proteins of the present invention depends on their conformational stability, the number of charged residues (pI of the protein), the ionic strength and pH of the formulation, and the protein concentration, among other possible factors. As discussed previously, the G-CSF

WO 03/076567

PCT/US03/03120

- 34 -

analog portion of the heterologous fusion proteins can be successfully glycosylated and expressed such that they maintain their three dimensional structure. Because these analogs are able to fold properly in a hyperglycosylated state, they will have improved conformational and physical stability relative to wild-type G-CSF.

While wild-type G-CSF produced in mammalian cells and bacterial cells has similar activity *in vivo*, the mammalian cell-produced protein has increased conformational and physical stability due to the presence of a single O-linked sugar moiety present at position 133. Thus, the G-CSF analog portion of the heterologous fusion proteins, which have an increased glycosylation content compared to wild-type G-CSF produced in mammalian or bacterial cells, will have increased stability. Furthermore, it is likely that glycosylation may inhibit inter-domain interactions and consequently enhance stability by preventing inter-domain disulfide shuffling.

The gene encoding a heterologous fusion protein can be constructed by ligating DNA encoding a G-CSF analog in-frame to DNA encoding an albumin or Fc protein. The gene encoding the G-CSF analog and the gene encoding the albumin or Fc protein can also be joined in-frame via DNA encoding a linker peptide.

The *in vivo* function and stability of the heterologous fusion proteins of the present invention can be optimized by adding small peptide linkers to prevent potentially unwanted domain interactions. Although these linkers can potentially be any length and consist of any combination of amino acids, it is preferred that the length be no longer than necessary to prevent unwanted domain interactions and/or optimize biological activity and/or stability. Generally, the linkers should not contain amino acids with extremely bulky side chains or amino acids likely to introduce significant secondary structure. It is preferred that the linker be serine-glycine rich and be less than 30 amino acids in

WO 03/076567

PCT/US03/03120

- 35 -

length. It is more preferred that the linker be no more than 20 amino acids in length. It is even more preferred that the linker be no more than 15 amino acids in length. A preferred linker contains repeats of the sequence Gly-Gly-Gly-Gly-Ser. It is preferred that there be between 2 and 6 repeats of this sequence. It is even more preferred that there be between 3 and 4 repeats of this sequence.

To construct the heterologous G-CSF fusion proteins, the DNA encoding wild-type G-CSF, albumin, and Fc polypeptides and fragments thereof can be mutated either before ligation or in the context of a cDNA encoding an entire fusion protein. A variety of mutagenesis techniques are well known in the art. For example, a mutagenic PCR method utilizes strand overlap extension to create specific base mutations for the purposes of changing a specific amino acid sequence in the corresponding protein. This PCR mutagenesis requires the use of four primers, two in the forward orientation (primers A and C) and two in the reverse orientation (primers B and D). A mutated gene is amplified from the wild-type template in two different stages. The first reaction amplifies the gene in halves by performing an A to B reaction and a separate C to D reaction wherein the B and C primers target the area of the gene to be mutated. When aligning these primers with the target area, they contain mismatches for the bases that are targeted to be changed. Once the A to B and C to D reactions are complete, the reaction products are isolated and mixed for use as the template for the A to D reaction. This reaction then yields the full, mutated product.

Once a gene encoding an entire fusion protein is produced it can be cloned into an appropriate expression vector. Specific strategies that can be employed to make the G-CSF fusion proteins of the present invention are described in example 1.

WO 03/076567

PCT/US03/03120

- 36 -

*General methods to recombinantly express the heterologous fusion proteins of the present invention:*

Host cells are transfected or transformed with expression or cloning vectors described herein for heterologous fusion protein production and cultured in conventional nutrient media modified as appropriate for inducing promoters, selecting transformants, or amplifying the genes encoding the desired sequences. The culture conditions, such as media, temperature, pH and the like, can be selected by the skilled artisan without undue experimentation. In general, principles, protocols, and practical techniques for maximizing the productivity of cell cultures can be found in *Mammalian Cell Biotechnology: A Practical Approach*, M. Butler, ed. (IRL Press, 1991) and Sambrook, et al., *supra*. Methods of transfection are known to the ordinarily skilled artisan, for example, CaPO<sub>4</sub> and electroporation. General aspects of mammalian cell host system transformations have been described in U.S. Patent No. 4,399,216. Transformations into yeast are typically carried out according to the method of van Solingen et al., *J Bact.* 130(2): 946-7 (1977) and Hsiao et al., *Proc. Natl. Acad. Sci. USA* 76(8): 3829-33 (1979). Suitable host cells for the expression of the fusion proteins of the present invention are derived from multicellular organisms.

The fusion proteins of the present invention may be recombinantly produced directly, or as a protein having a signal sequence or other additional sequences which create a specific cleavage site at the N-terminus of the mature fusion protein. In general, the signal sequence may be a component of the vector, or it may be a part of the fusion protein-encoding DNA that is inserted into the vector. The signal sequence may be a prokaryotic signal sequence selected, for example, from the group of the alkaline phosphatase, penicillinase, lpp, or heat-stable enterotoxin II leaders. For yeast secretion the signal sequence may be, e.g., the yeast invertase leader, alpha factor leader (including *Saccharomyces* and *Kluyveromyces* cc-factor leaders, the latter

WO 03/076567

PCT/US03/03120

- 37 -

described in U.S. Patent No. 5,010,182), or acid phosphatase leader, the *C. albicans* glucoamylase leader (EP 362,179), or the signal described in WO 90/13646. In mammalian cell expression, mammalian signal sequences may be used to direct secretion of the protein, such as signal sequences from secreted polypeptides of the same or related species as well as viral secretory leaders.

Both expression and cloning vectors contain a nucleic acid sequence that enables the vector to replicate in one or more selected host cells. Such sequences are well known for a variety of bacteria, yeast, and viruses. The origin of replication from the plasmid pBR322 is suitable for most Gram-negative bacteria, the 2 $\mu$  plasmid origin is suitable for yeast, and various viral origins (SV40, polyoma, adenovirus, VSV or BPV) are useful for cloning vectors in mammalian cells. Expression and cloning vectors will typically contain a selection gene, also termed a selectable marker. Typical selection genes encode proteins that (a) confer resistance to antibiotics or other toxins, e.g., ampicillin, neomycin, methotrexate, or tetracycline, (b) complement autotrophic deficiencies, or (c) supply critical nutrients not available from complex media, e.g., the gene encoding D-alanine racemase for *Bacilli*.

An example of suitable selectable markers for mammalian cells are those that enable the identification of cells competent to take up the fusion protein-encoding nucleic acid, such as DHFR or thymidine kinase. An appropriate host cell when wild-type DHFR is employed is the CHO cell line deficient in DHFR activity, prepared and propagated as described [Urlaub and Chasin, *Proc. Natl. Acad. Sci. USA*, 77(7): 4216-20 (1980)]. A suitable selection gene for use in yeast is the *trpl* gene present in the yeast plasmid Yrp7 [Stinchcomb, et al., *Nature* 282(5734): 39-43 (1979); Kingsman, et al., *Gene* 7(2): 141-52 (1979); Tschumper, et al., *Gene* 10(2): 157-66 (1980)]. The *trpl* gene provides a selection marker for a mutant strain of yeast lacking the ability to grow in

WO 03/076567

PCT/US03/03120

- 38 -

tryptophan, for example, ATCC No. 44076 or PEPC1 [Jones, *Genetics* 85: 23-33 (1977)].

Expression and cloning vectors usually contain a promoter operably linked to the fusion protein-encoding nucleic acid sequence to direct mRNA synthesis. Promoters recognized by a variety of potential host cells are well known. Promoters suitable for use with prokaryotic hosts include the  $\beta$ -lactamase and lactose promoter systems [Chang, et al., *Nature* 275(5681): 617-24 (1978); Goeddel, et al., *Nature* 281(5732): 544-8 (1979)], alkaline phosphatase, a tryptophan (up) promoter system [Goeddel, *Nucleic Acids Res.* 8(18): 4057-74 (1980); EP 36,776 published 30 September 1981], and hybrid promoters such as the tat promoter [deBoer, et al., *Proc. Natl. Acad. Sci. USA* 80(1): 21-5 (1983)]. Promoters for use in bacterial systems also will contain a Shine-Dalgarno (S.D.) sequence operably linked to the DNA encoding the fusion protein.

Transcription of a polynucleotide encoding a fusion protein by higher eukaryotes may be increased by inserting an enhancer sequence into the vector. Enhancers are cis-acting elements of DNA, usually about from 10 to 300 bp, that act on a promoter to increase its transcription. Many enhancer sequences are now known from mammalian genes (globin, elastase, albumin,  $\alpha$ -ketoprotein, and insulin). Typically, however, one will use an enhancer from a eukaryotic cell virus. Examples include the SV40 enhancer on the late side of the replication origin (bp 100-270), the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers. The enhancer may be spliced into the vector at a position 5' or 3' to the fusion protein coding sequence but is preferably located at a site 5' from the promoter.

Expression vectors used in eukaryotic host cells (yeast, fungi, insect, plant, animal, human, or nucleated cells from other multicellular organisms) will also contain sequences necessary for the termination of transcription and for

WO 03/076567

PCT/US03/03120

- 39 -

stabilizing the mRNA. Such sequences are commonly available from the 5' and occasionally 3' untranslated regions of eukaryotic or viral DNAs or cDNAs. These regions contain nucleotide segments transcribed as polyadenylated fragments in the untranslated portion of the mRNA encoding the fusion protein.

Various forms of a fusion protein may be recovered from culture medium or from host cell lysates. If membrane-bound, it can be released from the membrane using a suitable detergent solution (e.g., Triton-X 100) or by enzymatic cleavage. Cells employed in expression of a fusion protein can be disrupted by various physical or chemical means, such as freeze-thaw cycling, sonication, mechanical disruption, or cell lysing agents.

*Purification of the heterologous fusion proteins of the present invention:*

Once the heterologous fusion proteins of the present invention are expressed in the appropriate host cell, the analogs can be isolated and purified. The following procedures are exemplary of suitable purification procedures:

Various methods of protein purification may be employed and such methods are known in the art and described, for example, in Deutscher, *Methods in Enzymology* 182: 83-9 (1990) and Scopes, *Protein Purification: Principles and Practice*, Springer-Verlag, NY (1982). The purification step(s) selected will depend on the nature of the production process used and the particular fusion protein produced. For example, fusion proteins comprising an Fc fragment can be effectively purified using a Protein A or Protein G affinity matrix. Low or high pH buffers can be used to elute the fusion protein from the affinity matrix. Mild elution conditions will aid in preventing irreversible denaturation of the fusion protein. Imidazole-containing buffers can also be used. Example 3 describes some successful purification protocols for the fusion proteins of the present invention.

WO 03/076567

PCT/US03/03120

- 40 -

*Characterization of the heterologous fusion proteins of the present invention:*

Numerous methods exist to characterize the fusion proteins of the present invention. Some of these methods include: SDS-PAGE coupled with protein staining methods or immunoblotting using anti-IgG, anti-HA and anti-G-CSF antibodies. Other methods include matrix assisted laser desorption/ionization-mass spectrometry (MALDI-MS), liquid chromatography/mass spectrometry, isoelectric focusing, analytical anion exchange, chromatofocussing, and circular dichroism to name a few. A representative number of heterologous fusion proteins were characterized using SDS-PAGE coupled with immunoblotting as well as mass spectrometry.

For example, Table 2 illustrates the calculated molecular mass for a representative number of fusion proteins as well as the observed mass (as measured by protease mapping/LC-MS). The relative differences between observed mass and mass calculated for a nonglycosylated protein are indicative of the extent of glycosylation.

The heterologous fusion proteins of the present invention may be formulated with one or more excipients. The active fusion proteins of the present invention may be combined with a pharmaceutically acceptable buffer, and the pH adjusted to provide acceptable stability, and a pH acceptable for administration such as parenteral administration.

Optionally, one or more pharmaceutically-acceptable antimicrobial agents may be added. Meta-cresol and phenol are preferred pharmaceutically-acceptable microbial agents. One or more pharmaceutically-acceptable salts may be added to adjust the ionic strength or tonicity. One or more excipients may be added to adjust the isotonicity of the formulation. Glycerin is an example of an isotonicity-adjusting excipient. Pharmaceutically acceptable means suitable for administration to a human or other animal and thus, does not contain toxic

WO 03/076567

PCT/US03/03120

- 41 -

elements or undesirable contaminants and does not interfere with the activity of the active compounds therein.

A pharmaceutically-acceptable salt form of the heterologous fusion proteins of the present invention may be used in the present invention. Acids commonly employed to form acid addition salts are inorganic acids such as hydrochloric acid, hydrobromic acid, hydriodic acid, sulfuric acid, phosphoric acid, and the like, and organic acids such as *p*-toluenesulfonic acid, methanesulfonic acid, oxalic acid, *p*-bromophenyl-sulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, acetic acid, and the like. Preferred acid addition salts are those formed with mineral acids such as hydrochloric acid and hydrobromic acid.

Base addition salts include those derived from inorganic bases, such as ammonium or alkali or alkaline earth metal hydroxides, carbonates, bicarbonates, and the like. Such bases useful in preparing the salts of this invention thus include sodium hydroxide, potassium hydroxide, ammonium hydroxide, potassium carbonate, and the like.

#### *Administration of Compositions:*

Administration may be via any route known to be effective by the physician of ordinary skill. Peripheral, parenteral is one such method. Parenteral administration is commonly understood in the medical literature as the injection of a dosage form into the body by a sterile syringe or some other mechanical device such as an infusion pump. Peripheral parenteral routes can include intravenous, intramuscular, subcutaneous, and intraperitoneal routes of administration.

The heterologous fusion proteins of the present invention may also be amenable to administration by oral, rectal, nasal, or lower respiratory routes, which are non-parenteral routes. Of these non-parenteral routes, the lower respiratory route and the oral route are preferred.

The heterologous fusion proteins of the present invention can be used to treat patients with insufficient

WO 03/076567

PCT/US03/03120

- 42 -

circulating neutrophil levels, typically those undergoing cancer chemotherapy.

An "effective amount" of the heterologous fusion protein is the quantity which results in a desired therapeutic and/or prophylactic effect without causing unacceptable side-effects when administered to a subject in need of G-CSF receptor stimulation. A "desired therapeutic effect" includes one or more of the following: 1) an amelioration of the symptom(s) associated with the disease or condition; 2) a delay in the onset of symptoms associated with the disease or condition; 3) increased longevity compared with the absence of the treatment; and 4) greater quality of life compared with the absence of the treatment.

The present invention comprises G-CSF compounds that have improved biochemical and biophysical properties by virtue of being fused to an albumin protein, an albumin fragment, an albumin analog, a Fc protein, a Fc fragment, or a Fc analog. These heterologous proteins can be successfully expressed in host cells, retain signaling activities associated with activation of the G-CSF receptor, and have prolonged half-lives.

The following examples are presented to further describe the present invention. The scope of the present invention is not to be construed as merely consisting of the following examples. Those skilled in the art will recognize that the particular reagents, equipment, and procedures described are merely illustrative and are not intended to limit the present invention in any manner.

### EXAMPLES

#### Example 1: Construction of DNA encoding glycosylated G-CSF analogs:

Table 1 provides the sequence of primers used to create functional glycosylation sites in different regions of the protein (See Figure 1).

Table 1: Primer sequences used to introduce mutations into human G-CSF.

Mutation	A Primer*	B Primer*	C Primer*	D Primer*
WT	CF177 [SEQ ID NO:25] <b>GTAAGCTTGC GT</b> <b>CGACGCTAGCGG</b> <b>CGCGCCGCCATG</b> GCCGGACCTGCC ACCCAGAGCCCC ATGAAGCTG	CF178 [SEQ ID NO:26] GGGGCAGGGAGC TGGCTGGGCCA GTGGAGTGGCTT CCTGCACTGTCC AGAGTGCACTGT G	CF179 [SEQ ID NO:27] GGACAGTGCAGG AAGCCACTCCAC TGGGCCAGCCA GCTCCCTGCCCA AGAGCTTCCTG	CF176 [SEQ ID NO:28] <b>GAACCTCGAGGA</b> <b>TCCTCATTAGGG</b> CTGGGCAAGGTG CCTTAAGACGCG GTACGACACCTC CAGGAAGCTCTG
C17A <i>SacI</i>	CF177 [SEQ ID NO:29] <b>GTAAGCTTGC GT</b> <b>CGACGCTAGCGG</b> <b>CGCGCCGCCATG</b> GCCGGACCTGCC ACCCAGAGCCCC ATGAAGCTG	C17Arev [SEQ ID NO:30] GCTCTAACGGCCT TGAGCAGGAAGC TCTGGGCAGGG AGCTCGCTGGC CCAGTGGAG	C17Afor [SEQ ID NO:31] GGGCCAGCGAG CTCCCTGCCCA GAGCTTCCTGCT CAAGGCCTTAGA GCAAG	CF176 [SEQ ID NO:32] <b>GAACCTCGAGGA</b> <b>TCCTCATTAGGG</b> CTGGGCAAGGTG CCTTAAGACGCG GTACGACACCTC CAGGAAGCTCTG
A37N, Y39T <i>SpeI</i>	CF177 [SEQ ID NO:33] <b>GTAAGCTTGC GT</b> <b>CGACGCTAGCGG</b> <b>CGCGCCGCCATG</b> GCCGGACCTGCC ACCCAGAGCCCC ATGAAGCTG	A37Nrev [SEQ ID NO:34] GTCCGAGCAGCA CTAGTTCCCTCGG GGTGGCACAGCT TGGTGGTGT TAC ACAGCTTCTCCT G	A37Nfor [SEQ ID NO:35] GGCGCAGCGCTC CAGGAGAACGCTG TGTAAACACCACC AAGCTGTGCCAC CCCGAGGA ACTA GTGCTG	CF176 [SEQ ID NO:36] <b>GAACCTCGAGGA</b> <b>TCCTCATTAGGG</b> CTGGGCAAGGTG CCTTAAGACGCG GTACGACACCTC CAGGAAGCTCTG
T133N, G135T <i>Eco47III</i>	CF177 [SEQ ID NO:37] <b>GTAAGCTTGC GT</b> <b>CGACGCTAGCGG</b> <b>CGCGCCGCCATG</b> GCCGGACCTGCC ACCCAGAGCCCC ATGAAGCTG	T133Nrev [SEQ ID NO:38] GCCCGGCGCTGG AAAGCGCTGGCG AAGGCCGGCATG GCGGTCTGGTTG GGCTGCAGGGCA G	T133Nfor [SEQ ID NO:39] GGCCCCTGCCCT GCAGCCCAACCA GACCGCCATGCC GGCCTTCGCCAG CGCTTCCAGCG GTACGACACCTC CAGGAAGCTCTG	CF176 [SEQ ID NO:40] <b>GAACCTCGAGGA</b> <b>TCCTCATTAGGG</b> CTGGGCAAGGTG CCTTAAGACGCG GTACGACACCTC CAGGAAGCTCTG

WO 03/076567

PCT/US03/03120

- 44 -

A141N, A143T <i>SapI</i>	CF177 [SEQ ID NO:41] <b>GTAAGCTTGCCT</b> <b>CGACGCTAGCGG</b> <b>CCGGCCGCCATG</b> GCCGGACCTGCC ACCCAGAGCCCC ATGAAGCTG	A141Nrev [SEQ ID NO:42] GCCCGGCGCTGG AAGGTAGAGTTG AAGGCCGGCATG GCACCCCTGGGTG GGCTGAAGAGCA GGGGCCAT	A141Nfor [SEQ ID NO:43] GGGAATGGCCCC TGCTCTTCAGCC CACCCAGGGTGC CATGCCGGCCTT CAACTCTACCTT CCAGCGCCGGGC AG	CF176 [SEQ ID NO:44] <b>GAACCTCGAGGA</b> <b>TCCTCATTAGGG</b> CTGGGCAAGGTG CCTTAAGACGCG GTACGACACCTC CAGGAAGCTCTG
--------------------------------	--	--	---	--

P57V, W58N, P60T <i>HpaI</i>	JCB128 [SEQ ID NO:45] GCTAGCGCGCG CCACCATG	JCB136 [SEQ ID NO:46] GCTCAGGGTAGC <b>GTTAACGATGCC</b> CAGAGAGTG	JCB137 [SEQ ID NO:47] GGGCATCGTTAA <b>CGCTACCCCTGAG</b> CAGCTG	JCB129 [SEQ ID NO:48] <b>GACTCGAGGATC</b> CTCATTAGGGCT GGG
Q67N, L69T <i>NaeI</i>	JCB134 [SEQ ID NO:49] GCTAGCGCGCG CCACCATGGCCG GACCTGCCACCC AG	JCB138 [SEQ ID NO:50] CAAGCAGCCGGC CAGCTGGGTGGC <b>GTTGCTGGGGCA</b> GCTGCTCAG	JCB139 [SEQ ID NO:51] GCCCCAGCAACG CCACCCAGCTGG CCGGCTGCTTGA G	JCB135 [SEQ ID NO:52] <b>GACTCGAGGATC</b> CTCATTAGGGCT GGGCAAGGTGCC TTAAGACGCGG
P60N, S62T <i>SpeI</i>	JCB128 [SEQ ID NO:53] GCTAGCGCGCG CCACCATG	JCB130 [SEQ ID NO:54] GGGGCAACTAGT CAGGTTAGCCCA GGG	JCB131 [SEQ ID NO:55] GCTAACCTGACT AGTTGCCAGC CAG	JCB129 [SEQ ID NO:56] <b>GACTCGAGGATC</b> CTCATTAGGGCT GGG
S63N, P65T <i>MfeI</i>	JCB128 [SEQ ID NO:57] GCTAGCGCGCG CCACCATG	JCB132 [SEQ ID NO:58] GGTGCAATTGCT CAGGGGAGCCCA G	JCB133 [SEQ ID NO:59] GCAATTGCACCA GCCAGGCCCTG G	JCB129 [SEQ ID NO:60] <b>GACTCGAGGATC</b> CTCATTAGGGCT GGG
E93N, I95T <i>BspEI</i>	JCB134 [SEQ ID NO:61] GCTAGCGCGCG CCACCATGGCCG GACCTGCCACCC	JCB140 [SEQ ID NO:62] <b>CCGGACTGGTCC</b> CGTTCAGGGCCT GCAGGAGCCCCT	JCB141 [SEQ ID NO:63] <b>GAACGGGACCAG</b> TCCGGAGTTGGG TCCCACCTTGG	JCB135 [SEQ ID NO:64] <b>GACTCGAGGATC</b> CTCATTAGGGCT GGGCAAGGTGCC

WO 03/076567

PCT/US03/03120

- 45 -

	AG	G		TTAAGACGCGG
<i>Sali</i>	JCB155 [SEQ ID NO:65] <b><i>GTCGACGCTAGC</i></b> GGCGCGCCACCA TGGCCGGACCTG			

\*Nucleotides in bold represent changes imposed in the target sequence and nucleotides in bold and italics represent flanking sequences which may add restriction sites to facilitate cloning, Kozac sequences, or stop codons.

Preparation 1a: DNA encoding wild-type human G-CSF

A strand overlapping extension PCR reaction was used to create a wild type human G-CSF construct in order to eliminate the methylation of an ApaI site. Isolated human G-CSF cDNA served as the template for these reactions. The 5' end A primer was used to create a restriction enzyme site prior to the start of the coding region as well as to introduce a Kozac sequence (GGCGCC) 5' of the coding leader sequence to facilitate translation in cell culture.

The A-B product was generated using primers CF177 and CF178 in a PCR reaction. Likewise, the C-D product was produced with primers CF179 and CF176. The products were isolated and combined. The combined mixture was then used as a template with primers CF177 and CF178 to create the full-length wild-type construct. [Nelson, R.M. and Long, G.C. (1989), *Anal. Biochem.* 180:147-151].

The full-length product was ligated into the pCR2.1-Topo vector (Invitrogen, Inc. Cat. No. K4500-40) by way of a topoisomerase TA overhang system to create pCR2.1G-CSF.

The following protocol was used for preparation of the full-length wild-type G-CSF protein as well as each of the G-CSF analogs. Approximately 5 ng of template DNA and 15 pmol of each primer was used in the initial PCR reactions. The reactions were prepared using Platinum PCR Supermix® (GibcoBRL Cat. No. 11306-016). The PCR reactions were

WO 03/076567

PCT/US03/03120

- 46 -

denatured at 94°C for 5 min and then subject to 25 cycles wherein each cycle consisted of 30 seconds at 94°C followed by 30 seconds at 60°C followed by 30 seconds at 72°C. A final extension was carried out for 7 minutes at 72°C. PCR fragments were isolated from agarose gels and purified using a Qiaquick® gel extraction kit (Qiagen, Cat. No. #28706). DNA was resuspended in sterile water and used for the final PCR reaction to prepare full-length product.

Preparation 1b: DNA encoding G-CSF [A37N, Y39T, P57V, W58N, P60T, Q67N, L69T] was constructed as follows:

DNA encoding G-CSF [A37N, Y39T, Q67N, L69T] was subcloned into pJB02 to create pJB02G-CSF [A37N, Y39T, Q67N, L69T] and pJB02G-CSF [A37N, Y39T, P57V, W58N, P60T] served as the template for strand overlapping expression PCR. JCB155 and JCB136 served as the A and B primers and JCB137 and JCB135 served as the C and D primers. The full-length mutated cDNA was prepared as described previously using JCB155 and JCB134 primers. The resulting full-length DNA encodes a protein with consensus N-linked glycosylation sites in region 1, region 2, and region 9 of the protein (See Figure 1). The full-length cDNA was ligated back into pCR2.1-Topo to create pCR2.1G-CSF [A37N, Y39T, P57V, W58N, P60T, Q67N, L69T].

Preparation 1c: DNA encoding G-CSF [A37N, Y39T, S63N, P64T, E93N, I95T] was constructed as follows:

DNA encoding G-CSF [A37N, Y39T, E93N, I95T] was subcloned into pJB02 to create pJB02G-CSF [A37N, Y39T, E93N, I95T] and pJB02G-CSF [A37N, Y39T, E93N, I95T] served as the template for strand overlapping expression PCR. JCB155 and JCB132 served as the A and B primers and JCB133 and JCB135 served as the C and D primers. The full-length mutated cDNA was prepared as described previously using JCB155 and JCB135 primers. The resulting full-length DNA encodes a protein with consensus N-linked glycosylation sites in region 1, region 7, and

WO 03/076567

PCT/US03/03120

- 47 -

region 10 of the protein (See Figure 1). The full-length cDNA was ligated back into pCR2.1-Topo to create pCR2.1G-CSF [A37N, Y39T, S63N, P64T, E93N, I95T].

Preparation 1d: DNA encoding G-CSF [C17A] which is G-CSF wherein the amino acid at position 17 is substituted with Ala is constructed as follows:

The wild-type construct in the pCR2.1-Topo vector (pCR2.1G-CSF) serves as the PCR template for the C17A mutagenesis. Strand overlapping extension PCR is performed as described previously. CF177 and C17Arev serve as the A-B primers and C17Afor and CF176 serve as the C-D primers. The full-length mutated cDNA is prepared as described previously using the CF177 and CF176 primers. The B and C primers are used to mutate the DNA such that a *SacI* restriction site is created and the protein expressed from the full-length sequence contains an Alanine instead of a Cysteine at position 17. The full-length cDNA is ligated back into the pCR2.1-Topo vector to create pCR2.1G-CSF [C17A] wherein the sequence is confirmed. G-CSF analog encoding DNA is then cloned into the *Nhe*/*Xho* sites of mammalian expression vector pJB02 to create pJB02G-CSF [C17A].

Preparation 1e: DNA encoding G-CSF [A37N, Y39T] is constructed as follows:

Strand overlapping extension PCR is performed using pCR2.1G-CSF [C17A] as the template. Primers CF177 and A37Nrev serve as the A-B primers and CF176 and A37Nfor serve as the C-D primers. The full-length mutated cDNA is prepared as described previously using the CF177 and CF176 primers. The B and C primers contain mismatched sequences such that a *SpeI* site is created in the DNA and the protein expressed from the full-length sequence contains a consensus sequence for N-linked glycosylation in region 1 of the protein. The full-length cDNA is ligated back into the pCR2.1-Topo vector to create pCR2.1G-CSF [A37N, Y39T] wherein the sequence is

WO 03/076567

PCT/US03/03120

- 48 -

confirmed. G-CSF analog encoding DNA is then cloned into the *Nhe/Xho* sites of mammalian expression vector pJB02 to create pJB02G-CSF [A37N, Y39T].

Preparation 1f: DNA encoding G-CSF [P57V, W58N, P60T] is constructed as follows:

Strand overlapping extension PCR is performed using pJB02G-CSF [C17A] as the template. Primers JCB128 and JCB136 serve as the A-B primers and JCB137 and JCB129 serve as the C-D primers. The full-length mutated cDNA is prepared as described previously using the JCB128 and JCB129 primers. The B and C primers contain mismatched sequences such that a *HpaI* site is created and the protein expressed from the full-length sequence contains a consensus sequence for N-linked glycosylation in region 2 of the protein. The full-length cDNA is ligated back into the pCR2.1-Topo vector to create pCR2.1G-CSF [P57V, W58N, P60T] wherein the sequence is confirmed. G-CSF analog encoding DNA is then cloned into the *Nhe/Xho* sites of mammalian expression vector pJB02 to create pJB02G-CSF [P57V, W58N, P60T].

Preparation 1g: DNA encoding G-CSF [P60N, S62T] is constructed as follows:

Strand overlapping extension PCR is performed using pJB02G-CSF [C17A] as the template. Primers JCB128 and JCB130 serve as the A-B primers and JCB131 and JCB129 serve as the C-D primers. The full-length mutated cDNA is prepared as described previously using the JCB128 and JCB129 primers. The B and C primers contain mismatched sequences such that a *SpeI* site is created and the protein expressed from the full-length sequence contains a consensus sequence for N-linked glycosylation in region 4 of the protein. The full-length cDNA is ligated back into the pCR2.1-Topo vector to create pCR2.1G-CSF [P60N, S62T] wherein the sequence is confirmed. G-CSF analog encoding DNA is then cloned into the

WO 03/076567

PCT/US03/03120

- 49 -

*Nhe/Xho* sites of mammalian expression vector pJB02 to create pJB02G-CSF [P60N, S62T].

Preparation 1h: DNA encoding G-CSF [S63N, P65T] is constructed as follows:

Strand overlapping extension PCR is performed using pJB02G-CSF [C17A] as the template. Primers JCB128 and JCB132 serve as the A-B primers and JCB133 and JCB129 serve as the C-D primers. The full-length mutated cDNA is prepared as described previously using the JCB128 and JCB129 primers. The B and C primers contain mismatched sequences such that a *MfeI* site is created and the protein expressed from the full-length sequence contains a consensus sequence for N-linked glycosylation in region 7 of the protein. The full-length cDNA is ligated back into the pCR2.1-Topo vector to create pCR2.1G-CSF [S63N, P65T] wherein the sequence is confirmed. G-CSF analog encoding DNA is then cloned into the *Nhe/Xho* sites of mammalian expression vector pJB02 to create pJB02G-CSF [S63N, P65T].

Preparation 1i: DNA encoding G-CSF [Q67N, L69T] is constructed as follows:

Strand overlapping extension PCR is performed using pJB02G-CSF [C17A] as the template. Primers JCB134 and JCB138 serve as the A-B primers and JCB139 and JCB135 serve as the C-D primers. The full-length mutated cDNA is prepared as described previously using the JCB128 and JCB129 primers. The B and C primers contain mismatched sequences such that a *NaeI* site is created and the protein expressed from the full-length sequence contains a consensus sequence for N-linked glycosylation in region 9 of the protein. The full-length cDNA is ligated back into the pCR2.1-Topo vector to create pCR2.1G-CSF [Q67N, L69T] wherein the sequence is confirmed. G-CSF analog encoding DNA is then cloned into the *Nhe/Xho* sites of mammalian expression vector pJB02 to create pJB02G-CSF [Q67N, L69T].

WO 03/076567

PCT/US03/03120

- 50 -

Preparation 1j: DNA encoding G-CSF [E93N, I95T] is constructed as follows:

Strand overlapping extension PCR is performed using pJB02G-CSF [C17A] as the template. Primers JCB134 and JCB140 serve as the A-B primers and JCB141 and JCB135 serve as the C-D primers. The full-length mutated cDNA is prepared as described previously using the JCB128 and JCB129 primers. The B and C primers contain mismatched sequences such that a *BspEI* site is created and the protein expressed from the full-length sequence contains a consensus sequence for N-linked glycosylation in region 10 of the protein. The full-length cDNA is ligated back into the pCR2.1-Topo vector to create pCR2.1G-CSF [E93N, I95T] wherein the sequence is confirmed. G-CSF analog encoding DNA is then cloned into the *Nhe/Xho* sites of mammalian expression vector pJB02 to create pJB02G-CSF [E93T, I95T].

Preparation 1k: DNA encoding G-CSF [T133N, G135T] is constructed as follows:

Strand overlapping extension PCR is performed using pCR2.1G-CSF [C17A] as the template. Primers CF177 and T133Nrev serve as the A-B primers and T133Nfor and CF176 serve as the C-D primers. The full-length mutated cDNA is prepared as described previously using the CF177 and CF176 primers. The B and C primers contain mismatched sequences such that an *Eco47III* site is created and the protein expressed from the full-length sequence contains a consensus sequence for N-linked glycosylation in region 13 of the protein. The full-length cDNA is ligated back into the pCR2.1-Topo vector to create pCR2.1G-CSF [T133N, G135T] wherein the sequence is confirmed.

Preparation 1l: DNA encoding G-CSF [A141N, A143T] is constructed as follows:

WO 03/076567

PCT/US03/03120

- 51 -

Strand overlapping extension PCR is performed using pCR2.1G-CSF [C17A] as the template. Primers CF177 and A141Nrev serve as the A-B primers and A141Nfor and CF176 serve as the C-D primers. The full-length mutated cDNA is prepared as described previously using the CF177 and CF176 primers. The B and C primers contain mismatched sequences such that an *SapI* site is created and the protein expressed from the full-length sequence contains a consensus sequence for N-linked glycosylation in region 14 of the protein. The full-length cDNA is ligated back into the pCR2.1-Topo vector to create pCR2.1G-CSF [A141N, A143T] wherein the sequence is confirmed.

Preparation 1m: DNA encoding G-CSF [A37N, Y39T, T133N, G135T] is constructed as follows:

A 210 bp insert containing G-CSF [A37N, Y39T] is isolated from pCR2.1G-CSF [A37N, Y39T] using *EcoNI*. This fragment is ligated into pCR2.1G-CSF [T133N, G135T] which is prepared by cleavage with *EcoNI* and subsequent isolation of the vector (4359 bp) from a 210 bp fragment containing wild-type G-CSF sequences. This ligation creates pCR2.1G-CSF [A37N, Y39T, T133N, G135T]. Analog encoding DNA is then subcloned into pJB02 using *NheI/XhoI* to create pJB02G-CSF [A37N, Y39T, T133N, G135T].

Preparation 1n: DNA encoding G-CSF [A37N, Y39T, A141N, A143T] is constructed as follows:

A 210 bp insert containing G-CSF [A37N, Y39T] is isolated from pCR2.1G-CSF [A37N, Y39T] using *EcoNI*. This fragment is ligated into pCR2.1G-CSF [A141N, A143T] which is prepared by cleavage with *EcoNI* and subsequent isolation of the vector (4359 bp) from a 210 bp fragment containing wild-type G-CSF sequences. This ligation creates pCR2.1G-CSF [A37N, Y39T, A141N, A143T]. Analog encoding DNA is then subcloned into pJB02 (Figure 3) using *NheI/XhoI* to create pJB02G-CSF [A37N, Y39T, A141N, A143T].

WO 03/076567

PCT/US03/03120

- 52 -

Preparation 1o: DNA encoding G-CSF [A37N, Y39T, P57V, W58N, P60T] is constructed as follows:

DNA encoding G-CSF [A37N, Y39T] is subcloned into pJB02 to create pJB02G-CSF [A37N, Y39T] and pJB02G-CSF [A37N, Y39T] serves as the template for strand overlapping expression PCR. JCB128 and JCB136 serve as the A and B primers and JCB137 and JCB129 serve as the C and D primers. The full-length mutated cDNA is prepared as described previously using JCB128 and JCB129 primers. The resulting full-length DNA encodes a protein with consensus N-linked glycosylation sites in region 1 and region 2 of the protein. The full-length cDNA is ligated back into pCR2.1-Topo to create pCR2.1G-CSF [A37N, Y39T, P57V, W58N, P60T].

Preparation 1p: DNA encoding G-CSF [A37N, Y39T, Q67N, L69T] is constructed as follows:

DNA encoding G-CSF [A37N, Y39T] is subcloned into pJB02 to create pJB02G-CSF [A37N, Y39T] and pJB02G-CSF [A37N, Y39T] serves as the template for strand overlapping expression PCR. JCB134 and JCB138 serve as the A and B primers and JCB139 and JCB135 serve as the C and D primers. The full-length mutated cDNA is prepared as described previously using JCB128 and JCB129 primers. The resulting full-length DNA encodes a protein with consensus N-linked glycosylation sites in region 1 and region 9 of the protein. The full-length cDNA is ligated back into pCR2.1-Topo to create pCR2.1G-CSF [A37N, Y39T, Q67N, L69T].

Preparation 1q: DNA encoding G-CSF [A37N, Y39T, E93N, I95T] is constructed as follows:

DNA encoding G-CSF [A37N, Y39T] is subcloned into pJB02 to create pJB02G-CSF [A37N, Y39T] and pJB02G-CSF [A37N, Y39T] serves as the template for strand overlapping expression PCR. JCB134 and JCB140 serve as the A and B primers and JCB141 and JCB135 serve as the C and D primers. The full-

WO 03/076567

PCT/US03/03120

- 53 -

length mutated cDNA is prepared as described previously using JCB128 and JCB129 primers. The resulting full-length DNA encodes a protein with consensus N-linked glycosylation sites in region 1 and region 10 of the protein. The full-length cDNA is ligated back into pCR2.1-Topo to create pCR2.1G-CSF [A37N, Y39T, E93N, I95T].

Example 2: Expression of heterologous fusion proteins:

2a: Expression in 293/EBNA cells:

Each full-length DNA encoding a G-CSF analog was subcloned into the *NheI/XhoI* sites of mammalian expression vector pJB02 (Figure 3). This vector contains both the Ori P and Epstein Barr virus nuclear antigen (EBNA) components which are necessary for sustained, transient expression in 293 EBNA cells. This expression plasmid contains a puromycin resistance gene expressed from the CMV promoter as well as an ampicillin resistance gene. The gene of interest is also expressed from the CMV promoter.

The transfection mixture was prepared by mixing 73 µl of the liposome transfection agent Fugene 6® (Roche Molecular Biochemicals, Cat. No. 1815-075) with 820 µl Opti-Mem® (GibcoBRL Cat. No. 31985-062). G-CSF pJB02 DNA (12µg), prepared using a Qiagen plasmid maxiprep kit (Qiagen, Cat. No. 12163), was then added to the mixture. The mixture was incubated at room temperature for 15 minutes.

Cells were plated on 10 cm<sup>2</sup> plates in DMEM/F12 3:1 (GibcoBRL Cat. No. 93-0152DK) supplemented with 5% fetal bovine serum, 20mM HEPES, 2 mM L-glutamine, and 50 µg/mL Geneticin such that the plates were 60% to 80% confluent by the time of the transfection. Immediately before the transfection mixture was added to the plates, fresh media was added. The mixture was then added dropwise to cells with intermittent swirling. Plates were then incubated at 37°C in a 5% CO<sub>2</sub> atmosphere for 24 hours at which point the media was changed to Hybritech medium without serum. The

WO 03/076567

PCT/US03/03120

- 54 -

media containing a secreted form of a glycosylated G-CSF analog was then isolated 48 hours later.

2b: Expression in CHO cells:

The expression vector for expression in CHO-K1 cells pEE14.1 is illustrated in Figure 4. This vector includes the glutamine synthetase gene which enables selection using methionine sulfoximine. This gene includes two poly A signals at the 3' end. G-CSF analogs are expressed from the CMV promoter which includes 5' untranslated sequences from the hCMV-MIE gene to enhance mRNA levels and translatability. The SV40 poly A signal is cloned 3' of the G-CSF analog DNA. The SV40 late promoter drives expression of GS minigene. This expression vector encoding the gene of interest was prepared for transfection using a QIAGEN Maxi Prep Kit (QIAGEN, Cat. No. 12362). The final DNA pellet (50-100 µg) was resuspended in 100 µl of basal formulation medium (GibcoBRL CD-CHO Medium without L-Glutamine, without thymidine, without hypoxanthine). Before each transfection, CHO-K1 cells were counted and checked for viability. A volume equal to  $1 \times 10^7$  cells was centrifuged and the cell pellet rinsed with basal formulation medium. The cells were centrifuged a second time and the final pellet resuspended in basal formulation medium (700 µl final volume).

The resuspended DNA and cells were then mixed together in a standard electroporation cuvette (Gene Pulsar Cuvette) used to support mammalian transfections, and placed on ice for five minutes. The cell/DNA mix was then electroporated in a BioRad Gene Pulsar device set at 300V/975 µF and the cuvette placed back on ice for five minutes. The cell/DNA mixed was then diluted into 20 ml of cell growth medium in a non-tissue culture treated T75 flask and incubated at 37°C / 5% CO<sub>2</sub> for 48-72 hours.

The cells were counted, checked for viability, and plated at various cell densities in selective medium in 96

WO 03/076567

PCT/US03/03120

- 55 -

well tissue culture plates and incubated at 37°C in a 5% CO<sub>2</sub> atmosphere. Selective medium is basal medium with 1X HT Supplement (GibcoBRL 100X HT Stock), 100 µg/mL Dextran Sulfate (Sigma 100 mg/ml stock), 1X GS Supplements (JRH BioSciences 50X Stock) and 25 µM MSX (Methionine Sulphoximine). The plates were monitored for colony formation and screened for glycosylated G-CSF analog production.

Example 3: Purification of Heterologous Fusion Proteins

HA Fusions

The cell culture harvest was dialyzed against 20 mM Tris pH 7.4. An anion exchange column (1 ml Pharmacia HiTrap Q) was equilibrated with 20 mM Tris pH7.4 and the dialyzed material loaded at 2 ml/min. The protein was eluted from the column using a linear gradient from 0 to 500 mM NaCl in 80 min at 1 ml/min and elution was monitored by UV absorbance at 280 nm. SDS-PAGE analysis was used to identify and pool fractions of interest. This pool was dialyzed against 25 mM sodium acetate (NaOAc) pH 5.0

A cation exchange column (1 ml Pharmacia HiTrap S column) was equilibrated with 25 mM NaOAc pH 5.0 and the dialysate was loaded at 1 ml/min. The protein was eluted from the column using a linear gradient from 0 to 500 mM NaCl in 30 min. The fractions were immediately neutralized with 1 M Tris pH 8 to a final pH of 7. SDS-PAGE gels were used to identify and pool fractions of interest.

Fc Fusions

The cell culture harvest was dialyzed against 20 mM sodium phosphate pH 7.0. An affinity column (1 ml Pharmacia HiTrap Protein A or rProtein A) was equilibrated with 20 mM sodium phosphate pH 7.0 and the dialysate was loaded at 2 ml/min. 1 ml/min of 100 mM citric acid pH 3 was used to

WO 03/076567

PCT/US03/03120

- 56 -

elute the protein. Fractions were immediately neutralized with 1M Tris pH 8 to pH 7 and peak fractions (determined by in-line OD280 monitoring) were further diluted with 20 mM sodium phosphate pH 7.0. SDS-PAGE analysis was used to identify and pool fractions of interest.

WO 03/076567

PCT/US03/03120

- 57 -

WE CLAIM:

1. A heterologous fusion protein comprising a hyperglycosylated G-CSF analog fused to a polypeptide selected from the group consisting of
  - d) human albumin;
  - e) human albumin analogs; and
  - f) fragments of human albumin.
2. The heterologous fusion protein of claim 1, wherein the hyperglycosylated G-CSF analog is fused to the polypeptide via a peptide linker.
3. The heterologous fusion protein of the Claim 2 wherein the peptide linker is selected from the group consisting of:
  - c) a glycine rich peptide;
  - d) a peptide having the sequence [Gly-Gly-Gly-Gly-Ser]<sub>n</sub> where n is 1, 2, 3, 4, or 5; and
  - e) a peptide having the sequence [Gly-Gly-Gly-Gly-Ser]<sub>3</sub>.
4. The heterologous fusion protein of Claims 1, 2, or 3 wherein the hyperglycosylated G-CSF analog comprises the amino acid sequence of the formula I: [SEQ ID NO: 1]

1	5	10	15
Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu Lys			
20	25	30	
Xaa Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln			
35	40	45	
Glu Lys Leu Cys Xaa Xaa Xaa Lys Leu Cys His Pro Glu Glu Leu Val			
50	55	60	
Leu Leu Gly His Ser Leu Gly Ile Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa			
65	70	75	80
Xaa Xaa Xaa Xaa Xaa Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser			
85	90	95	
Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Xaa Xaa Xaa Ser			
100	105	110	
Xaa Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp			
115	120	125	
Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro			

- 58 -

130	135	140	
Ala Leu Gln Pro Xaa Xaa Xaa Ala Met Pro Ala Phe Xaa Xaa Xaa Phe			
145	150	155	160
Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Aln Ser Phe			
	165	170	
Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro (I)			

wherein:

Xaa at position 17 is Cys, Ala, Leu, Ser, or Glu;  
Xaa at position 37 is Ala or Asn;  
Xaa at position 38 is Thr, or any other amino acid except  
Pro;  
Xaa at position 39 is Tyr, Thr, or Ser;  
Xaa at position 57 is Pro or Val;  
Xaa at position 58 is Trp or Asn;  
Xaa at position 59 is Ala or any other amino acid except  
Pro;  
Xaa at position 60 is Pro, Thr, Asn, or Ser,  
Xaa at position 61 is Leu, or any other amino acid except  
Pro;  
Xaa at position 62 is Ser or Thr;  
Xaa at position 63 is Ser or Asn;  
Xaa at position 64 is Cys or any other amino acid except  
Pro;  
Xaa at position 65 is Pro, Ser, or Thr;  
Xaa at position 66 is Ser or Thr;  
Xaa at position 67 is Gln or Asn;  
Xaa at position 68 is Ala or any other amino acid except  
Pro;  
Xaa at position 69 is Leu, Thr, or Ser  
Xaa at position 93 is Glu or Asn  
Xaa at position 94 is Gly or any other amino acid except  
Pro;  
Xaa at position 95 is Ile, Asn, Ser, or Thr;  
Xaa at position 97 is Pro, Ser, Thr, or Asn;  
Xaa at position 133 is Thr or Asn;  
Xaa at position 134 is Gln or any other amino acid except  
Pro;  
Xaa at position 135 is Gly, Ser, or Thr  
Xaa at position 141 is Ala or Asn;  
Xaa at position 142 is Ser or any other amino acid except  
Pro; and  
Xaa at position 143 is Ala, Ser, or Thr;

and wherein:

Xaa at positions 37, 38, and 39 constitute region 1;  
Xaa at positions 58, 59, and 60 constitute region 2;  
Xaa at positions 59, 60, and 61 constitute region 3;

WO 03/076567

PCT/US03/03120

- 59 -

Xaa at positions 60, 61, and 62 constitute region 4;  
Xaa at positions 61, 62, and 63 constitute region 5;  
Xaa at positions 62, 63, and 64 constitute region 6;  
Xaa at positions 63, 64, and 65 constitute region 7;  
Xaa at positions 64, 65, and 66 constitute region 8;  
Xaa at positions 67, 68, and 69 constitute region 9;  
Xaa at positions 93, 94, and 95 constitute region 10;  
Xaa at positions 94, 95, and Ser at position 96  
constitute region 11;  
Xaa at positions 95, and 97, and Ser at position 96  
constitute region 12;  
Xaa at positions 133, 134, and 135 constitute  
region 13;  
Xaa at positions 141, 142, and 143 constitute  
region 14;

and provided that at least one of regions 1 through 14  
comprises the sequence Asn Xaa1 Xaa2 wherein Xaa1 is any  
amino acid except Pro and Xaa2 is Ser or Thr.

5. The heterologous fusion protein of Claim 4 wherein any  
two regions of regions 1 through 14 comprise the sequence  
Asn Xaa1 Xaa2 wherein Xaa1 is any amino acid except Pro and  
Xaa2 is Ser or Thr.

6. The heterologous fusion protein of Claim 4 wherein any  
three regions of regions 1 through 14 comprise the sequence  
Asn Xaa1 Xaa2 wherein Xaa1 is any amino acid except Pro and  
Xaa2 is Ser or Thr.

7. The heterologous fusion protein of Claim 4 wherein any  
four regions of regions 1 through 14 comprise the sequence  
Asn Xaa1 Xaa2 wherein Xaa1 is any amino acid except Pro and  
Xaa2 is Ser or Thr.

WO 03/076567

PCT/US03/03120

- 60 -

8. The heterologous fusion protein of Claim 4 wherein the hyperglycosylated G-CSF analog is selected from the group consisting of:

- a) G-CSF [A37N, Y39T]
- b) G-CSF [P57V, W58N, P60T]
- c) G-CSF [P60N, S62T]
- d) G-CSF [S63N, P65T]
- e) G-CSF [Q67N, L69T]
- f) G-CSF [E93N, I95T]
- g) G-CSF [T133N, G135T]
- h) G-CSF [A141N, A143T]
- i) G-CSF [A37N, Y39T, P57V, W58N, P60T]
- j) G-CSF [A37N, Y39T, P60N, S62T]
- k) G-CSF [A37N, Y39T, S63N, P65T]
- l) G-CSF [A37N, Y39T, Q67N, L69T]
- m) G-CSF [A37N, Y39T, E93N, I95T]
- n) G-CSF [A37N, Y39T, T133N, G135T]
- o) G-CSF [A37N, Y39T, A141N, A143T]
- p) G-CSF [A37N, Y39T, P57V, W58N, P60T, S63N, P65T]
- q) G-CSF [A37N, Y39T, P57V, W58N, P60T, Q67N, L69T]
- r) G-CSF [A37N, Y39T, S63N, P65T, E93N, I95T] .

9. The heterologous fusion protein of claim 8, wherein the hyperglycosylated G-CSF analog is G-CSF [A37N, Y39T, P57V, W58N, P60T, Q67N, L69T].

10. The heterologous fusion protein of claim 8, wherein the hyperglycosylated G-CSF analog is G-CSF [A37N, Y39T, S63N, P65T, E93N, I95T].

11. A heterologous fusion protein which is the product of the expression in a host cell of an exogenous DNA sequence which comprises a DNA sequence encoding a heterologous fusion protein of any one of Claims 1 through 11.

12. An isolated nucleic acid sequence, comprising a

WO 03/076567

PCT/US03/03120

- 61 -

polynucleotide encoding a heterologous fusion protein of any one of Claims 1 through 11.

13. An isolated nucleic acid sequence, comprising a polynucleotide which comprises a DNA sequence selected from the group consisting of:

a) SEQ ID NO:2

ACC CCC CTG GGC CCT GCC AGC TCC CTG CCC CAG AGC TTC CTG CTC AAG  
TGG GGG GAC CCG GGA CGG TCG AGG GAC GGG GTC TCG AAG GAC GAG TTC

GCC TTA GAG CAA GTG AGG AAG ATC CAG GGC GAT GGC GCA GCG CTC CAG  
CGG AAT CTC GTT CAC TCC TTC TAG GTC CCG CTA CCG CGT CGC GAG GTC

GAG AAG CTG TGT GCC ACC TAC AAG CTG TGC CAC CCC GAG GAG CTG GTG  
CTC TTC GAC ACA CGG TGG ATG TTC GAC ACG GTG GGG CTC CTC GAC CAC

CTG CTC GGA CAC TCT CTG GGC ATC CCC TGG GCT CCC CTG AGC AGC TGC  
GAC GAG CCT GTG ACA GAC CCG TAG GGG ACC CGA GGG GAC TCG TCG ACG

CCC AGC CAG GCC CTG CAG CTG GCA GGC TGC TTG AGC CAA CTC CAT AGC  
GGG TCG GTC CGG GAC GTC GAC CGT CCG ACG AAC TCG GTT GAG GTA TCG

GGC CTT TTC CTC TAC CAG GGG CTC CTG CAG GCC CTG GAA GGG ATC TCC  
CCG GAA AAG GAG ATG GTC CCC GAG GAC GTC CGG GAC CTT CCC TAG AGG

CCC GAG TTG GGT CCC ACC TTG GAC ACA CTG CAG CTG GAC GTC GCC GAC  
GGG CTC AAC CCA GGG TGG AAC CTG TGT GAC GTC GAC CTG CAG CGG CTG

TTT GCC ACC ACC ATC TGG CAG CAG ATG GAA GAA CTG GGA ATG GCC CCT  
AAA CGG TGG TGG TAG ACC GTC GTC TAC CTT GAC CCT TAC CGG GGA

GCC CTG CAG CCC AAC CAG ACC GCC ATG CCG GCC TTC GCC TCT GCT TTC  
CCG GAC GTC GGG TTG GTC TGG CGG TAC GGC CGG AAG CGG AGA CGA AAG

CAG CGC CGG GCA GGA GGG GTC CTG GTT GCC TCC CAT CTG CAG AGC TTC  
GTC GCG GCC CGT CCT CCC CAG GAC CAA CGG AGG GTA GAC GTC TCG AAG

CTG GAG GTG TCG TAC CGC GTC TTA AGG CAC CTT GCC CAG CCC  
GAC CTC CAC AGC ATG GCG CAG AAT TCC GTG GAA CGG GTC GGG

b) SEQ ID NO:3

ACC CCC CTG GGC CCT GCC AGC TCC CTG CCC CAG AGC TTC CTG CTC AAG  
TGG GGG GAC CCG GGA CGG TCG AGG GAC GGG GTC TCG AAG GAC GAG TTC

GCC TTA GAG CAA GTG AGG AAG ATC CAG GGC GAT GGC GCA GCG CTC CAG  
CGG AAT CTC GTT CAC TCC TTC TAG GTC CCG CTA CCG CGT CGC GAG GTC

GAG AAG CTG TGT GCC ACC TAC AAG CTG TGC CAC CCC GAG GAG CTG GTG  
CTC TTC GAC ACA CGG TGG ATG TTC GAC ACG GTG GGG CTC CTC GAC CAC

CTG CTC GGA CAC TCT CTG GGC ATC CCC TGG GCT CCC CTG AGC AGC TGC  
GAC GAG CCT GTG ACA GAC CCG TAG GGG ACC CGA GGG GAC TCG TCG ACG

CCC AGC CAG GCC CTG CAG CTG GCA GGC TGC TTG AGC CAA CTC CAT AGC

WO 03/076567

PCT/US03/03120

- 62 -

GGG TCG GTC CGG GAC GTC GAC CCG ACG AAC TCG GTT GAG GTA TCG  
GGC CTT TTC CTC TAC CAG GGG CTC CTG CAG GCC CTG GAA GGG ATC TCC  
CCG GAA AAG GAG ATG GTC CCC GAG GAC GTC CGG GAC CTT CCC TAG AGG  
CCC GAG TTG GGT CCC ACC TTG GAC ACA CTG CAG CTG GAC GTC GCC GAC  
GGG CTC AAC CCA GGG TGG AAC CTG TGT GAC GTC GAC CTG CAG CGG CTG  
TTT GCC ACC ACC ATC TGG CAG CAG ATG GAA GAA CTG GGA ATG GCC CCT  
AAA CGG TGG TGG TAG ACC GTC GTC TAC CTT GAC CCT TAC CGG GGA  
GCC CTG CAG CCC ACC CAG GGT GCC ATG CCG GCC TTC AAC TCT ACC TTC  
CGG GAC GTC CGG TGG GTC CCA CGG TAC GGC CGG AAG TTG AGA TGG AAG  
CAG CGC CGG GCA GGA GGG GTC CTG GTT GCC TCC CAT CTG CAG AGC TTC  
GTC CGG GCC CGT CCT CCC CAG GAC CAA CGG AGG GTA GAC GTC TCG AAG  
CTG GAG GTG TCG TAC CGC GTC TTA AGG CAC CTT GCC CAG CCC  
GAC CTC CAC AGC ATG GCG CAG AAT TCC GTG GAA CGG GTC GGG

c) SEQ ID NO:4

ACC CCC CTG GGC CCT GCC AGC TCC CTG CCC CAG AGC TTC CTG CTC AAG  
TGG GGG GAC CCG GGA CGG TCG AGG GAC GGG GTC TCG AAG GAC GAG TTC  
GCC TTA GAG CAA GTG AGG AAG ATC CAG GGC GAT GGC GCA GCG CTC CAG  
CGG AAT CTC GTT CAC TCC TTC TAG GTC CCG CTA CGG CGT CGC GAG GTC  
GAG AAG CTG TGT AAC ACC ACC AAG CTG TGC CAC CCC GAG GAG CTG GTG  
CTC TTC GAC ACA TTG TGG TGG TTC GAC ACG GTG GGG CTC CTC GAC CAC  
CTG CTC GGA CAC TCT CTG GGC ATC CCC TGG GCT CCC CTG AGC AGC TGC  
GAC GAG CCT GTG ACA GAC CCG TAG GGG ACC CGA GGG GAC TCG TCG ACG  
CCC AGC CAG GCC CTG CAG CTG GCA GGC TGC TTG AGC CAA CTC CAT AGC  
GGG TCG GTC CGG GAC GTC CGT CCG ACG AAC TCG GTT GAG GTA TCG  
GGC CTT TTC CTC TAC CAG GGG CTC CTG CAG GCC CTG GAA GGG ATC TCC  
CCG GAA AAG GAG ATG GTC CCC GAG GAC GTC CGG GAC CTT CCC TAG AGG  
CCC GAG TTG GGT CCC ACC TTG GAC ACA CTG CAG CTG GAC GTC GCC GAC  
GGG CTC AAC CCA GGG TGG AAC CTG TGT GAC GTC GAC CTG CAG CGG CTG  
TTT GCC ACC ACC ATC TGG CAG CAG ATG GAA GAA CTG GGA ATG GCC CCT  
AAA CGG TGG TGG TAG ACC GTC GTC TAC CTT GAC CCT TAC CGG GGA  
GCC CTG CAG CCC ACC CAG GGT GCC ATG CCG GCC TTC GCC TCT GCT TTC  
CGG GAC GTC CGG TGG GTC CCA CGG TAC GGC CGG AAG CGG AGA CGA AAG  
CAG CGC CGG GCA GGA GGG GTC CTG GTT GCC TCC CAT CTG CAG AGC TTC  
GTC CGC GCC CGT CCT CCC CAG GAC CAA CGG AGG GTA GAC GTC TCG AAG  
CTG GAG GTG TCG TAC CGC GTC TTA AGG CAC CTT GCC CAG CCC  
GAC CTC CAC AGC ATG GCG CAG AAT TCC GTG GAA CGG GTC GGG

d) SEQ ID NO:5

ACC CCC CTG GGC CCT GCC AGC TCC CTG CCC CAG AGC TTC CTG CTC AAG  
TGG GGG GAC CCG GGA CGG TCG AGG GAC GGG GTC TCG AAG GAC GAG TTC

WO 03/076567

PCT/US03/03120

- 63 -

GCC TTA GAG CAA GTG AGG AAG ATC CAG GGC GAT GGC GCA GCG CTC CAG  
CGG AAT CTC GTT CAC TCC TTC TAG GTC CCG CTA CCG CGT CGC GAG GTC  
  
GAG AAG CTG TGT GCC ACC TAC AAG CTG TGC CAC CCC GAG GAG CTG GTG  
CTC TTC GAC ACA CGG TGG ATG TTC GAC ACG GTG GGG CTC CTC GAC CAC  
  
CTG CTC GGA CAC TCT CTG GGC ATC CCC TGG GCT AAC ACT AGC AGC TGC  
GAC GAG CCT GTG ACA GAC CCG TAG GGG ACC CGA TTG GAC TCC TCG ACG  
  
CCC AGC CAG GCC CTG CAG CTG GCA GGC TGC TTG AGC CAA CTC CAT AGC  
GGG TCG GTC CGG GAC GTC GAC CGT CCG ACG AAC TCG GTT GAG GTA TCG  
  
GGC CTT TTC CTC TAC CAG GGG CTC CTG CAG GCC CTG GAA GGG ATC TCC  
CCG GAA AAG GAG ATG GTC CCC GAG GAC GTC CGG GAC CTT CCC TAG AGG  
  
CCC GAG TTG GGT CCC ACC TTG GAC ACA CTG CAG CTG GAC GTC GCC GAC  
GGG CTC AAC CCA GGG TGG AAC CTG TGT GAC GTC GAC CTG CAG CGG CTG  
  
TTT GCC ACC ACC ATC TGG CAG CAG ATG GAA GAA CTG GGA ATG GCC CCT  
AAA CGG TGG TAG ACC GTC GTC TAC CTT GAC CCT TAC CGG GGA  
  
GCC CTG CAG CCC ACC CAG GGT GCC ATG CCG GCC TTC GCC TCT GCT TTC  
CCG GAC GTC GGG TGG GTC CCA CGG TAC GGC CGG AAG CGG AGA CGA AAG  
  
CAG CGC CGG GCA GGA GGG GTC CTG GTT GCC TCC CAT CTG CAG AGC TTC  
GTC GCG GCC CGT CCT CCC CAG GAC CAA CGG AGG GTA GAC GTC TCG AAG  
  
CTG GAG GTG TCG TAC CGC GTC TTA AGG CAC CTT GCC CAG CCC  
GAC CTC CAC AGC ATG GCG CAG AAT TCC GTG GAA CGG GTC GGG  
  
e) SEQ ID NO: 6  
ACC CCC CTG GGC CCT GCC AGC TCC CTG CCC CAG AGC TTC CTG CTC AAG  
TGG GGG GAC CCG GGA CGG TCG AGG GAC GGG GTC TCG AAG GAC GAG TTC  
  
GCC TTA GAG CAA GTG AGG AAG ATC CAG GGC GAT GGC GCA GCG CTC CAG  
CGG AAT CTC GTT CAC TCC TTC TAG GTC CCG CTA CCG CGT CGC GAG GTC  
  
GAG AAG CTG TGT GCC ACC TAC AAG CTG TGC CAC CCC GAG GAG CTG GTG  
CTC TTC GAC ACA CGG TGG ATG TTC GAC ACG GTG GGG CTC CTC GAC CAC  
  
CTG CTC GGA CAC TCT CTG GGC ATC CCC TGG GCT CCC CTG AGC AAT TGC  
GAC GAG CCT GTG ACA GAC CCG TAG GGG ACC CGA GGG GAC TCG TTA ACG  
  
ACC AGC CAG GCC CTG CAG CTG GCA GGC TGC TTG AGC CAA CTC CAT AGC  
TGG TCG GTC CGG GAC GTC CGT CCG ACG AAC TCG GTT GAG GTA TCG  
  
GGC CTT TTC CTC TAC CAG GGG CTC CTG CAG GCC CTG GAA GGG ATC TCC  
CCG GAA AAG GAG ATG GTC CCC GAG GAC GTC CGG GAC CTT CCC TAG AGG  
  
CCC GAG TTG GGT CCC ACC TTG GAC ACA CTG CAG CTG GAC GTC GCC GAC  
GGG CTC AAC CCA GGG TGG AAC CTG TGT GAC GTC GAC CTG CAG CGG CTG  
  
TTT GCC ACC ACC ATC TGG CAG CAG ATG GAA GAA CTG GGA ATG GCC CCT  
AAA CGG TGG TAG ACC GTC GTC TAC CTT GAC CCT TAC CGG GGA  
  
GCC CTG CAG CCC ACC CAG GGT GCC ATG CCG GCC TTC GCC TCT GCT TTC  
CCG GAC GTC GGG TGG GTC CCA CGG TAC GGC CGG AAG CGG AGA CGA AAG

WO 03/076567

PCT/US03/03120

- 64 -

CAG CGC CGG GCA GGA GGG GTC CTG GTT GCC TCC CAT CTG CAG AGC TTC  
GTC GCG GCC CGT CCT CCC CAG GAC CAA CGG AGG GTA GAC GTC TCG AAG  
CTG GAG GTG TCG TAC CGC GTC TTA AGG CAC CTT GCC CAG CCC  
GAC CTC CAC AGC ATG GCG CAG AAT TCC GTG GAA CGG GTC GGG

f) SEQ ID NO:7

ACC CCC CTG GGC CCT GCC AGC TCC CTG CCC CAG AGC TTC CTG CTC AAG  
TGG GGG GAC CCG GGA CGG TCG AGG GAC GGG GTC TCG AAG GAC GAG TTC

GCC TTA GAG CAA GTG AGG AAG ATC CAG GGC GAT GGC GCA GCG CTC CAG  
CGG AAT CTC GTT CAC TCC TTC TAG GTC CCG CTA CCG CGT CGC GAG GTC

GAG AAG CTG TGT GCC ACC TAC AAG CTG TGC CAC CCC GAG GAG CTG GTG  
CTC TTC GAC ACA CGG TGG ATG TTC GAC ACG GTG GGG CTC CTC GAC CAC

CTG CTC GGA CAC TCT CTG GGC ATC GTT AAC GCT ACC CTG AGC AGC TGC  
GAC GAG CCT GTG ACA GAC CCG TAG CAA TTG CGA TGG GAC TCG TCG ACG

CCC AGC CAG GCC CTG CAG CTG GCA GGC TGC TTG AGC CAA CTC CAT AGC  
GGG TCG GTC CGG GAC GTC GAC CGT CCG ACG AAC TCG GTT GAG GTA TCG

GGC CTT TTC CTC TAC CAG GGG CTC CTG CAG GCC CTG GAA GGG ATC TCC  
CCG GAA AAG GAG ATG GTC CCC GAG GAC GTC CGG GAC CTT CCC TAG AGG

CCC GAG TTG GGT CCC ACC TTG GAC ACA CTG CAG CTG GAC GTC GCC GAC  
GGG CTC AAC CCA CGG TGG AAC CTG TGT GAC GTC GAC CTG CAG CGG CTG

TTT GCC ACC ACC ATC TGG CAG CAG ATG GAA GAA CTG GGA ATG GCC CCT  
AAA CGG TGG TGG TAG ACC GTC GTC TAC CTT CTT GAC CCT TAC CGG GGA

GCC CTG CAG CCC ACC CAG GGT GCC ATG CCG GCC TTC GCC TCT GCT TTC  
CCG GAC GTC GGG TGG GTC CCA CGG TAC GGC CGG AAG CGG AGA CGA AAG

CAG CGC CGG GCA GGA GGG GTC CTG GTT GCC TCC CAT CTG CAG AGC TTC  
GTC GCG GCC CGT CCT CCC CAG GAC CAA CGG AGG GTA GAC GTC TCG AAG

CTG GAG GTG TCG TAC CGC GTC TTA AGG CAC CTT GCC CAG CCC  
GAC CTC CAC AGC ATG GCG CAG AAT TCC GTG GAA CGG GTC GGG

g) SEQ ID NO:8

ACC CCC CTG GGC CCT GCC AGC TCC CTG CCC CAG AGC TTC CTG CTC AAG  
TGG GGG GAC CCG GGA CGG TCG AGG GAC GGG GTC TCG AAG GAC GAG TTC

GGC TTA GAG CAA GTG AGG AAG ATC CAG GGC GAT GGC GCA GCG CTC CAG  
CGG AAT CTC GTT CAC TCC TTC TAG GTC CCG CTA CCG CGT CGC GAG GTC

GAG AAG CTG TGT GCC ACC TAC AAG CTG TGC CAC CCC GAG GAG CTG GTG  
CTC TTC GAC ACA CGG TGG ATG TTC GAC ACG GTG GGG CTC CTC GAC CAC

CTG CTC GGA CAC TCT CTG GGC ATC CCC TGG GCT CCC CTG AGC AGC TGC  
GAC GAG CCT GTG ACA GAC CCG TAG GGG ACC CGA GGG GAC TCG TCG ACG

CCC AGC AAC GCC ACC CAG CTG GCA GGC TGC TTG AGC CAA CTC CAT AGC  
GGG TCG TTG CGG TGG GTC GAC CGT CCG ACG AAC TCG GTT GAG GTA TCG

GGC CTT TTC CTC TAC CAG GGG CTC CTG CAG GCC CTG GAA GGG ATC TCC

WO 03/076567

PCT/US03/03120

- 65 -

CCG GAA AAG GAG ATG GTC CCC GAG GAC GTC CGG GAC CTT CCC TAG AGG  
CCC GAG TTG GGT CCC ACC TTG GAC ACA CTG CAG CTG GAC GTC GCC GAC  
GGG CTC AAC CCA GGG TGG AAC CTG TGT GAC GTC GAC CTG CAG CGG CTG  
TTT GCC ACC ACC ATC TGG CAG CAG ATG GAA GAA CTG GGA ATG GCC CCT  
AAA CGG TGG TGG TAG ACC GTC GTC TAC CTT GAC CCT TAC CGG GGA  
GCC CTG CAG CCC ACC CAG GGT GCC ATG CCG GCC TTC GCC TCT GCT TTC  
CGG GAC GTC GGG TGG GTC CCA CGG TAC GGC CGG AAG CGG AGA CGA AAG  
CAG CGC CGG GCA GGA GGG GTC CTG GTT GCC TCC CAT CTG CAG AGC TTC  
GTC GCG GCC CGT CCT CCC CAG GAC CAA CGG AGG GTA GAC GTC TCG AAG  
CTG GAG GTG TCG TAC CGC GTC TTA AGG CAC CTT GCC CAG CCC  
GAC CTC CAC AGC ATG GCG CAG AAT TCC GTG GAA CGG GTC GGG  
h) SEQ ID NO:9

ACC CCC CTG GGC CCT GCC AGC TCC CTG CCC CAG AGC TTC CTG CTC AAG  
TGG GGG GAC CCG GGA CGG TCG AGG GAC GGG GTC TCG AAG GAC GAG TTC  
GCC TTA GAG CAA GTG AGG AAG ATC CAG GGC GAT GGC GCA GCG CTC CAG  
CGG AAT CTC GTT CAC TCC TTC TAG GTC CCG CTA CGG CGT CGC GAG GTC  
GAG AAG CTG TGT GCC ACC TAC AAG CTG TGC CAC CCC GAG GAG CTG GTG  
CTC TTC GAC ACA CGG TGG ATG TTC GAC ACG GTG GGG CTC CTC GAC CAC  
CTG CTC GGA CAC TCT CTG GGC ATC CCC TGG GCT CCC CTG AGC AGC TGC  
GAC GAG CCT GTG ACA GAC CCG TAG GGG ACC CGA GGG GAC TCG TCG ACG  
CCC AGC CAG GCC CTG CAG CTG GCA GGC TGC TTG AGC CAA CTC CAT AGC  
GGG TCG GTC CGG GAC GTC GAC CGT CCG ACG AAC TCG GTT GAG GTA TCG  
GGC CTT TTC CTC TAC CAG GGG CTC CTG CAG GCC CTG AAC GGG ACC TCC  
CCG GAA AAG GAG ATG GTC CCC GAG GAC GTC CGG GAC TTG CCC TGG AGG  
CCC GAG TTG GGT CCC ACC TTG GAC ACA CTG CAG CTG GAC GTC GCC GAC  
GGG CTC AAC CCA GGG TGG AAC CTG TGT GAC GTC GAC CTG CAG CGG CTG  
TTT GCC ACC ACC ATC TGG CAG CAG ATG GAA GAA CTG GGA ATG GCC CCT  
AAA CGG TGG TGG TAG ACC GTC GTC TAC CTT CTT GAC CCT TAC CGG GGA  
GCC CTG CAG CCC ACC CAG GGT GCC ATG CCG GCC TTC GCC TCT GCT TTC  
CGG GAC GTC GGG TGG GTC CCA CGG TAC GGC CGG AAG CGG AGA CGA AAG  
CAG CGC CGG GCA GGA GGG GTC CTG GTT GCC TCC CAT CTG CAG AGC TTC  
GTC GCG GCC CGT CCT CCC CAG GAC CAA CGG AGG GTA GAC GTC TCG AAG  
CTG GAG GTG TCG TAC CGC GTC TTA AGG CAC CTT GCC CAG CCC  
GAC CTC CAC AGC ATG GCG CAG AAT TCC GTG GAA CGG GTC GGG

i) SEQ ID NO:10

ACC CCC CTG GGC CCT GCC AGC TCC CTG CCC CAG AGC TTC CTG CTC AAG  
TGG GGG GAC CCG GGA CGG TCG AGG GAC GGG GTC TCG AAG GAC GAG TTC  
GCC TTA GAG CAA GTG AGG AAG ATC CAG GGC GAT GGC GCA GCG CTC CAG  
CGG AAT CTC GTT CAC TCC TTC TAG GTC CCG CTA CGG CGT CGC GAG GTC

WO 03/076567

PCT/US03/03120

- 66 -

GAG AAG CTG TGT AAC ACC ACC AAG CTG TGC CAC CCC GAG GAG CTG GTG  
CTC TTC GAC ACA TTG TGG TGG TTC GAC ACG GTG GGG CTC CTC GAC CAC  
  
CTG CTC GGA CAC TCT CTG GGC ATC CCC TGG GCT CCC CTG AGC AGC TGC  
GAC GAG CCT GTG ACA GAC CCG TAG GGG ACC CGA GGG GAC TCG TCG ACG  
  
CCC AGC CAG GCC CTG CAG CTG GCA GGC TGC TTG AGC CAA CTC CAT AGC  
GGG TCG GTC CGG GAC GTC CGT CCG ACG AAC TCG GTT GAG GTA TCG  
  
GGC CTT TTC CTC TAC CAG GGG CTC CTG CAG GCC CTG GAA GGG ATC TCC  
CCG GAA AAG GAG ATG GTC CCC GAG GAC GTC CGG GAC CTT CCC TAG AGG  
  
CCC GAG TTG GGT CCC ACC TTG GAC ACA CTG CAG CTG GAC GTC GCC GAC  
GGG CTC AAC CCA GGG TGG AAC CTG TGT GAC GTC CGG GAC CTT CCC TAG AGG  
  
TTT GCC ACC ACC ATC TGG CAG CAG ATG GAA GAA CTG GGA ATG GCC CCT  
AAA CGG TGG TGG TAG ACC GTC TAC CTT GAC CCT TAC CGG GGA  
  
GCC CTG CAG CCC AAC CAG ACC GCC ATG CCG GCC TTC GCC TCT GCT TTC  
CGG GAC GTC CGG TTG GTC TGG CGG TAC GGC CGG AAG CGG AGA CGA AAG  
  
CAG CGC CGG GCA GGA GGG GTC CTG GTT GCC TCC CAT CTG CAG AGC TTC  
GTC GCG GCC CGT CCT CCC CAG GAC CAA CGG AGG GTA GAC GTC TCG AAG  
  
CTG GAG GTG TCG TAC CGC GTC TTA AGG CAC CTT GCC CAG CCC  
GAC CTC CAC AGC ATG GCG CAG AAT TCC GTG GAA CGG GTC GGG  
  
j) SEQ ID NO:11  
ACC CCC CTG GGC CCT GCC AGC TCC CTG CCC CAG AGC TTC CTG CTC AAG  
TGG GGG GAC CCG GGA CGG TCG AGG GAC GGG GTC TCG AAG GAC GAG TTC  
  
GCC TTA GAG CAA GTG AGG AAG ATC CAG GGC GAT GGC GCA GCG CTC CAG  
CGG AAT CTC GTT CAC TCC TTC TAG GTC CCG CTA CCG CGT CGC GAG GTC  
  
GAG AAG CTG TGT AAC ACC ACC AAG CTG TGC CAC CCC GAG GAG CTG GTG  
CTC TTC GAC ACA TTG TGG TGG TTC GAC ACG GTG GGG CTC CTC GAC CAC  
  
CTG CTC GGA CAC TCT CTG GGC ATC CCC TGG GCT CCC CTG AGC AGC TGC  
GAC GAG CCT GTG ACA GAC CCG TAG GGG ACC CGA GGG GAC TCG TCG ACG  
  
CCC AGC CAG GCC CTG CAG CTG GCA GGC TGC TTG AGC CAA CTC CAT AGC  
GGG TCG GTC CGG GAC GTC CGT CCG ACG AAC TCG GTT GAG GTA TCG  
  
GGC CTT TTC CTC TAC CAG GGG CTC CTG CAG GCC CTG GAA GGG ATC TCC  
CCG GAA AAG GAG ATG GTC CCC GAG GAC GTC CGG GAC CTT CCC TAG AGG  
  
CCC GAG TTG GGT CCC ACC TTG GAC ACA CTG CAG CTG GAC GTC GCC GAC  
GGG CTC AAC CCA GGG TGG AAC CTG TGT GAC GTC CGG GAC CTG CAG CGG CTG  
  
TTT GCC ACC ACC ATC TGG CAG CAG ATG GAA GAA CTG GGA ATG GCC CCT  
AAA CGG TGG TGG TAG ACC GTC TAC CTT GAC CCT TAC CGG GGA  
  
GCC CTG CAG CCC ACC CAG GGT GCC ATG CCG GCC TTC AAC TCT ACC TTC  
CGG GAC GTC CGG TGG GTC CCA CGG TAC GGC CGG AAG TTG AGA TGG AAG  
  
CAG CGC CGG GCA GGA GGG GTC CTG GTT GCC TCC CAT CTG CAG AGC TTC  
GTC GCG GCC CGT CCT CCC CAG GAC CAA CGG AGG GTA GAC GTC TCG AAG

WO 03/076567

PCT/US03/03120

- 67 -

CTG GAG GTG TCG TAC CGC GTC TTA AGG CAC CTT GCC CAG CCC  
GAC CTC CAC AGC ATG GCG CAG AAT TCC GTG GAA CGG GTC GGG

k) SEQ ID NO:12

ACC CCC CTG GGC CCT GCC AGC TCC CTG CCC CAG AGC TTC CTG CTC AAG  
TGG GGG GAC CCG GGA CGG TCG AGG GAC GGG GTC TCG AAG GAC GAG TTC

GCC TTA GAG CAA GTG AGG AAG ATC CAG GGC GAT GGC GCA GCG CTC CAG  
CGG AAT CTC GTT CAC TCC TTC TAG GTC CCG CTA CCG CGT CGC GAG GTC

GAG AAG CTG TGT AAC ACC ACC AAG CTG TGC CAC CCC GAG GAG CTG GTG  
CTC TTC GAC ACA TTG TGG TTC GAC ACG GTG GGG CTC CTC GAC CAC

CTG CTC GGA CAC TCT CTG GGC ATC GTT AAC GCT ACC CTG AGC AGC TGC  
GAC GAG CCT GTG ACA GAC CCG TAG CAA TTG CGA TGG GAC TCG TCG ACG

CCC AGC CAG GCC CTG CAG CTG GCA GGC TGC TTG AGC CAA CTC CAT AGC  
GGG TCG GTC CGG GAC GTC GAC CGT CCG ACG AAC TCG GTT GAG GTA TCG

GGC CTT TTC CTC TAC CAG GGG CTC CTG CAG GCC CTG GAA GGG ATC TCC  
CCG GAA AAG GAG ATG GTC CCC GAG GAC GTC CGG GAC CTT CCC TAG AGG

CCC GAG TTG GGT CCC ACC TTG GAC ACA CTG CAG CTG GAC GTC GCC GAC  
GGG CTC AAC CCA GGG TGG AAC CTG TGT GAC GTC GAC CTG CAG CGG CTG

TTT GCC ACC ACC ATC TGG CAG CAG ATG GAA GAA CTG GGA ATG GCC CCT  
AAA CGG TGG TGG TAG ACC GTC GTC TAC CTT CTT GAC CCT TAC CGG GGA

GCC CTG CAG CCC ACC CAG GGT GCC ATG CCG GCC TTC GCC TCT GCT TTC  
CCG GAC GTC GGG TGG GTC CCA CGG TAC GGC CGG AAG CGG AGA CGA AAG

CAG CGC CGG GCA GGA GGG GTC CTG GTT GCC TCC CAT CTG CAG AGC TTC  
GTC GCG GCC CGT CCT CCC CAG GAC CAA CGG AGG GTA GAC GTC TCG AAG

CTG GAG GTG TCG TAC CGC GTC TTA AGG CAC CTT GCC CAG CCC  
GAC CTC CAC AGC ATG GCG CAG AAT TCC GTG GAA CGG GTC GGG

1) SEQ ID NO:13

ACC CCC CTG GGC CCT GCC AGC TCC CTG CCC CAG AGC TTC CTG CTC AAG  
TGG GGG GAC CCG GGA CGG TCG AGG GAC GGG GTC TCG AAG GAC GAG TTC

GCC TTA GAG CAA GTG AGG AAG ATC CAG GGC GAT GGC GCA GCG CTC CAG  
CGG AAT CTC GTT CAC TCC TTC TAG GTC CCG CTA CCG CGT CGC GAG GTC

GAG AAG CTG TGT AAC ACC ACC AAG CTG TGC CAC CCC GAG GAG CTG GTG  
CTC TTC GAC ACA TTG TGG TTC GAC ACG GTG GGG CTC CTC GAC CAC

CTG CTC GGA CAC TCT CTG GGC ATC CCC TGG GCT CCC CTG AGC AGC TGC  
GAC GAG CCT GTG ACA GAC CCG TAG GGG ACC CGA GGG GAC TCG TCG ACG

CCC AGC AAC GCC ACC CAG CTG GCA GGC TGC TTG AGC CAA CTC CAT AGC  
GGG TCG TTG CGG TGG GTC GAC CGT CCG ACG AAC TCG GTT GAG GTA TCG

GGC CTT TTC CTC TAC CAG GGG CTC CTG CAG GCC CTG GAA GGG ATC TCC  
CCG GAA AAG GAG ATG GTC CCC GAG GAC GTC CGG GAC CTT CCC TAG AGG

WO 03/076567

PCT/US03/03120

- 68 -

CCC GAG TTG GGT CCC ACC TTG GAC ACA CTG CAG CTG GAC GTC GCC GAC  
GGG CTC AAC CCA GGG TGG AAC CTG TGT GAC GTC GAC CTG CAG CGG CTG  
  
TTT GCC ACC ACC ATC TGG CAG CAG ATG GAA GAA CTG GGA ATG GCC CCT  
AAA CGG TGG TGG TAG ACC GTC GTC TAC CTT CTT GAC CCT TAC CGG GGA  
  
GCC CTG CAG CCC ACC CAG GGT GCC ATG CCG GCC TTC GCC TCT GCT TTC  
CGG GAC GTC GGG TGG GTC CCA CGG TAC GGC CGG AAG CGG AGA CGA AAG  
  
CAG CGC CGG GCA GGA GGG GTC CTG GTT GCC TCC CAT CTG CAG AGC TTC  
GTC GCG GCC CGT CCT CCC CAG GAC CAA CGG AGG GTA GAC GTC TCG AAG  
  
CTG GAG GTG TCG TAC CGC GTC TTA AGG CAC CTT GCC CAG CCC  
GAC CTC CAC AGC ATG GCG CAG AAT TCC GTG GAA CGG GTC GGG

m) SEQ ID NO:14

ACC CCC CTG GGC CCT GCC AGC TCC CTG CCC CAG AGC TTC CTG CTC AAG  
TGG GGG GAC CCG GGA CGG TCG AGG GAC GGG GTC TCG AAG GAC GAG TTC  
  
GCC TTA GAG CAA GTG AGG AAG ATC CAG GGC GAT GGC GCA GCG CTC CAG  
CGG AAT CTC GTT CAC TCC TTC TAG GTC CCG CTA CGG CGT CGC GAG GTC  
  
GAG AAG CTG TGT AAC ACC ACC AAG CTG TGC CAC CCC GAG GAG CTG GTG  
CTC TTC GAC ACA TTG TGG TGG TTC GAC ACG GTG GGG CTC CTC GAC CAC  
  
CTG CTC GGA CAC TCT CTG GGC ATC CCC TGG GCT CCC CTG AGC AGC TGC  
GAC GAG CCT GTG ACA GAC CCG TAG GGG ACC CGA GGG GAC TCG TCG ACG  
  
CCC AGC CAG GCC CTG CAG CTG GCA GGC TGC TTG AGC CAA CTC CAT AGC  
GGG TCG GTC CGG GAC GTC GAC CGT CCG ACG AAC TCG GTT GAG GTA TCG  
  
GGC CTT TTC CTC TAC CAG GGG CTC CTG CAG GCC CTG GAA GGG ATC TCC  
CCG GAA AAG GAG ATG GTC CCC GAG GAC GTC CGG GAC CTT CCC TAG AGG  
  
AAC GGT ACC GGT CCC ACC TTG GAC ACA CTG CAG CTG GAC GTC GCC GAC  
TTG CCA TGG CCA GGG TGG AAC CTG TGT GAC GTC GAC CTG CAG CGG CTG

TTT GCC ACC ACC ATC TGG CAG CAG ATG GAA GAA CTG GGA ATG GCC CCT  
AAA CGG TGG TGG TAG ACC GTC GTC TAC CTT CTT GAC CCT TAC CGG GGA  
  
GCC CTG CAG CCC ACC CAG GGT GCC ATG CCG GCC TTC GCC TCT GCT TTC  
CGG GAC GTC GGG TGG GTC CCA CGG TAC GGC CGG AAG CGG AGA CGA AAG  
  
CAG CGC CGG GCA GGA GGG GTC CTG GTT GCC TCC CAT CTG CAG AGC TTC  
GTC GCG GCC CGT CCT CCC CAG GAC CAA CGG AGG GTA GAC GTC TCG AAG  
  
CTG GAG GTG TCG TAC CGC GTC TTA AGG CAC CTT GCC CAG CCC  
GAC CTC CAC AGC ATG GCG CAG AAT TCC GTG GAA CGG GTC GGG

n) SEQ ID NO:15

ACC CCC CTG GGC CCT GCC AGC TCC CTG CCC CAG AGC TTC CTG CTC AAG  
TGG GGG GAC CCG GGA CGG TCG AGG GAC GGG GTC TCG AAG GAC GAG TTC  
  
GCC TTA GAG CAA GTG AGG AAG ATC CAG GGC GAT GGC GCA GCG CTC CAG  
CGG AAT CTC GTT CAC TCC TTC TAG GTC CCG CTA CGG CGT CGC GAG GTC  
  
GAG AAG CTG TGT AAC ACC ACC AAG CTG TGC CAC CCC GAG GAG CTG GTG  
CTC TTC GAC ACA TTG TGG TGG TTC GAC ACG GTG GGG CTC CTC GAC CAC

WO 03/076567

PCT/US03/03120

- 69 -

CTG CTC GGA CAC TCT CTG GGC ATC GTT AAC GCT ACC CTG AGC AGC TGC  
GAC GAG CCT GTG ACA GAC CCG TAG CAA TTG CGA TGG GAC TCG TCG ACG

CCC AGC AAC GCC ACC CAG CTG GCA GGC TGC TTG AGC CAA CTC CAT AGC  
GGG TCG TTG CGG TGG GTC GAC CGT CCG AGC AAC TCG GTT GAG GTA TCG

GGC CTT TTC CTC TAC CAG GGG CTC CTG CAG GCC CTG GAA GGG ATC TCC  
CCG GAA AAG GAG ATG GTC CCC GAG GAC GTC CGG GAC CTT CCC TAG AGG

CCC GAG TTG GGT CCC ACC TTG GAC ACA CTG CAG CTG GAC GTC GCC GAC  
GGG CTC AAC CCA GGG TGG AAC CTG TGT GAC GTC GAC CTG CAG CGG CTG

TTT GCC ACC ACC ATC TGG CAG CAG ATG GAA GAA CTG GGA ATG GCC CCT  
AAA CGG TGG TGG TAG ACC GTC GTC TAC CTT GAC CCT TAC CGG GGA

GCC CTG CAG CCC ACC CAG GGT GCC ATG CCG GCC TTC GCC TCT GCT TTC  
CGG GAC GTC GGG TGG GTC CCA CGG TAC GGC CGG AAG CGG AGA CGA AAG

CAG CGC CGG GCA GGA GGG GTC CTG GTT GCC TCC CAT CTG CAG AGC TTC  
GTC GCG GCC CGT CCT CCC CAG GAC CAA CGG AGG GTA GAC GTC TCG AAG

CTG GAG GTG TCG TAC CGC GTC TTA AGG CAC CTT GCC CAG CCC  
GAC CTC CAC AGC ATG GCG CAG AAT TCC GTG GAA CGG GTC GCG GGG

o) SEQ ID NO:16

ACC CCC CTG GGC CCT GCC AGC TCC CTG CCC CAG AGC TTC CTG CTC AAG  
TGG GGG GAC CCG GGA CGG TCG AGG GAC GGG GTC TCG AAG GAC GAG TTC

GCC TTA GAG CAA GTG AGG AAG ATC CAG GGC GAT GGC GCA GCG CTC CAG  
CGG AAT CTC GTT CAC TCC TTC TAG GTC CCG CTA CCG CGT CGC GAG GTC

GAG AAG CTG TGT AAC ACC AAG CTG TGC CAC CCC GAG GAG CTG GTG  
CTC TTC GAC ACA TTG TGG TGG TTC GAC ACG GTG GGG CTC CTC GAC CAC

CTG CTC GGA CAC TCT CTG GGC ATC CCC TGG GCT CCC CTG AGC AAT TGC  
GAC GAG CCT GTG ACA GAC CCG TAG GGG ACC CGA GGG GAC TCG TTA ACG

ACC AGC CAG GCC CTG CAG CTG GCA GGC TGC TTG AGC CAA CTC CAT AGC  
TGG TCG GTC CGG GAC GTC GAC CGT CCG ACG AAC TCG GTT GAG GTA TCG

GGC CTT TTC CTC TAC CAG GGG CTC CTG CAG GCC CTG AAC GGG ACC TCC  
CCG GAA AAG GAG ATG GTC CCC GAG GAC GTC CGG GAC TTG CCC TGG AGG

CCC GAG TTG GGT CCC ACC TTG GAC ACA CTG CAG CTG GAC GTC GCC GAC  
GGG CTC AAC CCA GGG TGG AAC CTG TGT GAC GTC GAC CTG CAG CGG CTG

TTT GCC ACC ACC ATC TGG CAG CAG ATG GAA GAA CTG GGA ATG GCC CCT  
AAA CGG TGG TGG TAG ACC GTC GTC TAC CTT GAC CCT TAC CGG GGA

GCC CTG CAG CCC ACC CAG GGT GCC ATG CCG GCC TTC GCC TCT GCT TTC  
CGG GAC GTC GGG TGG GTC CCA CGG TAC GGC CGG AAG CGG AGA CGA AAG

CAG CGC CGG GCA GGA GGG GTC CTG GTT GCC TCC CAT CTG CAG AGC TTC  
GTC GCG GCC CGT CCT CCC CAG GAC CAA CGG AGG GTA GAC GTC TCG AAG

CTG GAG GTG TCG TAC CGC GTC TTA AGG CAC CTT GCC CAG CCC  
GAC CTC CAC AGC ATG GCG CAG AAT TCC GTG GAA CGG GTC GCG GGG,

WO 03/076567

PCT/US03/03120

- 70 -

fused to a DNA encoding a protein selected from the group consisting of:

- a) human albumin,
- b) human albumin analog; and
- c) fragments of human albumin.

14. The heterologous fusion protein of any one of Claims 1 through 11 wherein the polypeptide is human albumin.

15. The heterologous fusion protein of Claim 12, wherein the second polypeptide has the sequence of SEQ ID NO: 35.

16. The heterologous fusion protein of any one of Claims 1 through 11 wherein the second polypeptide is an N-terminal fragment of albumin.

17. A method for increasing neutrophil levels in a mammal comprising the administration of a therapeutically effective amount of the heterologous fusion protein of any one of Claims 1 through 11, 14 and 15.

18. The use of the heterologous fusion protein as claimed in any one of Claims 1 through 11, 14 and 15 for the manufacture of a medicament for the treatment of patients with insufficient circulating neutrophil levels.

19. Use of a heterologous fusion protein of any one of Claims 1 through 11, 14, and 15 as a medicament.

20. Use of a heterologous fusion protein of any one of Claims 1 through 11, 14, and 15 for the treatment of patients with insufficient circulating neutrophil levels.

21. A pharmaceutical formulation adapted for the treatment of patients with insufficient neutrophil levels comprising a

WO 03/076567

PCT/US03/03120

- 71 -

heterologous fusion protein of any one of Claims 1 through 11, 14, and 15.

22. A heterologous fusion protein comprising a hyperglycosylated G-CSF analog fused to a polypeptide selected from the group consisting of

- a) the Fc portion of an immunoglobulin;
- b) an analog of the Fc portion of an immunoglobulin;  
and
- c) fragments of the Fc portion of an immunoglobulin.

23. The heterologous fusion protein of Claim 22, wherein the hyperglycosylated G-CSF analog is fused to the polypeptide via a peptide linker.

24. The heterologous fusion protein of the Claim 23 wherein the peptide linker is selected from the group consisting of:

- a) a glycine rich peptide;
- b) a peptide having the sequence [Gly-Gly-Gly-Gly-Ser]<sub>n</sub> where n is 1, 2, 3, 4, or 5; and
- c) a peptide having the sequence [Gly-Gly-Gly-Gly-Ser]<sub>3</sub>.

23. The heterologous fusion protein of Claims 22, 23 or 24, wherein the hyperglycosylated G-CSF analog comprises the amino acid sequence of the formula I: [SEQ ID NO: 1]

1	5	10	15
Thr Pro Leu Gly Pro Ala Ser Ser	Leu Pro Gln Ser Phe Leu Leu Lys		
20	25	30	
Xaa Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln			
35	40	45	
Glu Lys Leu Cys Xaa Xaa Xaa Lys Leu Cys His Pro Glu Glu Leu Val			
50	55	60	
Leu Leu Gly His Ser Leu Gly Ile Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa			
65	70	75	80
Xaa Xaa Xaa Xaa Xaa Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser			
85	90	95	
Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Xaa Xaa Xaa Ser			
100	105	110	
Xaa Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp			
115	120	125	
Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro			
130	135	140	
Ala Leu Gln Pro Xaa Xaa Xaa Ala Met Pro Ala Phe Xaa Xaa Xaa Phe			
145	150	155	160

WO 03/076567

PCT/US03/03120

- 72 -

Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Aln Ser Phe  
165 170  
Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro (I)

wherein:

Xaa at position 17 is Cys, Ala, Leu, Ser, or Glu;  
Xaa at position 37 is Ala or Asn;  
Xaa at position 38 is Thr, or any other amino acid except Pro;  
Xaa at position 39 is Tyr, Thr, or Ser;  
Xaa at position 57 is Pro or Val;  
Xaa at position 58 is Trp or Asn;  
Xaa at position 59 is Ala or any other amino acid except Pro;  
Xaa at position 60 is Pro, Thr, Asn, or Ser,  
Xaa at position 61 is Leu, or any other amino acid except Pro;  
Xaa at position 62 is Ser or Thr;  
Xaa at position 63 is Ser or Asn;  
Xaa at position 64 is Cys or any other amino acid except Pro;  
Xaa at position 65 is Pro, Ser, or Thr;  
Xaa at position 66 is Ser or Thr;  
Xaa at position 67 is Gln or Asn;  
Xaa at position 68 is Ala or any other amino acid except Pro;  
Xaa at position 69 is Leu, Thr, or Ser  
Xaa at position 93 is Glu or Asn  
Xaa at position 94 is Gly or any other amino acid except Pro;  
Xaa at position 95 is Ile, Asn, Ser, or Thr;  
Xaa at position 97 is Pro, Ser, Thr, or Asn;  
Xaa at position 133 is Thr or Asn;  
Xaa at position 134 is Gln or any other amino acid except Pro;  
Xaa at position 135 is Gly, Ser, or Thr  
Xaa at position 141 is Ala or Asn;  
Xaa at position 142 is Ser or any other amino acid except Pro; and  
Xaa at position 143 is Ala, Ser, or Thr;

and wherein:

Xaa at positions 37, 38, and 39 constitute region 1;  
Xaa at positions 58, 59, and 60 constitute region 2;  
Xaa at positions 59, 60, and 61 constitute region 3;  
Xaa at positions 60, 61, and 62 constitute region 4;

WO 03/076567

PCT/US03/03120

- 73 -

Xaa at positions 61, 62, and 63 constitute region 5;  
Xaa at positions 62, 63, and 64 constitute region 6;  
Xaa at positions 63, 64, and 65 constitute region 7;  
Xaa at positions 64, 65, and 66 constitute region 8;  
Xaa at positions 67, 68, and 69 constitute region 9;  
Xaa at positions 93, 94, and 95 constitute region 10;  
Xaa at positions 94, 95, and Ser at position 96  
constitute region 11;  
Xaa at positions 95, and 97, and Ser at position 96  
constitute region 12;  
Xaa at positions 133, 134, and 135 constitute  
region 13;  
Xaa at positions 141, 142, and 143 constitute  
region 14;

and provided that at least one of regions 1 through 14  
comprises the sequence Asn Xaa1 Xaa2 wherein Xaa1 is any  
amino acid except Pro and Xaa2 is Ser or Thr.

26. The heterologous fusion protein of Claim 25 wherein any  
two regions of regions 1 through 14 comprise the sequence  
Asn Xaa1 Xaa2 wherein Xaa1 is any amino acid except Pro and  
Xaa2 is Ser or Thr.

27. The heterologous fusion protein of Claim 25 wherein any  
three regions of regions 1 through 14 comprise the sequence  
Asn Xaa1 Xaa2 wherein Xaa1 is any amino acid except Pro and  
Xaa2 is Ser or Thr.

28. The heterologous fusion protein of Claim 25 wherein any  
four regions of regions 1 through 14 comprise the sequence  
Asn Xaa1 Xaa2 wherein Xaa1 is any amino acid except Pro and  
Xaa2 is Ser or Thr.

WO 03/076567

PCT/US03/03120

- 74 -

29. The heterologous fusion protein of Claim 25 wherein the hyperglycosylated G-CSF analog is selected from the group consisting of:

- a) G-CSF [A37N, Y39T]
- b) G-CSF [P57V, W58N, P60T]
- c) G-CSF [P60N, S62T]
- d) G-CSF [S63N, P65T]
- e) G-CSF [Q67N, L69T]
- f) G-CSF [E93N, I95T]
- g) G-CSF [T133N, G135T]
- h) G-CSF [A141N, A143T]
- i) G-CSF [A37N, Y39T, P57V, W58N, P60T]
- j) G-CSF [A37N, Y39T, P60N, S62T]
- k) G-CSF [A37N, Y39T, S63N, P65T]
- l) G-CSF [A37N, Y39T, Q67N, L69T]
- m) G-CSF [A37N, Y39T, E93N, I95T]
- n) G-CSF [A37N, Y39T, T133N, G135T]
- o) G-CSF [A37N, Y39T, A141N, A143T]
- p) G-CSF [A37N, Y39T, P57V, W58N, P60T, S63N, P65T]
- q) G-CSF [A37N, Y39T, P57V, W58N, P60T, Q67N, L69T]
- r) G-CSF [A37N, Y39T, S63N, P65T, E93N, I95T].

30. The heterologous fusion protein of Claim 29 wherein the hyperglycosylated G-CSF analog is G-CSF [A37N, Y39T, P57V, W58N, P60T, Q67N, L69T].

31. The heterologous fusion protein of Claim 29 wherein the hyperglycosylated G-CSF analog is G-CSF [A37N, Y39T, S63N, P65T, E93N, I95T].

32. The heterologous fusion protein of any one of Claims 22 through 31 wherein the second polypeptide is the Fc portion of an Ig selected from the group consisting of: IgG1, IgG2, IgG3, IgG4, IgE, IgA, IgD, or IgM.

WO 03/076567

PCT/US03/03120

- 75 -

33. The heterologous fusion protein of any one of Claims 22 through 32 wherein the second polypeptide is the Fc portion of an Ig selected from the group consisting of: IgG1, IgG2, IgG3, and IgG4.

34. The heterologous fusion protein of Claim 33 wherein the second polypeptide is the Fc portion of an IgG1 immunoglobulin.

35. The heterologous fusion protein of Claim 33 wherein the second polypeptide is the Fc portion of an IgG4 immunoglobulin.

36. The heterologous fusion protein of Claims 22 through 35 wherein the IgG is human.

37. The heterologous fusion protein of any one of Claims 22 through 36 wherein the Fc portion comprises the hinge, CH<sub>2</sub>, and CH<sub>3</sub> domains.

38. The heterologous fusion protein of Claim 34 wherein the polypeptide has the sequence of SEQ ID NO: 33.

39. The heterologous fusion protein of Claim 34, wherein the polypeptide has the following nucleic acid sequence:

tccaccaaggcccattcggtttcccgctagcgccctgctccaggagcaccccgagac  
acagccgcctggctgcctgg  
tcaaggactactccccaaacctggtaacgggtgtcgtaactcaggcgccctgaccagcg  
gcgtgcacacccctccggctgtc  
ctacagtctcaggactactccctcagcagcgtggtaaccgtgccctccagcagcttg  
ggcacgaagacactacacctgcaac  
gtagatcacaagcccagcaacacccaagggtggacaagagagttgagtccaaatatgtccc  
ccatgcccacccctgcccagca  
cctgagttcctgggggaccatcagtcttcgttccccccaaaacccaaggacactctc  
atgatctcccgaccctgaggtcac  
gtgcgtgggtggacgtgagccaggaagaccccgaggtccagttcaactggtaacgtgga  
tggcgtggaggtgcataatgcca  
agacaaagccgcgggaggagcgttcaacacagcacgtaccgtgtggtagcgtcctcaccg  
tcctgcaccaggactggctgaa  
cgcaaggagatacaagtcaagggtctccaacaaaggcctccgtcctccatcgagaaaaac  
catctccaaagccaaaggcga

WO 03/076567

PCT/US03/03120

- 76 -

gccccgagagccacagggtacaccctgccccatcccaggaggagatgaccaagaacca  
ggtcagcctgacctgcctggtc  
aaaggcttctaccccagcgacatcgccgtggagtggagagcaatggcagccggagaac  
aactacaagaccacgcctccc  
gtgctggactccgacggctccttcttcatcagcaggctaaccgtggacaagagcagg  
tggcaggagggaatgtttctcatgc  
tccgtgatgcatgaggcttgacaaaccactacacacagaagagcctccctgtctctg  
ggtaaatga.

40. A polynucleotide encoding a heterologous fusion protein of any one of Claims 1 through 389.

41. A vector comprising the polynucleotide of Claim 40.

42. A host cell comprising the vector of Claim 41.

43. A host cell expressing at least one heterologous fusion protein of any one of Claims 1 through 39.

44. The host cell of Claim 43 wherein said host cell is a CHO cell.

45. A process for producing a heterologous fusion protein comprising the steps of transcribing and translating a polynucleotide of Claim 40 under conditions wherein the heterologous fusion protein is expressed in detectable amounts.

46. A method for increasing neutrophil levels in a mammal comprising the administration of a therapeutically effective amount of the heterologous fusion protein of any one of Claims 27 through 36.

47. The use of the heterologous fusion protein as claimed in any one of Claims 22 through 29 for the manufacture of a medicament for the treatment of patients with insufficient circulating neutrophil levels.

WO 03/076567

PCT/US03/03120

- 77 -

48. Use of a heterologous fusion protein of any one of Claims 22 through 29 as a medicament.

49. Use of a heterologous fusion protein of any one of Claims 22 through 29 for the treatment of patients with insufficient circulating neutrophil levels.

50. A pharmaceutical formulation adapted for the treatment of patients with insufficient neutrophil levels comprising a heterologous fusion protein of any one of Claims 22 through 29.

51. A heterologous fusion protein as hereinbefore described with reference to any one of the Examples.

WO 03/076567

PCT/US03/03120

1/48

SEQUENCE LISTING

<110> Beals, John

Kuchibhotla, Uma

<120> HETEROLOGOUS G-CSF FUSION PROTEINS

<130> P-15648

<160> 66

<170> PatentIn version 3.1

<210> 1

<211> 174

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic construct

<220>

<221> MISC\_FEATURE

<222> (17)..(17)

<223> Xaa at position 17 is Cys, Ala, Leu, Ser, or Glu;

<220>

<221> MISC\_FEATURE

<222> (37)..(37)

<223> Xaa at position 37 is Ala or Asn;

WO 03/076567

PCT/US03/03120

2/48

<220>

<221> MISC\_FEATURE

<222> (38) .. (38)

<223> Xaa at position 38 is Thr, or any other amino acid except Pro;

<220>

<221> MISC\_FEATURE

<222> (39) .. (39)

<223> Xaa at position 39 is Tyr, Thr, or Ser;

<220>

<221> MISC\_FEATURE

<222> (57) .. (57)

<223> Xaa at position 57 is Pro or Val;

<220>

<221> MISC\_FEATURE

<222> (58) .. (58)

<223> Xaa at position 58 is Trp or Asn;

<220>

<221> MISC\_FEATURE

<222> (59) .. (59)

<223> Xaa at position 59 is Ala or any other amino acid except Pro;

<220>

<221> MISC\_FEATURE

<222> (60) .. (60)

WO 03/076567

PCT/US03/03120

3/48

<223> Xaa at position 60 is Pro, Thr, Asn, or Ser;  
  
<220>  
<221> MISC\_FEATURE  
<222> (61)..(61)  
<223> Xaa at position 61 is Leu, or any other amino acid except Pro;  
  
<220>  
<221> MISC\_FEATURE  
<222> (62)..(62)  
<223> Xaa at position 62 is Ser or Thr;  
  
<220>  
<221> MISC\_FEATURE  
<222> (63)..(63)  
<223> Xaa at position 63 Ser or Asn;  
  
<220>  
<221> MISC\_FEATURE  
<222> (64)..(64)  
<223> Xaa at position 64 is Cys or any other amino acid except Pro;  
  
<220>  
<221> MISC\_FEATURE  
<222> (65)..(65)  
<223> Xaa at position 65 is Pro, Ser, or Thr;  
  
<220>  
<221> MISC\_FEATURE

WO 03/076567

PCT/US03/03120

4/48

<222> (66) .. (66)

<223> Xaa at position 66 is Ser or Thr;

<220>

<221> MISC\_FEATURE

<222> (67) .. (67)

<223> Xaa at position 67 is Gln or Asn;

<220>

<221> MISC\_FEATURE

<222> (68) .. (68)

<223> Xaa at position 68 is Ala or any other amino acid except Pro;

<220>

<221> MISC\_FEATURE

<222> (69) .. (69)

<223> Xaa at position 69 is Leu, Thr, or Ser;

<220>

<221> MISC\_FEATURE

<222> (93) .. (93)

<223> Xaa at position 93 is Glu or Asn;

<220>

<221> MISC\_FEATURE

<222> (94) .. (94)

<223> Xaa at position 94 is Gly or any other amino acid except Pro;

<220>

WO 03/076567

PCT/US03/03120

5/48

<221> MISC\_FEATURE

<222> (95)..(95)

<223> Xaa at position 95 is Ile, Asn, Ser, or Thr;

<220>

<221> MISC\_FEATURE

<222> (97)..(97)

<223> Xaa at position 97 is Pro, Ser, Thr, or Asn;

<220>

<221> MISC\_FEATURE

<222> (133)..(133)

<223> Xaa at position 133 is Thr or Asn;

<220>

<221> MISC\_FEATURE

<222> (134)..(134)

<223> Xaa at position 134 is Gln or any other amino acid except Pro;

<220>

<221> MISC\_FEATURE

<222> (135)..(135)

<223> Xaa at position 135 is Gly, Ser, or Thr;

<220>

<221> MISC\_FEATURE

<222> (141)..(141)

<223> Xaa at position 141 is Ala or Asn;

WO 03/076567

PCT/US03/03120

6/48

<220>

<221> MISC FEATURE

<222> (142) .. (142)

<223> Xaa at position 142 is Ser or any other amino acid except Pro;

<220>

<221> MISC FEATURE

<222> (143) . . (143)

<223> Xaa at position 143 is Ala, Ser, or Thr.

<400> 1

Xaa Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln  
20 25 30

Glu Lys Leu Cys Xaa Xaa Xaa Lys Leu Cys His Pro Glu Glu Leu Val  
 35                  40                  45

Leu Leu Gly His Ser Leu Gly Ile Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa  
50 55 60

Xaa Xaa Xaa Xaa Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser  
65                    70                    75                    80

Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Xaa Xaa Xaa Ser  
85 90 95

Xaa Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp  
100 105 110

Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro  
115 120 125

Ala Leu Gln Pro Xaa Xaa Xaa Ala Met Pro Ala Phe Xaa Xaa Xaa Phe  
130 135 140

WO 03/076567

PCT/US03/03120

7/48

Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe  
145 150 155 160

Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro  
165 170

<210> 2

<211> 1044

<212> DNA

<213> Artificial Sequence

<220>

<223> synthetic construct

<400> 2  
accccccctgg gcccgtccag ctccctgccc cagagcttcc tgctcaagtg gggggacccg 60  
ggacggtcga gggacgggggt ctcgaaggac gagttcgct tagagcaagt gaggaagatc 120  
cagggcgatg ggcgcagcgct ccagcggaat ctcgttcaact ccttcttaggt cccgctaccg 180  
cgtcgcgagg tcgagaagct gtgtgccacc tacaagctgt gccaccccgaa ggagctggtg 240  
ctcttcgaca cacggtgttat gttcgacacg gtggggctcc tcgaccacct gtcggacac 300  
tctctggca tccccctggc tccccctgagc agctgcgacg agcctgtgac agacccgtag 360  
gggaccccgag gggactcgtc gacgcccagc caggccctgc agctggcagg ctgcttgagc 420  
caactccata gcgggtcggt ccgggacggtc gaccgtccga cgaactcggt tgaggtatcg 480  
ggcctttcc tctaccaggg gtcctgcag gcccctgaaag ggatctcccc ggaaaaggag 540  
atggtccccg aggacgtccg ggaccttccc tagaggcccg agttgggtcc caccttggac 600  
acactgcagc tggacgtcgc cgacgggctc aacccagggta ggaacctgtg tgacgtcgc 660  
ctgcagcggc tgtttgcac caccatctgg cagcagatgg aagaacttggg aatggccct 720  
aaacgggttgt ggttagaccgt cgtctacctt cttgaccctt accggggagc cctgcagccc 780  
aaccagacccg ccatgcggc cttcgctct gcttccggg acgtcggtt ggtctggcgg 840  
tacggccgga agcggagacg aaagcagcgc cggcaggag gggtccttgt tgcctccat 900  
ctgcagagct tcgtcgcgcc cctgcctccc caggaccaac ggagggtaga cgtctcgaag 960  
ctggaggtgt cgtaccgcgt cttaaggcac cttgcccagc ccgacaccttcca cagcatggcg 1020  
cagaattccg tggAACGGGT CGGG 1044

WO 03/076567

PCT/US03/03120

8/48

&lt;210&gt; 3

&lt;211&gt; 1044

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic construct

<400> 3	
accccccctgg	60
gcccctgccag	
ctccctgccc	
cagagcttcc	
tgctcaagtg	
gggggaccgg	
ggacggtcga	120
gggcacgggt	
ctcgaaggac	
gagttcgccct	
tagagcaagt	
gaggaagatc	
cagggcgatg	180
gcmcagcgct	
ccagcggaat	
ctcgttcaact	
ccttcttaggt	
cccgctaccg	
cgtcgcgagg	240
tcgagaagct	
gtgtgccacc	
tacaagctgt	
gccaccccgaa	
ggagctggtg	
ctcttcgaca	300
cacggtggt	
gttcgacacg	
gtggggctcc	
tcgaccacct	
gctcggacac	
tctctggca	360
tccccctgggc	
tccccctgagc	
agctgcgacg	
agcctgtgac	
agacccgtag	
gggacccgag	420
gggactcgtc	
gacgcccagc	
caggccctgc	
agctggcagg	
ctgcttgagc	
caactccata	480
gccccgtcggt	
ccgggacgtc	
gaccgtccga	
cgaactcggt	
tgaggtatcg	
ggcctttcc	540
tctaccaggg	
gctcctgcag	
gcccttggaa	
ggatctcccc	
ggaaaaggag	
atggtccccg	600
aggacgtccg	
ggaccttccc	
tagaggcccc	
agttgggtcc	
caccttggac	
acactgcagc	660
tggacgtcgc	
cgacgggctc	
aaccagggtt	
ggacccagggt	
ggatctgtg	
tgacgtcgcac	
ctgcagcggc	720
tgtttgcac	
caccatctgg	
cagcagatgg	
aagaactggg	
aatggccct	
aaacgggtgt	780
ggtagaccgt	
cgtctacctt	
cttgaccctt	
accggggagc	
cctgcagccc	
acccagggtg	840
ccatgccggc	
cttcaactct	
accttccggg	
acgtcgggtg	
ggtcccacgg	
tacggccgga	900
agttgagatg	
gaagcagcgc	
cgggcaggag	
gggtcctggt	
tgcctccat	
ctgcagagct	960
tcgtcgcggc	
ccgtccctccc	
caggaccaac	
ggagggtaga	
cgtctcgaag	
ctggaggtgt	1020
cgtaccgcgt	
cttaaggcac	
cttgcccagc	
ccgacacctca	
cagcatggcg	
cagaattccg	1044
tggAACGGGT	
CGGG	

&lt;210&gt; 4

&lt;211&gt; 1044

WO 03/076567

PCT/US03/03120

9/48

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic construct

<400> 4						
accccccctgg	gccctgccag	ctccctgccc	cagagcttcc	tgtcaagtg	ggggggaccccg	60
ggacggtcga	gggacgggggt	ctcgaaggac	gagttcgct	tagagcaagt	gaggaagatc	120
cagggcgatg	gcgcagcgct	ccagcggaat	ctcgttcaact	ccttcttaggt	cccgctaccg	180
cgtcgcgagg	tcgagaagct	gtgtaaacacc	accaagctgt	gccaccccgaa	ggagctggtg	240
ctcttcgaca	cattgtggtg	gttcgacacg	gtggggctcc	tcgaccacct	gctcgacac	300
tctctgggca	tccccctgggc	tcccctgagc	agctgcgacg	agcctgtgac	agacccgtag	360
gggaccccgag	gggactcgtc	gacgcccagc	caggccctgc	agctggcagg	ctgcttgagc	420
caactccata	gcgggctcggt	ccgggacgtc	gaccgtccga	cgaactcggt	tgaggtatcg	480
ggcctttcc	tctaccaggg	gctcctgcag	gccctggaaag	ggatctcccc	ggaaaaggag	540
atggtccccg	aggacgtccg	ggaccttccc	tagaggcccg	agttgggtcc	caccttggac	600
acactgcagc	tggacgtcgc	cgacgggctc	aacccagggt	ggaacctgtg	tgacgtcgac	660
ctgcagcggc	tgtttgccac	caccatctgg	cagcagatgg	aagaactggg	aatggcccct	720
aaacggtgtt	ggttagaccgt	cgtctacctt	cttgaccctt	accggggagc	cctgcagccc	780
acccagggtg	ccatgccggc	cttcgcctct	gctttccggg	acgtcggttg	ggtcccacgg	840
tacggccgga	agcggagacg	aaagcagcgc	cgggcaggag	gggtcttggt	tgcctcccat	900
ctgcagagct	tcgtcgccggc	ccgtcctccc	caggaccaac	ggagggtaga	cgtctcgaaag	960
ctggagggtgt	cgtaccgcgt	cttaaggcac	cttgcccagc	ccgacctcca	cagcatggcg	1020
cagaattccg	tggaacgggt	cggg				1044

&lt;210&gt; 5

&lt;211&gt; 1044

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

WO 03/076567

PCT/US03/03120

10/48

&lt;220&gt;

&lt;223&gt; synthetic construct

&lt;400&gt; 5

accccccctgg	gccctgccag	ctccctgccc	cagagcttcc	tgctcaagtg	gggggaccccg	60
ggacggtcga	gggacgggggt	ctcgaaggac	gagttcgccct	tagagcaagt	gaggaagatc	120
cagggcgatg	gcgcagcgct	ccagcggaat	ctcgttcaact	ccttcttaggt	cccgctaccg	180
cgtcgcgagg	tcgagaagct	gtgtgccacc	tacaagctgt	gccacccccga	ggagctggtg	240
ctcttcgaca	cacggtggat	gttcgacacg	gtggggctcc	tcgaccacct	gctcggacac	300
tctctggca	tcccctgggc	taacactagc	agctgcgacg	agcctgtgac	agacccgtag	360
gggacccgat	tggactcctc	gacgcccagc	caggccctgc	agctggcagg	ctgcttgagc	420
caactccata	gcggggtcggt	ccgggacgtc	gaccgtccga	cgaactcggt	tgaggtatcg	480
ggccttttcc	tctaccaggg	gctcctgcag	gccctggaag	ggatctcccc	ggaaaaggag	540
atggtccccg	aggacgtccg	ggaccttccc	tagaggccc	agttgggtcc	caccttggac	600
acactgcagc	tggacgtcgc	cgacgggctc	aaccagggt	ggaacctgtg	tgacgtcgcac	660
ctgcagcggc	tgtttgccac	caccatctgg	cagcagatgg	aagaactggg	aatggcccct	720
aaacgggttgt	ggtagaccgt	cgtctacctt	cttgaccctt	accggggagc	cctgcagccc	780
acccagggtg	ccatgccggc	cttcgcctct	gcttccggg	acgtcgggtg	ggtcccacgg	840
tacggccgga	agcggagacg	aaagcagcgc	cggcaggag	gggtccttgt	tgcctcccat	900
ctgcagagct	tcgtcgcggc	ccgtcctccc	caggaccaac	ggagggtaga	cgtctcgaag	960
ctggaggtgt	cgtaccgcgt	cttaaggcac	cttgcccagc	ccgacacctcca	cagcatggcg	1020
cagaattccg	tggaacgggt	cggg				1044

&lt;210&gt; 6

&lt;211&gt; 1044

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic construct

&lt;400&gt; 6

accccccctgg	gccctgccag	ctccctgccc	cagagcttcc	tgctcaagtg	gggggaccccg	60
-------------	------------	------------	------------	------------	-------------	----

WO 03/076567

PCT/US03/03120

11/48

ggacggtcga	gggacggggt	ctcgaaggac	gagttcgccct	tagagcaagt	gaggaagatc	120
cagggcgatg	gchgacgcgt	ccagcgaat	ctcgttcaact	ccttcttaggt	cccgttaccg	180
cgtcgcgagg	tcgagaagct	gtgtgccacc	tacaagctgt	gccaccccgaa	ggagctggtg	240
ctcttcgaca	cacggtggat	gttcgacacg	gtggggctcc	tcgaccacct	gtcgacac	300
tctctggca	tcccctggc	tcccctgagc	aattgcgacg	agcctgtgac	agacccgtag	360
gggacccgag	gggactcggt	aacgaccacg	caggccctgc	agctggcagg	ctgcttgcgc	420
caactccata	gctggtcggt	ccgggacgta	gaccgtccga	cgaactcggt	tgaggtatcg	480
ggcctttcc	tctaccaggg	gctcctgcag	gcccttggaa	ggatctcccc	ggaaaaggag	540
atggtccccg	aggacgtccg	ggaccttccc	tagaggcccc	agttgggtcc	cacccggac	600
acactgcagc	tggacgtcgc	cgacgggctc	aaccagggt	ggaacctgtg	tgacgtcgac	660
ctgcagcggc	tgtttgccac	caccatctgg	cagcagatgg	aagaactggg	aatggcccc	720
aaacgggtgt	ggtagaccgt	cgtctacctt	cttgcaccctt	accggggagc	cctgcagccc	780
acccagggtg	ccatgcccggc	cttcgcctct	gtttccggg	acgtcggtg	ggtcccacgg	840
tacggccgga	agcggagacg	aaagcagcgc	cgggcaggag	gggtccttgt	tgcctccat	900
ctgcagagct	tcgtcgccggc	ccgtccccc	caggaccaac	ggagggtaga	cgtctcgaa	960
ctggaggtgt	cgtaccgcgt	cttaaggcac	cttgcaccac	ccgaccccca	cagcatggcg	1020
cagaattccg	tggAACGGGT	cggg				1044

&lt;210&gt; 7

&lt;211&gt; 1044

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic construct

<400> 7	accccccctgg	gccctgccag	ctccctgccc	cagagcttcc	tgctcaagt	gggggacccg	60
ggacggtcga	gggacggggt	ctcgaaggac	gagttcgccct	tagagcaagt	gaggaagatc	120	
cagggcgatg	gchgacgcgt	ccagcgaat	ctcgttcaact	ccttcttaggt	cccgttaccg	180	
cgtcgcgagg	tcgagaagct	gtgtgccacc	tacaagctgt	gccaccccgaa	ggagctggtg	240	

WO 03/076567

PCT/US03/03120

12/48

ctcttcgaca cacgggtggat gttcgacacg gtggggctcc tcgaccacct gctcggacac	300
tctctggca tcgttaacgc taccctgagc agctgcgacg agcctgtgac agacccgtag	360
caattgcgtat gggactcgtc gacgcccagc caggccctgc agctggcagg ctgcttgagc	420
caactccata gcgggtcggt ccgggacgac gaccgtccga cgaactcggt tgaggtatcg	480
ggcctttcc tctaccaggg gctcctgcag gcccttggaa ggatctcccc gaaaaaggag	540
atggtccccg aggacgtccg ggaccttccc tagaggcccc agttgggtcc caccttggac	600
acactgcagc tggacgtcgc cgacgggctc aaccagggtt ggaacctgtg tgacgtcgcac	660
ctgcagcggc tgtttgcac caccatctgg cagcagatgg aagaacttggg aatggccct	720
aaacgggtgt ggttagaccgt cgtctacctt cttgaccctt accggggagc cctgcagccc	780
acccagggtg ccatgccggc cttgcctct gcttccggg acgtcggtt ggtcccacgg	840
tacggccgga agcggagacg aaagcagcgc cggcaggag gggtccttgt tgcctccat	900
ctgcagagct tcgtcgccgc ccgtctccc caggaccaac ggagggtaga cgtctcgaag	960
ctggaggtgt cgtaccgcgt cttaaggcac cttgcccagc ccgacctcca cagcatggcg	1020
cagaattccg tggAACGGGT CGGG	1044

&lt;210&gt; 8

&lt;211&gt; 1044

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic construct

<400> 8 accccccctgg gccctgccag ctccctgccc cagagttcc tgctcaagt gggggacccg	60
ggacggtcga gggacgggtt ctcgaaggac gagttcgct tagagcaagt gaggaagatc	120
cagggcgatg ggcgcagcgct ccagcggaat ctcgttcaact ccttctaggt cccgttaccg	180
cgtcgcgagg tcgagaagct gtgtgccacc tacaagctgt gccacccga ggagctggtg	240
ctcttcgaca cacgggtggat gttcgacacg gtggggctcc tcgaccacct gctcggacac	300
tctctggca tccccctggcc tccccctgagc agctgcgacg agcctgtgac agacccgtag	360
gggacccgag gggactcgtc gacgcccagc aacgccaccc agctggcagg ctgcttgagc	420

WO 03/076567

PCT/US03/03120

13/48

caactccata gcgggtcggt gcggtggtc gaccgtccga cgaactcggt tgaggtatcg	480
ggcctttcc tctaccaggg gctcctgcag gccctggaag ggatctcccc ggaaaaggag	540
atggtccccg aggacgtccg ggacctccc tagaggccc agttggtcc caccttggac	600
acactgcagc tggacgtcgc cgacgggctc aaccagggt ggaacctgtg tgacgtcgac	660
ctgcagcggc tggccac caccatctgg cagcagatgg aagaactggg aatggccct	720
aaacgggtgt ggttagaccgt cgtctacctt cttagccctt accggggagc cctgcagccc	780
acccagggtg ccatgcggc ctgcctct gcttccggg acgtcgggtg ggtcccacgg	840
tacggccgga agcggagacg aaagcagcgc cggcaggag gggctctgt tgccctccat	900
ctgcagagct tcgtcgccgc ccgtccccc caggaccaac ggagggtaga cgtctcgaag	960
ctggagggtgt cgtaccgcgt cttaaggcac cttagcccagc ccgacctcca cagcatggcg	1020
cagaattccg tggAACGGGT CGGG	1044

&lt;210&gt; 9

&lt;211&gt; 1044

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic construct

<400> 9	
accccccctgg gccctgccag ctccctgccc cagagttcc tgctcaagt gggggacccg	60
ggacggtcga gggacgggt ctcgaaggac gagttcgct tagagcaagt gaggaagatc	120
cagggcgatg ggcgcgcgt ccagcggaat ctgcgttact cttcttaggt cccgttaccg	180
cgtcgcgagg tcgagaagct gtgtgccacc tacaagctgt gccacccga ggagctggtg	240
ctcttcgaca cacggtgat gttcgacacg gtggggctcc tcgaccacct gtcggacac	300
tctctggca tccccctggc tccccctgagc agctgcgcacg agcctgtgac agacccgtag	360
gggacccgag gggactcgtc gacgcccagc caggccctgc agctggcagg ctgcttgagc	420
caactccata gcgggtcggt ccggacgtccg gaccgtccga cgaactcggt tgaggtatcg	480
ggcctttcc tctaccaggg gctcctgcag gccctgaacg ggacctcccc ggaaaaggag	540
atggtccccg aggacgtccg ggacttgcgc tggaggcccg agttggtcc caccttggac	600

WO 03/076567

PCT/US03/03120

14/48

acactgcagc tggacgtcgc cgacgggctc aaccagggt ggaacctgtg tgacgtcgac 660  
ctgcagcggc tggggccac caccatctgg cagcagatgg aagaactggg aatggcccct 720  
aaacgggtggt ggttagaccgt cgtctacctt cttgaccctt accggggagc cctgcagccc 780  
acccagggtg ccatgccggc cttcgctct gcttccggg acgtcggtg ggtcccacgg 840  
tacggccgga agcggagacg aaagcagcgc cggcaggag gggtcctggt tgcctccat 900  
ctgcagagct tcgtcgccggc ccgtccccc caggaccaac ggagggtaga cgtctcgaag 960  
ctggaggtgt cgtaccgcgt cttaaggcac cttgcccagc ccgacacctca cagcatggcg 1020  
cagaattccg tggAACGGGT cggg 1044

&lt;210&gt; 10

&lt;211&gt; 1044

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic construct

<400> 10  
accccccctgg gccctgccag ctccctgccc cagagcttcc tgctcaagtg gggggacccg 60  
ggacggtcga gggacgggggt ctcgaaggac gagttcgct tagagcaagt gaggaagatc 120  
cagggcgatg ggcgcgcgcct ccagcggaat ctcgttcaact cttcttaggt cccgctaccg 180  
cgtcgcgagg tcgagaagct gtgtAACACC accaagctgt gccacccccga ggagctggtg 240  
ctttcgaca cattgtggtg gttcgacacg gtggggctcc tcgaccacct gtcggacac 300  
tctctggca tccccctggc tccccctgagc agctgcgacg agcctgtgac agacccgtag 360  
gggacccgag gggactcgtc gacgcccagc caggccctgc agctggcagg ctgcttgcgc 420  
caactccata gcgggtcggt ccgggacggtc gaccgtccga cgaactcggt tgaggtatcg 480  
ggcctttcc tctaccagggg gctcctgcag gccctggaaag ggatctcccc ggaaaaggag 540  
atggtccccg aggacgtccg ggacctcccc tagaggcccg agttgggtcc caccttggac 600  
acactgcagc tggacgtcgc cgacgggctc aaccagggt ggaacctgtg tgacgtcgac 660  
ctgcagcggc tggggccac caccatctgg cagcagatgg aagaactggg aatggcccct 720  
aaacgggtggt ggttagaccgt cgtctacctt cttgaccctt accggggagc cctgcagccc 780

WO 03/076567

PCT/US03/03120

15/48

aaccagacccg ccatgccggc ctgcgcctct gcttccggg acgtcggtt ggtctggcgg	840
tacggccgga agcggagacg aaagcagcgc cggcaggag gggtccttgt tgcctccat	900
ctgcagagct tcgtcgccgc ccgtcctccc caggaccaac ggagggtaga cgtctcgaag	960
ctggaggtgt cgtaccgcgt cttaaggcac ctgcgcgc cgcacccatcc cagcatggcg	1020
cagaattccg tggAACGGGT cggg	1044

&lt;210&gt; 11

&lt;211&gt; 1044

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic construct

<400> 11 acccccctgg gccctgccag ctccctgccc cagagcttcc tgctcaagtg gggggacccg	60
ggacggtcga gggacggggt ctcgaaggac gagttcgccct tagagcaagt gaggaagatc	120
cagggcgatg ggcgcagcgct ccagcggaat ctcgttcaact cttcttaggt cccgctaccg	180
cgtcgcgagg tcgagaagct gtgtAACACC accaagctgt gccaccccgaa gagctggtg	240
ctcttcgaca cattgtggtg gttcgacacg gtggggctcc tcgaccacct gctcgacac	300
tctctggca tccccctggc tccccctgagc agctgcgacg agcctgtgac agacccgtag	360
gggacccgag gggactcgtc gacgcccage caggccctgc agctggcagg ctgcttgagc	420
caactccata gcgggtcggt ccgggacgac gaccgtccga cgaactcggt tgaggtatcg	480
ggcctttcc tctaccaggg gtcctgcag gcccggaaag ggtctcccc ggaaaaggag	540
atggcccccg aggacgtccg ggacccccc tagaggcccg agttgggtcc caccttggac	600
acactgcagc tggacgtcgc cgacgggctc aaccagggtt ggaacctgtg tgacgtcgc	660
ctgcagcggc tggccac caccatctgg cagcagatgg aagaactggg aatggcccc	720
aaacgggtgt ggttagaccgt cgtctacctt cttgaccctt accggggagc cctgcagccc	780
acccagggtg ccatgccggc cttcaactct accttccggg acgtcggtt ggtccacgg	840
tacggccgga agttgagatg gaagcagcgc cggcaggag gggtccttgt tgcctccat	900
ctgcagagct tcgtcgccgc ccgtcctccc caggaccaac ggagggtaga cgtctcgaag	960

WO 03/076567

PCT/US03/03120

16/48

ctggaggtgt cgtaccgcgt cttaaggcac cttgccca cccgacccatcca cagcatggcg 1020  
cagaattccg tggAACGGGT CGGG 1044

<210> 12

<211> 1044

<212> DNA

<213> Artificial Sequence

<220>

<223> synthetic construct

<400> 12  
accccccctgg gcccctgccag ctccccctggcc cagagcttcc tgctcaagtgg gggggacccgg 60  
ggacggtcga gggacgggggt ctcgaaggac gagttcgccct tagagcaagt gaggaagatc 120  
cagggcgatg ggcgcagcgct ccagcggaaat ctcgttcaact ccttcttaggt cccgctaccgg 180  
cgtcgcgagg tcgagaagct gtgttaacacc accaagctgt gcccacccgg ggagctggtg 240  
ctcttcgaca cattgtggtg gttcgacacg gtggggctcc tcgaccacct gctcgacac 300  
tctctggca tcgttaacgc taccctgagc agctgcgacg agcctgtgac agacccgtag 360  
caattgcgat gggactcgtc gacgcccggc caggccctgc agctggcagg ctgcttgagc 420  
caactccata gcgggtcggt ccgggacggtc gaccgtccgg cgaactcggt tgaggtatcg 480  
ggcctttcc tctaccagggt gctcctgcag gcccggaaag ggatctcccc ggaaaaggag 540  
atggtccccg aggacgtccg ggacccccc tagaggcccg agttgggtcc caccttggac 600  
acactgcagc tggacgtcgcc cgacgggctc aacccagggt ggaacctgtg tgacgtcgac 660  
ctgcagcggc tgtttgcac caccatctgg cagcagatgg aagaactggg aatggccct 720  
aaacgggtggt ggttagaccgt cgtctacctt cttgaccctt accggggagc cctgcagcccc 780  
acccagggtg ccatgcccggc cttcgccctt gcttccggg acgtcggtgg ggtcccacgg 840  
tacggccggaa agcggagacg aaagcagcgc cgggcaggag gggtcctggg tgccctccat 900  
ctgcagagct tcgtcgccggc ccgtccccc caggaccaac ggagggtaga cgtctcgaaag 960  
ctggaggtgt cgtaccgcgt cttaaggcac cttgccca cccgacccatcca cagcatggcg 1020  
cagaattccg tggAACGGGT CGGG 1044

WO 03/076567

PCT/US03/03120

17/48

<210> 13  
<211> 1044  
<212> DNA  
<213> Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic construct

<400> 13  
accccccctgg gcccgtgccag ctccctgccc cagagcttcc tgctcaagtg gggggacccg 60  
ggacggtcga gggacggggt ctcgaaggac gagttcgct tagagcaagt gaggaagatc 120  
cagggcgatg ggcgcagcgct ccagcggaat ctcgttcaact ccttcttaggt cccgctaccg 180  
cgtcgcgagg tcgagaagct gtgttaacacc accaagctgt gccaccccgaa ggagctggtg 240  
ctcttcgaca cattgtggtg gttcgacacg gtggggctcc tcgaccacct gctcggacac 300  
tctctggca tccccctggc tccccctgagc agctgcgacg agcctgtgac agaccctgtag 360  
gggaccctgag gggactcgtc gacgcccagc aacgccaccc agctggcagg ctgcttgcgc 420  
caactccata gccccgtcggtt gccccgtggc gaccgtccga cgaactcggt tgaggtatcg 480  
ggccctttcc tctaccaggc gctcctgcag gcccctggaaag ggatctcccc ggaaaaggag 540  
atggtcccccg aggacgtccg ggaccttccc tagaggcccg agttgggtcc caccttggac 600  
acactgcagc tggacgtcgc cgacgggctc aacccaggggt ggaacctgtg tgacgtcgc 660  
ctgcagcggc tgtttgcac caccatctgg cagcagatgg aagaactggg aatggccct 720  
aaacgggtggt ggttagaccgt cgtctacctt cttgaccctt accggggagc cctgcagccc 780  
acccaggggtg ccatgcccggc cttcgccctct gctttccggg acgtcggtgg ggtcccacgg 840  
tacggccgga agcggagacg aaagcagcgc cgggcaggag gggtcctggt tgccctccat 900  
ctgcagagct tcgtcgccggc ccgtccctccc caggaccaac ggagggtaga cgtctcgaag 960  
ctggaggtgt cgtaccgcgt cttaaggcac cttgcccagc ccgacacctcca cagcatggcg 1020  
cagaattccg tggAACGGGT cggg 1044

&lt;210&gt; 14

&lt;211&gt; 1044

&lt;212&gt; DNA

WO 03/076567

PCT/US03/03120

18/48

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic construct

&lt;400&gt; 14

accccccctgg	gcccgtgccag	ctccctgccc	cagagcttcc	tgctcaagtg	gggggacccg	60
ggacggtcga	gggacggggt	ctcgaaggac	gagttcgctt	tagagcaagt	gaggaagatc	120
cagggcgatg	gcgcagcgct	ccagcggaat	ctcggttact	ccttcttaggt	cccgctaccg	180
cgtcgcgagg	tcgagaagct	gtgtaaacacc	accaagctgt	gccaccccgaa	ggagctggtg	240
ctcttcgaca	cattgtggtg	gttcgacacg	gtggggctcc	tcgaccacct	gctcgacac	300
tctctggca	tccccctgggc	tccccctgagc	agctgcgacg	agcctgtgac	agaccctgtag	360
gggaccctgag	gggactcgtc	gacgcccagc	caggccctgc	agctggcagg	ctgcttgagc	420
caactccata	gcgggctcggt	ccgggacgtc	gaccgtccga	cgaactcggt	tgaggtatcg	480
ggcctttcc	tctaccaggg	gctcctgcag	gcccttggaa	ggatctcccc	ggaaaaggag	540
atggtccccg	aggacgtccg	ggaccttccc	tagaggaacg	gtaccggtcc	caccttggac	600
acactgcagc	tggacgtcgc	cgacttgcca	tggccagggt	ggaacctgtg	tgacgtcgac	660
ctgcagcggc	tgtttgccac	caccatctgg	cagcagatgg	aagaactggg	aatggccct	720
aaacgggttgt	ggtagaccgt	cgtctacctt	cttgaccctt	accggggagc	cctgcagccc	780
acccagggtg	ccatgccggc	cttcgcctct	gcttccggg	acgtcgggtg	ggtccccacgg	840
tacggccgga	agcggagacg	aaagcagcgc	cgggcaggag	gggtccttgtt	tgcotcccat	900
ctgcagagct	tcgtcgcgcc	ccgtcctccc	caggaccaac	ggagggtaga	cgtotcgaag	960
ctggaggtgt	cgtaccgcgt	cttaaggcac	cttgcccagc	ccgacctcca	cagoatggcg	1020
cagaattccg	tggAACGGGT	cggg				1044

&lt;210&gt; 15

&lt;211&gt; 1044

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

WO 03/076567

PCT/US03/03120

19/48

&lt;223&gt; synthetic construct

&lt;400&gt; 15

accccccctgg	gccctgccag	ctccctgccc	cagagttcc	tgctcaagtg	gggggaccgg	60
ggacggtcga	gggacgggggt	ctcgaaggac	gagttcgct	tagagcaagt	gaggaagatc	120
cagggcgatg	gchgagcgct	ccagcggaat	ctcgttcaact	ccttcttaggt	cccgctaccg	180
cgtcgcgagg	tcgagaagct	gtgtaaacacc	accaagctgt	gccaccccg	ggagctggtg	240
ctcttcgaca	cattgtggtg	gttcgacacg	gtggggctcc	tcgaccacct	gctcggacac	300
tctctggca	tcgttaacgc	taccctgagc	agctgcgacg	agcctgtgac	agacccgtag	360
caattgcgtat	gggactcgctc	gacgcccagc	aacgccaccc	agctggcagg	ctgcttgagc	420
caactccata	gcgggctcggt	gcgggtggtc	gaccgtccga	cgaactcggt	tgaggtatcg	480
ggcctttcc	tctaccaggg	gctcctgcag	gccctggaag	ggatctcccc	ggaaaaggag	540
atggtccccg	aggacgtccg	ggaccttccc	tagaggcccg	agttgggtcc	caccttggac	600
acactgcagc	tggacgtcgc	cgacgggctc	aaccagggt	ggaacctgtg	tgacgtcgac	660
ctgcagcggc	tgttgtccac	caccatctgg	cagcagatgg	aagaactggg	aatggcccct	720
aaacgggtgt	ggtagaccgt	cgtctacctt	cttgaccctt	accggggagc	cctgcagccc	780
acccagggtg	ccatgccggc	cttcgcctct	gctttccggg	acgtcgggtg	ggtcccacgg	840
tacggccgga	agcggagacg	aaagcagcgc	cgggcaggag	gggtcctgg	tgcctccat	900
ctgcagagct	tcgtcgcgcc	ccgtcctccc	caggaccaac	ggagggtaga	cgtctcgaag	960
ctggagggtgt	cgtaccgcgt	cttaaggcac	cttgcggcagc	ccgacacctca	cagcatggcg	1020
cagaattccg	tggaacgggt	cggg				1044

&lt;210&gt; 16

&lt;211&gt; 1044

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic construct

&lt;400&gt; 16

accccccctgg	gccctgccag	ctccctgccc	cagagttcc	tgctcaagtg	gggggaccgg	60
ggacggtcga	gggacgggggt	ctcgaaggac	gagttcgct	tagagcaagt	gaggaagatc	120

WO 03/076567

PCT/US03/03120

20/48

cagggcgatg ggcgcggcgt ccaggaaat ctcgttcaact cttcttaggt cccgcgtaccg	180
cgtcgcgagg tcgagaagct gtgttaacacc accaagctgt gccaccccgaa ggagctggtg	240
ctcttcgaca cattgtggtg gttcgacacg gtggggctcc tcgaccacct gctcgacac	300
tctctggca tcccctgggc tcccctgagc aattgcgacg agcctgtgac agaccctgtag	360
gggaccctgag gggactcggtt aacgaccacg caggccctgc agctggcagg ctgcttgagc	420
caactccata gctggtcggtt ccgggacgac gaccgtccga cgaactcggt tgaggtatcg	480
ggcctttcc tctaccaggg gtcctgcag gccctgaacg ggacctcccc ggaaaaggag	540
atggtccccg aggacgtccg ggacttgcac tggaggcccc agttgggtcc caccttggac	600
acactgcagc tggacgtcgc cgacgggctc aaccctgggt ggaacctgtg tgacgtcgac	660
ctgcagcggc tgtttgcac caccatctgg cagcagatgg aagaactggg aatggccct	720
aaacgggtgtt ggttagaccgt cgtctacctt cttgaccctt accggggagc cctgcagccc	780
acccagggtg ccatgccggc cttgcctct gcttccggg acgtcggtg ggtcccacgg	840
tacggccgga agcggagacg aaagcagcgc cggcaggag gggtcctgggt tgcctccat	900
ctgcagagct tcgtcgccgc ccgtccccc caggaccaac ggagggtaga cgtctcgaa	960
ctggagggtgtt cgtaccgcgtt cttaaaggcac cttgcccagc ccgacctcca cagcatggcg	1020
cagaattcccg tggaaacgggtt cggg	1044

<210> 17

<211> 1762

<212> DNA

<213> Artificial Sequence

<220>

<223> synthetic construct

<400> 17	
gatgcgcaca agagtgggt tgctcatcggtt ttaaagatt tggagaaga aaatttcaaa	60
gccttgggtgt tgattgcctt tgctcagtat cttcagcagt gtccatttga agatcatgtaa	120
aaatttgtaa atgaagtaac tgaatttgca aaaacatgtt ttgctgtatgt gtcagctgaa	180
aatttgtaca aatcacttca taccctttt ggagacaaat tatgcacagt tgcaactt	240
cgtgaaacct atgggtaaat ggctgactgc tggcaaaaac aagaacctga gagaaatgaa	300

WO 03/076567

PCT/US03/03120

21/48

tgcttcttgc aacacaaaaga tgacaaccca aacccccc gattggtag accagaggtt	360
gatgtatgt gcactgcttt tcatgacaat gaagagacat ttttggaaaa atacttat	420
gaaattgccca gaagacatcc ttactttat gcccccgaac tcctttctt tgctaaaagg	480
tataaagctg ctttacaga atgttgccaa gctgctgata aagctgcctg cctgttgccca	540
aagctcgatg aacttcggga tgaagggaaag gcttcgtctg ccaaacagag actcaagtgt	600
gccagtcctcc aaaaatttgg agaaagagct ttcaaagcat gggcagtagc tcgcctgagc	660
cagagattc ccaaagctga gtttgcagaa gtttccaagt tagtgcacaga tcttaccaa	720
gtcccacacgg aatgctgcca tggagatctg cttgaatgtg ctgatgacag ggccggacctt	780
gccaagtata tctgtggaaa tcaagattcg atctccagta aactgaagga atgctgtgaa	840
aaacctctgt tggaaaaatc ccactgcatt gccgaagtgg aaaatgtga gatgcctgt	900
gacttgcctt cattagctgc tgattttgtt gaaagtaagg atgtttgcaa aaactatgt	960
gaggcaaagg atgttttgcct gggcatgttt ttgtatgaat atgcaagaag gcatcctgat	1020
tactctgtcg tgctgctgct gagacttgcc aagacatatg aaaccactct agagaagtgc	1080
tgtgccgctg cagatcctca tgaatgtat gccaaagtgt tcgatgaatt taaacctt	1140
gtggaagagc ctcagaattt aatcaaacaa aattgtgagc ttttgagca gcttggagag	1200
tacaaattcc agaatgcgct attagttcgt tacaccaaga aagtacccca agtgtcaact	1260
ccaaactctt tagaggtctc aagaaaccta ggaaaagtgg gcagcaaatg ttgtaaacat	1320
cctgaagcaa aaagaatgcc ctgtgcagaa gactatctat ccgtggcct gaaccagtta	1380
tgtgtgttgc atgagaaaaac gccagtaagt gacagagtca ccaaattgtg cacagaatcc	1440
ttggtaaca ggcgaccatg ctttcagct ctgaaagtgc atgaaacata cgttccaaa	1500
gagttaatg ctgaaacatt caccttccat gcagatatat gcacacttgc tgagaaggag	1560
agacaaatca agaaacaaac tgcacttgtt gagctcgtga aacacaagcc caaggcaaca	1620
aaagagcaac tggaaagctgt tatggatgat ttgcagctt ttgttagagaa gtgctgcaag	1680
gctgacgata aggagacctg ctttgccag gagggtaaaa aacttgttgc tgcaagtcaa	1740
gctgccttag gcttataatg ac	1762

&lt;210&gt; 18

&lt;211&gt; 232

&lt;212&gt; PRT

WO 03/076567

PCT/US03/03120

22/48

<213> Artificial Sequence

<220>

<223> synthetic construct

<400> 18

Ala Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro  
1 5 10 15

Ala Pro Glu Lys Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro  
20 25 30

Lys Asp Thr Lys Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val  
35 40 45

Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val  
50 55 60

Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln  
65 70 75 80

Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln  
85 90 95

Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala  
100 105 110

Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro  
115 120 125

Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr  
130 135 140

Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser  
145 150 155 160

Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr  
165 170 175

Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr  
180 185 190

WO 03/076567

PCT/US03/03120

23/48

Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe  
195 200 205

Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys  
210 215 220

Ser Leu Ser Leu Ser Pro Gly Lys  
225 230

<210> 19

<211> 229

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic construct

<400> 19

Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe  
1 5 10 15

Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr  
20 25 30

Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val  
35 40 45

Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val  
50 55 60

Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser  
65 70 75 80

Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu  
85 90 95

Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser  
100 105 110

Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro  
115 120 125

WO 03/076567

PCT/US03/03120

24/48

Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln  
130 135 140

Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala  
145 150 155 160

Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr  
165 170 175

Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu  
180 185 190

Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser  
195 200 205

Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser  
210 215 220

Leu Ser Leu Gly Lys  
225

<210> 20

<211> 585

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic construct

<400> 20

Asp Ala His Lys Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu  
1 5 10 15

Glu Asn Phe Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln  
20 25 30

Gln Cys Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu  
35 40 45

WO 03/076567

PCT/US03/03120

25/48

Phe Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys  
50 55 60

Ser Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu  
65 70 75 80

Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro  
85 90 95

Glu Arg Asn Glu Cys Phe Leu Gln His Lys Asp Asp Asn Pro Asn Leu  
100 105 110

Pro Arg Leu Val Arg Pro Glu Val Asp Val Met Cys Thr Ala Phe His  
115 120 125

Asp Asn Glu Glu Thr Phe Leu Lys Lys Tyr Leu Tyr Glu Ile Ala Arg  
130 135 140

Arg His Pro Tyr Phe Tyr Ala Pro Glu Leu Leu Phe Phe Ala Lys Arg  
145 150 155 160

Tyr Lys Ala Ala Phe Thr Glu Cys Cys Gln Ala Ala Asp Lys Ala Ala  
165 170 175

Cys Leu Leu Pro Lys Leu Asp Glu Leu Arg Asp Glu Gly Lys Ala Ser  
180 185 190

Ser Ala Lys Gln Arg Leu Lys Cys Ala Ser Leu Gln Lys Phe Gly Glu  
195 200 205

Arg Ala Phe Lys Ala Trp Ala Val Ala Arg Leu Ser Gln Arg Phe Pro  
210 215 220

Lys Ala Glu Phe Ala Glu Val Ser Lys Leu Val Thr Asp Leu Thr Lys  
225 230 235 240

Val His Thr Glu Cys Cys His Gly Asp Leu Leu Glu Cys Ala Asp Asp  
245 250 255

Arg Ala Asp Leu Ala Lys Tyr Ile Cys Glu Asn Gln Asp Ser Ile Ser  
260 265 270

Ser Lys Leu Lys Glu Cys Cys Glu Lys Pro Leu Leu Glu Lys Ser His  
275 280 285

WO 03/076567

PCT/US03/03120

26/48

Cys Ile Ala Glu Val Glu Asn Asp Glu Met Pro Ala Asp Leu Pro Ser  
290 295 300

Leu Ala Ala Asp Phe Val Glu Ser Lys Asp Val Cys Lys Asn Tyr Ala  
305 310 315 320

Glu Ala Lys Asp Val Phe Leu Gly Met Phe Leu Tyr Glu Tyr Ala Arg  
325 330 335

Arg His Pro Asp Tyr Ser Val Val Leu Leu Leu Arg Leu Ala Lys Thr  
340 345 350

Tyr Glu Thr Thr Leu Glu Lys Cys Cys Ala Ala Ala Asp Pro His Glu  
355 360 365

Cys Tyr Ala Lys Val Phe Asp Glu Phe Lys Pro Leu Val Glu Glu Pro  
370 375 380

Gln Asn Leu Ile Lys Gln Asn Cys Glu Leu Phe Glu Asn Leu Gly Glu  
385 390 395 400

Tyr Lys Phe Gln Asn Ala Leu Leu Val Arg Tyr Thr Lys Lys Val Pro  
405 410 415

Gln Val Ser Thr Pro Thr Leu Val Glu Val Ser Arg Asn Leu Gly Lys  
420 425 430

Val Gly Ser Lys Cys Cys Lys His Pro Glu Ala Lys Arg Met Pro Cys  
435 440 445

Ala Glu Asp Tyr Leu Ser Val Val Leu Asn Gln Leu Cys Val Leu His  
450 455 460

Glu Lys Thr Pro Val Ser Asp Arg Val Thr Lys Cys Cys Thr Glu Ser  
465 470 475 480

Leu Val Asn Arg Arg Pro Cys Phe Ser Ala Leu Glu Val Asp Glu Thr  
485 490 495

Tyr Val Pro Lys Glu Phe Asn Ala Glu Thr Phe Thr Phe His Ala Asp  
500 505 510

WO 03/076567

PCT/US03/03120

27/48

Ile Cys Thr Leu Ser Glu Lys Glu Arg Gln Ile Lys Lys Gln Thr Ala  
515 520 525

Leu Val Glu Leu Val Lys His Lys Pro Lys Ala Thr Lys Glu Gln Leu  
530 535 540

Lys Ala Val Met Asp Asp Phe Ala Ala Phe Val Glu Lys Cys Cys Lys  
545 550 555 560

Ala Asp Asp Lys Glu Thr Cys Phe Ala Glu Glu Gly Lys Lys Leu Val  
565 570 575

Ala Ala Ser Gln Ala Ala Leu Gly Leu  
580 585

<210> 21

<211> 703

<212> DNA

<213> Artificial Sequence

<220>

<223> synthetic construct

<400> 21  
gagccaaat cttgtaccaa aactcacaca tgcccaccgt gcccagcacc tgaactcctg 60  
gggggaccgt cagtcttcct ctcccccca aaacccaagg acaccctcat gatctcccg 120  
acccctgagg tcacatgcgt ggtggggac gtgagccacg aagaccctga ggtcaagttc 180  
aactggtacg tggacggcgt ggaggtgcat aatgccaaga caaagccgcg ggaggagcag 240  
tacaacagca cgtaccgtgt ggtcagcgtc ctcaccgtcc tgcaccagga ctggctgaat 300  
ggcaaggagt acaagtgc当地 ggtctccaac aaagccctcc cagccccat cgagaaaacc 360  
atctccaaag ccaaaggc当地 gccccgagaa ccacaggtgt acaccctgcc cccatcccg 420  
gaggagatga ccaagaacca ggtcagcctg acctgcctgg tcaaaggctt ctatcccagc 480  
gacatcgccg tggagtggg当地 gagcaatggg cagccggaga acaactacaa gaccacgcct 540  
cccggtctgg actccgacgg ctccttc当地 ctctatagca agctcaccgt ggacaagagc 600  
aggtgtgc当地 agggaaacgt cttctcatgc tccgtgatgc atgaggctct gcacaaccac 660  
tacacgc当地 agagcctctc cctgtctccg ggtaaatgat agt 703

WO 03/076567

PCT/US03/03120

28/48

&lt;210&gt; 22

&lt;211&gt; 981

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic construct

&lt;400&gt; 22

tccaccaagg gcccatacggt cttcccgcta gcgcctgct ccaggagcac ctccgagagc	60
acagccgcccc tgggctgcct ggtcaaggac tacttccccg aaccggtgac ggtgtcggtgg	120
aactcaggcg ccctgaccag cgccgtgcac accttcccggt ctgtcctaca gtcctcagga	180
ctctactccc tcagcagcgt ggtgaccgtg ccctccagca gcttgggcac gaagacctac	240
acctgcaacg tagatcacaa gcccagcaac accaagggtgg acaagagagt tgagtccaaa	300
tatggtcccc catgcccacc ctgcccagca cctgagttcc tggggggacc atcagtcttc	360
ctgttccccca caaaacccaa ggacactctc atgatctccc ggacccctga ggtcacgtgc	420
gtgggtgggtgg acgtgagcca ggaagacccc gaggtccagt tcaactggta cgtggatggc	480
gtggaggtgc ataatgccaa gacaaagccg cgggaggagc agttcaacag cacgtaccgt	540
gtggtcagcg tcctcaccgt cctgcaccag gactggctga acggcaagga gtacaagtgc	600
aaggtctcca acaaaggcct cccgtcctcc atcgagaaaa ccatctccaa agccaaagg	660
cagccccgag agccacaggt gtacaccctg ccccccattccc aggaggagat gaccaagaac	720
caggtcagcc tgacactgcct ggtcaaaaggc ttctacccca gcgcacatgc cgtggagtgg	780
gagagcaatg ggcagccgga gaacaactac aagaccacgc ctcccggtct ggactccgac	840
ggctccttct tcctctacag caggctaaccc gtggacaaga gcaggtggca ggagggaaat	900
gtcttctcat gctccgtgat gcatgaggct ctgcacaacc actacacacaca gaagagcctc	960
tccctgtctc tggtaaatg a	981

&lt;210&gt; 23

&lt;211&gt; 406

&lt;212&gt; PRT

WO 03/076567

PCT/US03/03120

29/48

<213> Artificial Sequence

<220>

<223> synthetic construct

<400> 23

Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu Lys  
1 5 10 15

Ala Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln  
20 25 30

Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val  
35 40 45

Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys  
50 55 60

Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser  
65 70 75 80

Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser  
85 90 95

Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp  
100 105 110

Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro  
115 120 125

Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe  
130 135 140

Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe  
145 150 155 160

Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Glu Pro  
165 170 175

Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu  
180 185 190

WO 03/076567

PCT/US03/03120

30/48

Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp  
195 200 205

Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp  
210 215 220

Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly  
225 230 235 240

Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn  
245 250 255

Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp  
260 265 270

Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro  
275 280 285

Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu  
290 295 300

Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn  
305 310 315 320

Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile  
325 330 335

Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr  
340 345 350

Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys  
355 360 365

Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys  
370 375 380

Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu  
385 390 395 400

Ser Leu Ser Pro Gly Lys  
405

WO 03/076567

PCT/US03/03120

31/48

<211> 403

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic construct

<400> 24

Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu Lys  
1 5 10 15

Ala Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln  
20 25 30

Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val  
35 40 45

Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys  
50 55 60

Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser  
65 70 75 80

Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser  
85 90 95

Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp  
100 105 110

Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro  
115 120 125

Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe  
130 135 140

Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe  
145 150 155 160

Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Glu Ser  
165 170 175

WO 03/076567

PCT/US03/03120

32/48

Lys Tyr Gly Pro Pro Cys Pro Ser Cys Pro Ala Pro Glu Phe Leu Gly  
180 185 190

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met  
195 200 205

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln  
210 215 220

Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val  
225 230 235 240

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr  
245 250 255

Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly  
260 265 270

Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile  
275 280 285

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val  
290 295 300

Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser  
305 310 315 320

Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu  
325 330 335

Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro  
340 345 350

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val  
355 360 365

Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met  
370 375 380

His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser  
385 390 395 400

Leu Gly Lys

WO 03/076567

PCT/US03/03120

33/48

<210> 25

<211> 500

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic construct

<400> 25

Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu Lys  
1 5 10 15

Ala Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln  
20 25 30

Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val  
35 40 45

Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys  
50 55 60

Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser  
65 70 75 80

Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser  
85 90 95

Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp  
100 105 110

Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro  
115 120 125

Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe  
130 135 140

Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe  
145 150 155 160

WO 03/076567

PCT/US03/03120

34/48

Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro Gly Gly  
165 170 175

Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Asp Ala His  
180 185 190

Lys Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu Glu Asn Phe  
195 200 205

Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln Gln Cys Pro  
210 215 220

Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu Phe Ala Lys  
225 230 235 240

Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys Ser Leu His  
245 250 255

Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu Arg Glu Thr  
260 265 270

Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro Glu Arg Asn  
275 280 285

Glu Cys Phe Leu Gln His Lys Asp Asp Asn Pro Asn Leu Pro Arg Leu  
290 295 300

Val Arg Pro Glu Val Asp Val Met Cys Thr Ala Phe His Asp Asn Glu  
305 310 315 320

Glu Thr Phe Leu Lys Lys Tyr Leu Tyr Glu Ile Ala Arg Arg His Pro  
325 330 335

Tyr Phe Tyr Ala Pro Glu Leu Leu Phe Phe Ala Lys Arg Tyr Lys Ala  
340 345 350

Ala Phe Thr Glu Cys Cys Gln Ala Ala Asp Lys Ala Ala Cys Leu Leu  
355 360 365

Pro Lys Leu Asp Glu Leu Arg Asp Glu Gly Lys Ala Ser Ser Ala Lys  
370 375 380

Gln Arg Leu Lys Cys Ala Ser Leu Gln Lys Phe Gly Glu Arg Ala Phe  
385 390 395 400

WO 03/076567

PCT/US03/03120

35/48

Lys Ala Trp Ala Val Ala Arg Leu Ser Gln Arg Phe Pro Lys Ala Glu  
405 410 415

Phe Ala Glu Val Ser Lys Leu Val Thr Asp Leu Thr Lys Val His Thr  
420 425 430

Glu Cys Cys His Gly Asp Leu Leu Glu Cys Ala Asp Asp Arg Ala Asp  
435 440 445

Leu Ala Lys Tyr Ile Cys Glu Asn Gln Asp Ser Ile Ser Ser Lys Leu  
450 455 460

Lys Glu Cys Cys Glu Lys Pro Leu Leu Glu Lys Ser His Cys Ile Ala  
465 470 475 480

Glu Val Glu Asn Asp Glu Met Pro Ala Asp Leu Pro Ser Leu Ala Ala  
485 490 495

Asp Phe Val Glu  
500

<210> 26

<211> 69

<212> DNA

<213> Artificial Sequence

<220>

<223> synthetic construct

<400> 26

gtaagcttgc gtcgacgcta gcggcgccgc gccatggccg gacctgccac ccagagcccc 60

atgaagctg 69

<210> 27

<211> 61

<212> DNA

<213> Artificial Sequence

WO 03/076567

PCT/US03/03120

36/48

<220>

<223> synthetic construct

<400> 27

ggggcaggga gctggctggg cccagtgag tggcttcctg cactgtccag agtgcactgt 60  
g 61

<210> 28

<211> 59

<212> DNA

<213> Artificial Sequence

<220>

<223> synthetic construct

<400> 28

ggacagtgca ggaaggccact ccactgggcc cagccagctc cctgccccag agcttcctg 59

<210> 29

<211> 72

<212> DNA

<213> Artificial Sequence

<220>

<223> synthetic construct

<400> 29

gaacctcgag gatcctcatt agggctgggc aagggtgcctt aagacgcggc acgacacac 60  
caggaagctc tg 72

<210> 30

<211> 69

<212> DNA

<213> Artificial Sequence

WO 03/076567

PCT/US03/03120

37/48

<220>

<223> synthetic construct

<400> 30  
gtaagcttgc gtcgacgcta gcggcgccgc gccatggccg gacctgccac ccagagcccc 60  
atgaagctg 69

<210> 31

<211> 57

<212> DNA

<213> Artificial Sequence

<220>

<223> synthetic construct

<400> 31  
gctctaaggc cttgagcagg aagctctggg gcagggagct cgctggggcc agtggag 57

<210> 32

<211> 53

<212> DNA

<213> Artificial Sequence

<220>

<223> synthetic construct

<400> 32  
gggccccagcg agctccctgc cccagagctt cctgctcaag gccttagagc aag 53

<210> 33

<211> 72

<212> DNA

<213> Artificial Sequence

WO 03/076567

PCT/US03/03120

38/48

&lt;220&gt;

&lt;223&gt; synthetic construct

&lt;400&gt; 33

gaacctcgag gatcctcatt agggctggc aaggtgcctt aagacgcggt acgacacctc 60  
caggaagctc tg 72

&lt;210&gt; 34

&lt;211&gt; 69

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic construct

&lt;400&gt; 34

gtaagcttgc gtcgacgcta gcggcgccgc gccatggccg gacctgccac ccagagcccc 60  
atgaagctg 69

&lt;210&gt; 35

&lt;211&gt; 61

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic construct

&lt;400&gt; 35

gtccgagcac cactagttcc tcgggtggc acagcttggt ggtgttacac agcttctcct 60  
g 61

&lt;210&gt; 36

&lt;211&gt; 66

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

WO 03/076567

PCT/US03/03120

39/48

&lt;220&gt;

&lt;223&gt; synthetic construct

&lt;400&gt; 36

ggcgcagcgc tccaggagaa gctgtgtaac accaccaagc tgtgccaccc cgaggaacta 60  
gtgctg 66

&lt;210&gt; 37

&lt;211&gt; 72

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic construct

&lt;400&gt; 37

gaacctcgag gatcctcatt agggctggc aaggtgcctt aagacgcggt acgacacctc 60  
caggaagctc tg 72

&lt;210&gt; 38

&lt;211&gt; 69

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic construct

&lt;400&gt; 38

gtaagcttgc gtcgacgcta gcggcgccc gccatggccg gacctgccac ccagagcccc 60  
atgaagctg 69

&lt;210&gt; 39

&lt;211&gt; 61

&lt;212&gt; DNA

WO 03/076567

PCT/US03/03120

40/48

<213> Artificial Sequence

<220>

<223> synthetic construct

<400> 39

gccccggcgct ggaaagcgct ggcgaaggcc ggcatggcgg tctgggttggg ctgcagggca 60  
g 61

<210> 40

<211> 60

<212> DNA

<213> Artificial Sequence

<220>

<223> synthetic construct

<400> 40

ggcccccgtgcc ctgcagccca accagaccgc catgccggcc ttccgcagcg ctttccagcg 60

<210> 41

<211> 72

<212> DNA

<213> Artificial Sequence

<220>

<223> synthetic construct

<400> 41

gaacctcgag gatcctcatt agggctgggc aaggtgcctt aagacgcggc acgacacactc. 60  
caggaagctc tg 72

<210> 42

<211> 69

<212> DNA

WO 03/076567

PCT/US03/03120

41/48

<213> Artificial Sequence

<220>

<223> synthetic construct

<400> 42

gtaagcttgc gtcgacgcta gcggcgccgc gccatggccg gacctgccac ccagagcccc 60  
atgaagctg 69

<210> 43

<211> 68

<212> DNA

<213> Artificial Sequence

<220>

<223> synthetic construct

<400> 43

gccccggcgt ggaaggtaga gttgaaggcc ggcatggcac cctgggtggg ctgaagagca 60  
ggggccat 68

<210> 44

<211> 74

<212> DNA

<213> Artificial Sequence

<220>

<223> synthetic construct

<400> 44

gggaatggcc cctgctttc agcccaccca gggtgccatg ccggccttca actctacctt 60  
ccagcgccgg gcag 74

<210> 45

<211> 72

WO 03/076567

PCT/US03/03120

42/48

<212> DNA

<213> Artificial Sequence

<220>

<223> synthetic construct

<400> 45

gaacctcgag gatcctcatt agggctgggc aaggtgcctt aagacgcggt acgacacacctc 60  
caggaagctc tg 72

<210> 46

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> synthetic construct

<400> 46

gctagcggcg cgccaccatg 20

<210> 47

<211> 33

<212> DNA

<213> Artificial Sequence

<220>

<223> synthetic construct

<400> 47

gctcagggtta cggttaacga tgcccagaga gtg 33

<210> 48

<211> 30

<212> DNA

<http://www.paleobios.net>

WO 03/076567

PCT/US03/03120

43/48

<213> Artificial Sequence

<220>

<223> synthetic construct

<400> 48

gggcatcggtt aacgctaccc tgagcagctg

30

<210> 49

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> synthetic construct

<400> 49

gactcgagga tcctcattag ggctggg

27

<210> 50

<211> 38

<212> DNA

<213> Artificial Sequence

<220>

<223> synthetic construct

<400> 50

gctagcggcg cgccaccatg gccggacctg ccacccag

38

<210> 51

<211> 45

<212> DNA

<213> Artificial Sequence

WO 03/076567

PCT/US03/03120

44/48

<220>

<223> synthetic construct

<400> 51

caagcagccg gccagctggg tggcggtgct ggggcagctg ctcag

45

<210> 52

<211> 37

<212> DNA

<213> Artificial Sequence

<220>

<223> synthetic construct

<400> 52

gccccagcaa cgccacccag ctggccggct gcttgag

37

<210> 53

<211> 47

<212> DNA

<213> Artificial Sequence

<220>

<223> synthetic construct

<400> 53

gactcgagga tcctcattag ggctgggcaa ggtgccttaa gacgcgg

47

<210> 54

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> synthetic construct

WO 03/076567

PCT/US03/03120

45/48

<400> 54  
gctagcggcg cgccaccatg

20

<210> 55  
<211> 27  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> synthetic construct  
<400> 55  
ggggcaacta gtcaggtag cccaggg

27

<210> 56  
<211> 27  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> synthetic construct  
<400> 56  
gctaacctga ctatgtccc cagccag

27

<210> 57  
<211> 27  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> synthetic construct  
<400> 57  
gactcgagga tcctcattag ggctggg

27

WO 03/076567

PCT/US03/03120

46/48

<210> 58  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> synthetic construct

<400> 58  
gctagcggcg cggccaccatg

20

<210> 59  
<211> 25  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> synthetic construct  
<400> 59  
ggtgcaattg ctcaggggag cccag

25

<210> 60  
<211> 23  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> synthetic construct  
<400> 60  
gcaattgcac cagccaggcc ctg

23

<210> 61  
<211> 27

WO 03/076567

PCT/US03/03120

47/48

<212> DNA

<213> Artificial Sequence

<220>

<223> synthetic construct

<400> 61

gactcgagga tcctcatttag ggctggg

27

<210> 62

<211> 38

<212> DNA

<213> Artificial Sequence

<220>

<223> synthetic construct

<400> 62

gctagcggcg cgccaccatg gccggacctg ccacccag

38

<210> 63

<211> 37

<212> DNA

<213> Artificial Sequence

<220>

<223> synthetic construct

<400> 63

ccggactggc cccgttcagg gcctgcagga gccccctg

37

<210> 64

<211> 35

<212> DNA

<213> Artificial Sequence

WO 03/076567

PCT/US03/03120

48/48

<220>

<223> synthetic construct

<400> 64

gaacgggacc agtccggagt tgggtcccac cttgg

35

<210> 65

<211> 47

<212> DNA

<213> Artificial Sequence

<220>

<223> synthetic construct

<400> 65

gactcgagga tcctcattag ggctggcaa ggtgccttaa gacgcgg

47

<210> 66

<211> 36

<212> DNA

<213> Artificial Sequence

<220>

<223> synthetic construct

<400> 66

gtcgacgcta gcggcgccc accatggccg gacctg

36